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Abstract
The experiments described in the chapters of this thesis were part of a collaborative 
project with colleagues at the Universities of Bournemouth, Manchester and 
Southampton. This Cancer Research-UK and National Blood Service (NBS) 
sponsored clinical trial reports on one of the first DNA vaccine trials in humans in 
patients with low-grade follicular lymphoma. Twenty-five patients were enrolled and 
the V genes encoding the V domains of their surface immunoglobulin (slg) on the 
dominant malignant clone were isolated from a lymph node biopsy and single chain 
variable domain antibody fragments (scFv) were constructed. The V gene cassettes 
were cloned into the vaccine plasmid, pVAC2. pVAC2 fuses the scFv gene cassette in 
open reading frame to the gene for fragment C of tetanus toxoid. Each patient vaccine 
was produced to GMP standards and subjected to pre-release quality and sterility 
controls. In parallel with the clinical trial all the vaccines were administered to Dutch 
rabbits and antibody responses were measured. To measure anti-idiotypic responses an 
inducible/secretable Drosophila expression system was modified and calmodulin 
(CaM) tagged scFv was produced. The scFv-CaM fusion proteins were then used to 
measure the anti-idiotypic responses in the patients pre- and post-vaccination.
The variable domains from another FL patient (but not enrolled in the trial) with an 
IgM paraprotein and suffering from severe autoimmune thrombocytopenia, were 
isolated, the scFv constructed, a DNA vaccine prepared and idiotypic antibodies 
raised. These reagents were used to determine whether the IgM paraprotein produced 
by the dominant Lymphoma clone was exhibiting anti-platelet reactivity.
18
Chapter 1 -  Introduction
1.1 Overview
Cancer is the generic name for a class of diseases characterised by uncontrolled cell 
division and the ability of these cells to invade other tissues, either by direct growth 
into adjacent tissue (invasion) or by migration of cells to distant sites (metastasis). 
Cancer can affect all the cells of the body and each cancer has its own signature. There 
is no single cause of cancer although certain environmental agents and genetic 
predispositions can increase a persons propensity to acquire the disease. Treatment for 
cancer is usually a combination of chemo- and radiotherapy to attack the fast growing 
malignant cells. However, there is no distinction between malignant cells and healthy 
fast growing cells in the hair follicles and gastrointestinal (GI) tract. Therapies that 
target only the cancerous cells are more appealing although this approach requires that 
the malignant cells express a unique marker that can be preferentially targeted.
This thesis focuses on Follicular Lymphoma (FL), one of the many cancers affecting 
the cells of the blood and bone marrow. FL is a B cell malignancy that occurs after the 
B-cell has been exposed to antigen during its development (Figure 1.1). The malignant 
B cell expresses surface immunoglobulin (slg) that confers a unique set of antigenic 
determinants, the idiotype. This idiotype is unique to the malignant B cells and can 
therefore be used as a target for immunotherapy. Together with colleagues in 
Southampton, Bournemouth and Manchester a DNA vaccine encoding the amino acid 
sequence of the idiotype from patients with FL was developed and administered to the 
patients in a phase I/II clinical trial, the first of its kind in cancer patients.
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1.2 Immune system
All immune responses involve two steps, firstly, recognition of the pathogen and 
secondly, a reaction to eliminate it. Immune responses fall into two categories, innate 
and adaptive. The communication and collaboration between the cells of the immune 
system is tightly regulated and can be achieved either by direct interaction of surface 
receptors and ligands, or by secretion of soluble mediators specific for receptors 
expressed on certain classes of immune cells. This defends the body against non-self.
The innate immune system is the first line of defence, it is not antigen specific and it 
relies on the body’s natural barriers and secretions to eliminate microbes and prevent 
infections. Elements of the innate system are anatomical barriers, secretory molecules 
and cellular components. There are three cell types involved in innate immune 
responses. Firstly, the phagocytic cells (neutrophils, monocytes, and macrophages). 
Secondly, cells that release inflammatory mediators (basophils, mast cells, and 
eosinophils) and finally natural killer (NK) cells.
Adaptive, or acquired, immunity refers to an antigen-specific defence mechanism that 
takes several days to become protective and is specific for a particular pathogen. 
Adaptive immunity is a constant process that develops throughout life and generally 
improves upon repeated exposure to a given infection. The main components of the 
adaptive immune system are the professional antigen presenting cells (APC) and the B 
and T lymphocytes (B and T cells) (so called because they were originally discovered 
in the Bursa of Fabricius and differentiate in the adult bone marrow and thymus 
respectively) (Miller & Mitchell, 1967; Tonegawa, 1983). B and T cells will recognise 
the same antigen in different forms, by virtue of their respective antigen specific
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receptors, slg or B cell receptor (BcR) and T cell receptor TcR, expressed on the cell 
surface (Figure 1.2). Naive B cells are genetically programmed to encode a slg. The 
population of polyclonal B cells expresses a vast repertoire of slg with an estimated 
diversity of 1012 different specificities. Activation and subsequent proliferation of B 
cells by antigen causes clonal proliferation and selection. During clonal selection the 
affinity of slg for the antigen increases by somatic hypermutation (SHM) of the 
rearranged V genes. Mature antigen selected B cells may differentiate into plasma 
cells and secrete large amounts of specific soluble Ig (Schebesta et al., 2002). Some 
will differentiate into memory B cells allowing a more rapid and vigorous immune 
response when re-challenged.
T cells recognise antigens only when presented on the surface of other cells in the 
context of the major histocompatibility complex (MHC). The TcR recognises short 
oligo peptides (9-12 amino acids) derived from the antigen presented in the context of 
one of two specialised protein complexes - MHC class I and II. The former is 
expressed on the surface of all somatic cells (except red blood cells) and the latter on 
specialised cells of the immune system such as antigen presenting cells (APCs), B 
cells and activated T cells (Roitt etal., 2001). Subsets of T cells have different 
functions dependant on whether they bind MHC class I (CD8 positive T cells) 
Cytotoxic T lymphocytes (CTL), responsible for the destruction of host cells that have 
become infected by intracellular pathogens, or class II (CD4 positive T cells). CD4+ T 
cells can be further subdivided into type-1 (TH1) and type-2 (TH2) helper T cells on the 
basis of their cytokine profiles. TH1 cells promote cell-mediated inflammatory 
reactions and TH2 cells promote strong antibody and allergic responses.
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The complex nature of the immune system is typified by the integration of multiple 
signals that result in either activation or inhibition of a response. A two-step model 
(Bretscher & Cohn, 1970; Jenkins & Schwartz, 1987), where a positive result will only 
occur if two activation signals (antigen specific and generic) are received, is required 
for T cell and full B cell activation and clonal expansion. This introduces a greater 
degree of control over clonal proliferation with the consequences of antigen 
recognition and antigen elimination. In the early phase of the response against 
exogenous antigen professional APC educate T cells, which in turn interact with B 
cells and in the later phase B cells may become the preferred cells for antigen 
presentation (Figure 1.2). The cooperation between the different cell types of the 
immune system and the resulting degree of regulatory complexity is a pre-requisite to 
maintain tolerance for self, whilst retaining the capacity to achieve effective immune 
responses against non-self.
23
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1.3 B cell development
B cells differentiate from lymphoid stem cells and originate in the bone marrow. There 
are two main stages of B cell development. The initial development is largely 
independent of T cells and antigen (Figure 1.1).
The earliest stage of B-cell development has been identified as the progenitor B (pro- 
B) cell stage, where the Ig genes are in germline configuration. Pro-B cells can be 
divided into three groups (early, intermediate and late) based on the differential 
expression of the intranuclear enzyme, terminal deoxynucleotidyltransferase (TdT) 
and/or the marker B220, a high molecular weight (220 kDa) isoform of CD45R 
(reviewed by Roitt (Roitt et al., 2001)). As the cells progress through the pro-B stage 
they rearrange their immunoglobulin (Ig) heavy chain genes and begin to express 
CD43, CD 19, recombination activating gene (RAG)-l and RAG-2. The late pro-B 
cells become precursor B (pre-B) cells, during this stage they downregulate TdT, 
RAG-1, RAG-2 and CD43. Pre-B cells are divided into large mitotically active and 
small non-dividing pre-B cells. Both express the Ig p heavy chains in the cytoplasm 
(cp) and the pre-B receptor complex on their surface. Large pre-B cells have 
successfully rearranged their Ig heavy chain genes and as they differentiate into small 
pre-B cells they begin to rearrange their Ig light chain genes and upregulate RAG-1 
and RAG-2. Finally they differentiate into the immature B cell, which has successfully 
rearranged light chain genes and expresses surface IgM. Immature B cells develop into 
mature B cells and begin to express both IgM and IgD on their surface. Mature B cells 
can exit the bone marrow and migrate into the periphery.
Upon exposure to antigen, specific B cells enlarge and express new cell surface 
molecules. The enlarged B cells can be stimulated to enter the cell cycle and
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differentiate and mature into plasma cells. These cells do not divide and secrete large 
amounts of antibody. Following the removal of antigen, B cells stop dividing and 
differentiate into memory B cells. B cells that fail to encounter antigen are removed 
from the repertoire within a few weeks either by apoptosis or by becoming anergised.
1.4 Immunoglobulins
Immunoglobulins are glycoproteins in the immunoglobulin superfamily that are found 
both secreted in the blood and tissue fluids of all mammals (antibodies) and carried on 
the surface of B cells, where they act as specific receptors for antigen (slg). The terms 
antibody and immunoglobulin are often used interchangeably. One portion of the 
antibody molecule binds antigen whilst the other has effector functions.
1.4.1 Immunoglobulin structure
There are five classes of antibody IgG, IgA, IgM, IgD and IgE; they differ in size, 
charge, amino acid composition and carbohydrate content. Most B cells express two 
classes of slg known as IgM and IgD (Melchers et al., 2000).
The basic structure of all immunoglobulins is a unit consisting of two identical heavy 
(H) chains and two identical light (L) chains of approximately 55 and 24 kDa 
respectively. The H chain is divided into four domains, one amino terminal variable 
(VH) domain and three constant (C) domains CHI, CH2 and CH3 (or four in the case 
of IgM and IgE). The light chain is divided into two domains VL (N-terminal) and CL. 
The VH and VL domains are linked to the CHI and CL domains respectively and CHI 
is linked to CH2 and CH3 by the hinge region (Figure 1.3).
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Two or more disulphide bonds in the hinge region unite the two heavy chains and a 
disulphide bond couples the CHI and CL domains. Strong non-covalent attractions 
bring together the N terminal VH and VL domains to form the antigen recognition 
site, these bonds form the classic Y-shape of the antibody molecule.
The Ig molecule can be divided into three fragments by digestion with papain (Figure 
1.3); two representing the antigen binding V domains with heavy and light chain 
constant domains CHI/CL (Fab), and one of only the CH2 and CH3 domains (Fc); or 
after digestion with pepsin a F(ab’)2 fragment composed of both antigen binding 
domains joined by disulphide bonds, and smaller fragments of the constant domains 
(reviewed by Roitt (Roitt et al., 2001)). Each of these separate domains has a similar 
structure known as the immunoglobulin fold, consisting of seven (C domain) or nine 
(V domains) p strands arranged so that four strands form one p sheet, and three or five 
strands form a second p sheet (Figure 1.4). Each of the two V domains has three 
surface exposed hairpin loops connecting the p strands, also known as hypervariable 
loops or complementarity determining regions (CDR). These six surface exposed 
loops (three from each VH and VL) form contacts with antigen.
27
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Figure 1.3 A schematic representation of an antibody of the IgG isotype. IgG is 
composed of two pairs of identical light and heavy polypeptide chains composed of 
Constant (C) Heavy (H)l, CH2, CH3 or C light (L) domains and Variable (V) H or VL 
domains. The structure is stabilised by intra- and inter-chain disulphide bonds. Pepsin 
and papain cleavage sites produce Fc, F(ab) or F(ab)2 products as. Antigen is bound at 
the antigen binding sites formed by the association of the VH and VL domains at the 
amino terminus of the polypeptide chain. (Adapted from the thesis of Darren Hughes 
with kind permission, University of Cambridge).
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1.4.2 Immunoglobulin classification
Structural differences between immunoglobulins are used for their classification. 
There are three classes of immunoglobulin, which can also be described as 
immunoglobulin variability.
Firstly, the type of heavy chain an immunoglobulin possesses determines isotypic 
variation. There are five heavy chains (fx, 6, y, e, a) giving rise to the nine human 
isotypes IgM, IgD, IgG 1, 2, 3 and 4, IgE and IgA 1 and 2 respectively (Walter et al., 
1991). Secondly, allotypic variation is a genetic difference between individuals within 
a species, involving different alleles at a given locus. Immunoglobulin allotypes occur 
mostly as variants of heavy chain constant regions. Finally, idiotypic variation refers 
to the sequence diversity at the antigen binding site, particularly in the hypervariable 
regions. The antigen binding site itself is also an antigenic determinant and the 
collection of epitopes that it produces is known as the idiotype (Slater et al., 1955). 
Idiotypes are usually specific for individual B-cell clones (private idiotypes), but are 
sometimes shared between different B-cell clones (public or cross-reactive idiotypes) 
(Roitt et al., 2001).
1.4.3 Immunoglobulin function
The primary function of an antibody is to bind antigen. Antibodies have a variety of 
ways to eliminate the antigen that elicited their production. Some functions are 
independent of the isotype and reflect the antigen binding capacity of the molecule as 
defined by its idiotype, for example by neutralizing bacterial toxin or by preventing 
viral attachment to host cells. Other functions are dependent upon the isotype and are
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mediated by the constant regions of the molecule. The constant domains of human Ig 
molecules can bind to the surface of macrophages via Fc receptors (FcR) to promote 
and enhance phagocytosis. These FcR are expressed on leucocytes and platelets but 
not on erythrocytes. Only IgG and IgM have the ability to interact with and initiate the 
complement cascade for the elimination of pathogens and the modulation of 
inflammation. IgG is the most important class of immunoglobulin in secondary 
immune responses, it is the only class able to cross the placenta and confer a high 
degree of passive immunity to the newborn. IgM is the predominant antibody in 
primary immune responses. IgD is a B cell receptor, IgA is primarily involved with the 
humoral protection of mucosal surfaces and IgE is thought to have evolved as an anti­
parasite response but is now most commonly associated with allergic diseases such as 
asthma and hay fever (reviewed by Roitt (Roitt et al., 2001)).
1.5 Antibody diversity
1.5.1 Clonal theory of selection
The clonal theory of selection is attributed to Burnet (Burnet, 1959) and provides an 
explanation of the specificity of the adaptive humoral immune response. Briefly, the 
theory states that an antigen selects a lymphocyte, from a variety of lymphocytes, with 
a receptor capable of reacting with part of that antigen. The selected lymphocyte is 
then activated to proliferate (clonal expansion) and secrete the cognate antibody. The 
concept of clonal selection proposed by Burnet in 1959 is in essence correct but we
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now know that the selection and diversification of the humoral response is more 
complex.
1.5.2 Generation of antibody diversity
There are four main ways in which to generate antibody diversity, three are 
consequences of the process of recombination of immunoglobulin genes used to create 
novel gene segments encoding complete immunoglobulin variable domains. Ig can 
either be membrane bound or secreted and this is regulated by alternative splicing. The 
carboxy-termini of the transmembrane and secreted forms of the Ig H chains are 
encoded in separate exons. The last exon of the constant region gene contains the 
sequence encoding the transmembrane region of the heavy chain. If the primary 
transcript includes all exons, slg is produced. If transcription is terminated before the 
last exon, only the secreted molecule can be produced. The fourth is a mutational 
process that only occurs on the rearranged DNA encoding the variable domains. The 
sequence of the rearranged V genes can be altered by a process of somatic 
hypermutation (SHM), which can result in affinity maturation (Neuberger & Milstein, 
1995). B cells in which hypermutation leads to an increased affinity for antigen will be 
preferentially selected and expanded. The site of mutations are not random but occur 
in hotspots (Rogozin et al., 2001) corresponding to the CDR. The process of affinity 
maturation is coupled with class switching, which is an ordered process leading to the 
replacement of the original constant domain gene of the heavy chain (pi or 8) by other 
constant domain genes (y. b or a) leading to the production of IgG, IgE or IgA.
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1.5.3 Immunoglobulin gene recombination
The primary antibody repertoire is generated independent of antigen by a process of 
random gene rearrangement, and it is this rearrangement of Ig V domain genes, which 
is responsible for the generation of diversity of the amino acid sequence of the 
antigen-binding site. Each B cell expresses a slg with a unique antigen-binding site. 
These are produced de novo in infinite permutations by the random recombination of 
each of two or three genes; variable (V), diversity (D) (Ig heavy chain only), and 
joining (J) gene (Figure 1.5), producing a diverse repertoire of up to 1012 antigen 
binding specificities (Tonegawa, 1983). The position at which V and J (light chain) 
and D and J (heavy chain) join also varies. These slight differences in the position at 
which recombination occurs generates variations in the amino acid sequence leading 
to additional diversity. Furthermore, a few nucleotides may be inserted or deleted 
between D and JH and VH and D by the enzyme terminal deoxynucleotidyl 
transferase (TdT), which is referred to as N-region diversity.
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1.5.4 Activation-induced cytidine deaminase
Activation-induced cytidine deaminase (AID) is an essential enzyme in the regulation 
of class switch recombination (CSR), SHM (Muramatsu et al., 2000) and gene 
conversion (GC) (Arakawa et al., 2002) (reviewed by Honjo et al (Honjo et al.,
2004)). Different species employ different strategies of diversification, eg mice and 
humans use exclusively hypermutation (Milstein & Rada, 1995), whereas rabbits, 
cows and pigs use mainly gene conversion (Butler, 1998). The gene for AID is 
induced by B cell stimulation and is homologous to the cytidine deaminase 
apolipoprotein B mRNA editing enzyme (APOBEC-1) gene (Muramatsu et al., 1999), 
leading to the hypothesis that AID is a mRNA editing enzyme (Muramatsu et al., 
1999). However, further studies on the mechanism of SHM indicate that AID directly 
modifies DNA by deamination of cytosine (C) to uracil (U) (Di Noia & Neuberger, 
2002).
AID expression closely correlates with the immunopathological phenotype of B-cell 
malignancies, therefore AID, as a genome mutator, may play a role in ongoing 
transformation of the germinal centre derived B cell non-Hodgkin’s lymphomas (B- 
NHL) (Smit et al., 2003).
1.5.4.1 Somatic hypermutation
The theory of SHM was one of the first hypotheses to explain the genetic-diversity of 
antibody-forming cells (Lederberg, 1959). SHM is the alteration of germline 
immunoglobulin sequences by introduction of nucleotide changes during the lifetime 
of a B-cell (Lederberg, 1959). Studies on Bence-Jones proteins established that
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antibody diversity is largely confined to the amino-terminal (variable) domains of the 
polypeptide chains (Hilschmann & Craig, 1965; Milstein, 1966; Titani et al., 1966). 
More recently the demonstration that SHM contributes substantially to the diversity of 
the antibody repertoire (Parham, 1998) and the discovery of several low-fidelity DNA 
polymerases encoded by the mammalian genome (Ohmori et al., 2001) led to the 
understanding that the substantial proportions of the mutations generated by SHM are 
as a result of direct modification of the DNA duplex itself rather than from errors in 
copying the DNA (Neuberger et al., 2005).
SHM can now be divided into two phases; AID dependent first phase is triggered by 
specific enzyme catalysed deamination of C (deoxycytidine) residues to U 
(deoxyuracil) residues. Resulting in the generation of a lesion composed of U 
mispaired with G. Replication over the U.G mispair could be responsible for 
generating many (or possibly all) of the mutations at G.C pairs. The second phase of 
SHM depends on the recognition of the DNA lesions generated in the first phase, 
leading to mutations that are mainly (or possibly all) at A.T
(deoxyadenosine.deoxythymidine) pairs, but the mechanism for this is still unknown 
(Neuberger et al., 2005). Recombinant AID has the predicted DNA-deaminating 
activity, and its preference for C residues with adjacent 5’ -(A/T)-(A/G) sequences 
(Petersen-Mahrt et al., 2002; Bransteitter et al., 2003; Chaudhuri et a l, 2003; Pham et 
al., 2003) supports the sequence of intrinsic mutation hot spots in Ig genes (Rada et 
al., 1998; Rogozin etal., 2001).
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1.5.4.2 Class switch recombination
CSR is a region-specific recombination that switches isotypes from IgM or IgD to 
IgG, IgA or IgE contributing diverse effector functions to immunoglobulin with a 
given antigen specificity. The gene for the heavy chain is cut on the 3' side of the 
assembled V-region segments and the assembly moved to the 5 ' side of another of the 
CH gene segments, upstream in the locus. The ability of a B cell to switch CH gene 
segments depends on its receiving help from helper T cells.
AID-deficient mice show the complete loss of class switching and accumulation of 
IgM in sera and faeces (Muramatsu et al., 2000). Patients with the autosomal recessive 
disease, hyper IgM syndrome type-2 (HIGM2) have severe defects in class switching 
(Revy et al., 2000). Genetic linkage analysis has revealed that the mutation is mapped 
to chromosome 12pl3, which coincides with the AID gene locus (Muto et al., 2000). 
All HIGM2 patients have mutations in the AID gene and are defective in CSR (Ta et 
al., 2003).
1.5.4.3 Gene conversion
GC modifies an antibody by swapping part of its antigen-binding region for a 
replacement gene segment. Rabbits, cows and pigs favour gene conversion. Chicken B 
cells first develop their Ig repertoire by gene conversion in the bursa (Reynaud et al., 
1987; Arakawa & Buerstedde, 2004) and later fine-tune it by hypermutation in splenic 
germinal centres (Arakawa et al., 1996).
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AID is a requirement for all three gene diversification processes. However, the 
cytosine deamination activity must be further regulated, because only differences in 
the type, the location or the processing of the AID-induced DNA modification can 
explain the selective occurrence of recombination or hypermutation in different 
species and B cell environments. Based on the finding that certain AID mutations 
affect CSR but not SHM, it was suggested that AID needs the binding of a cofactor to 
initiate CSR (Barreto et al., 2003; Ta et al., 2003; Basu et al., 2005).
1.5.5 Receptor editing
Receptor editing is a phenomenon that occurs in the bone marrow and serves to rescue 
immature self-reactive B cells. The clonal selection theory anticipated that a random 
collection of Igs would include self-reactive specificities that require silencing 
(Burnet, 1959). The tolerization of these autoreactive B cells was deduced using 
transgenic mice carrying antibody genes coding for self-reactive Igs (Goodnow et al., 
1988; Nemazee & Burki, 1989; Gay et al., 1993; Tiegs et al., 1993; Tze et al., 2000). 
It was shown that the autoreactive B cells confronted with antigen were eliminated, 
anergised or the Ig specificity altered by continued gene recombination (receptor 
editing). It has been shown in IgK knock-in mouse strains that 25% of the light chains 
found on the surface of developing B cells in vivo are produced by receptor editing 
(Casellas et al., 2001), however, it has not been confirmed whether all these 
replacements are induced by self-reactivity. This data is strongly suggestive that 
receptor editing plays an important role in the generation of the normal antibody 
repertoire.
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1.6 Lymphoma
Lymphoma is a general term for a malignancy of lymphocytes. The prefix "lymph-" 
indicates the origin of the malignancy and the suffix "-oma" is derived from the Greek 
word meaning "tumour". Lymphomas result from a chromosomal translocation of a 
lymphocyte with subsequent further acquired DNA mutations resulting in a malignant 
transformation. These acquired genetic events cause uncontrolled and excessive clonal 
cell proliferation conferring a survival advantage on the malignant lymphocyte and its 
progeny. The accumulation of these dividing cells results in the tumour masses in the 
lymph nodes and other sites. Traditionally lymphomas can be divided into two 
categories: Hodgkin lymphoma or Hodgkin’s disease (HD) named after Thomas 
Hodgkin, an English physician who described several cases in 1832, and non-Hodgkin 
lymphomas (NHL), a term covering all other lymphomas. HD is histologically 
distinguished from NHL by the presence of large bilobed nuclear cells known as 
Reed-Stemberg (RS) cells (Sternberg, 1898; Reed, 1902) and represents ~13% of all 
the lymphomas diagnosed annually.
1.6.1 Non-Hodgkin Lymphoma
The Revised European-American Lymphoma (REAL) classification (Harris et al., 
1994) lists more than 20 types of NHL divided between B- and T-cell lymphomas. B- 
cell lymphomas are a diverse group of diseases that are classified histologically into 
low, intermediate and high-grade varieties. B-cell lymphomas account for about 87% 
of all cases of NHL and approximately 40% of these are of the low-grade variety.
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1.6.2 Follicular Lymphoma
Follicular lymphoma (FL) is the most common type of slow-growing or indolent non- 
Hodgkin's lymphoma. FL is named because the malignant cells usually grow in a 
circular or follicular pattern in the lymph nodes. FL occurs in the germinal centre B 
cell after the mature B cell has encountered antigen (Figure 1.1).
1.6.3 Development of Follicular Lymphoma
FL originates from B-cell lymphocytes developing and maturing in the lymphoid 
tissues. FL tumours are characterised by the presence of small-cleaved cells 
(centrocytes) or large cells (centroblasts) in the lymphatic system (Figure 1.6).
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Figure 1.6 Lymph node section from patient with follicular lymphoma. Paraffin 
mounted section of lymph node stained with Haematoxylin and Eosin. High power 
magnification showing a mixture of centrocytes and centroblasts. Centrocytes are the 
small cleaved cells and the centroblasts are the large non-cleaved cells. Reproduced 
from http://pleiad.umdnj.edu/~dweiss/follicular/gradel_fcc_img.html.
Typically, the malignant masses are dominated by centrocytes, even though 
centroblasts are always present. In rare cases, a patient may have a FL that consists 
almost entirely of centroblasts.
The lymphoma can transform and become more aggressive over many years, and the 
follicular pattern may change from a lower percentage to primarily centroblasts. 
Although the lymphoma usually begins in lymphoid tissue, it is not uncommon for 
metastases to form in the bone marrow and peripheral blood.
The chromosomal translocation t(14:18)(q32:q21) is present in over 80% of NHL 
(Hoffbrand & Pettit, 1994). The translocation involves the immunoglobulin heavy 
chain locus (JH Ig H) on chromosome 14 and the bcl-2 gene on chromosome 18. Bel-2 
is an anti-apoptotic protein that resides in the outer mitochondrial membrane (OMM) 
and the membrane of the endoplasmic reticulum (ER). Over expression of bcl-2 is 
known to block the release of cytochrome c into the cytoplasm thereby preventing 
activation of caspase-9 and -3 preventing caspase induced apoptosis (Zamzami et al., 
1998). The bcl-2 IgH fusion gene in FL is deregulated, leading to the transcription of 
excessively high levels of the anti-apoptotic bcl-2 protein (Vaux et al, 1988), thus 
decreasing the propensity of these cells to undergo apoptosis (Yunis et al., 1987). This 
confers a survival advantage and therefore a gradual accumulation of the malignant 
cells.
1.6.4 Incidence of Follicular Lymphoma
FL is the second most common lymphoma in the United States and Western Europe. 
About one in five people with non-Hodgkin's lymphoma have FL, and in more than 
two thirds of patients the low-grade lymphoma is of the follicular type (Glass et al.,
42
1997). FL usually affects middle-aged and elderly people. It is rarely diagnosed in 
children or adolescents. The median age at the time of diagnosis is 60 years; it is 
slightly more frequent in women than men and is more common in white Caucasoid 
than in Asian or black populations. In the UK the recorded incidence is currently 
4/100,000 and is increasing at about 5% a year.
1.6.5 Classification
The World Health Organization (WHO) classifies FL into three grades, low, 
intermediate and high. These are based on the number of centroblasts in the tumour 
sections under high field microscopy. In short: Grade I, a patient has fewer than five 
centroblasts, this is the most common type. Grade II, a patient has between six and 
fifteen centroblasts. Grades I and II are considered to be indolent or slow growing. 
Grade III, a patient has more than 15 centroblasts; this is a rare more aggressive type.
1.6.6 Signs and symptoms
In most cases, patients seek medical advice because of the appearance of swollen 
glands in the neck, armpits or groin. These swollen lymph nodes are mostly painless 
and can be present for several weeks before attention is directed toward them. General 
symptoms may include feeling tired, having a flu-like syndrome or aching all over. 
Others experience night sweats and some may have recurring high-grade or constant 
low-grade fevers. Since all these symptoms are common to many illnesses, from minor 
ailments to serious disorders, the correct diagnostic procedures must be performed in 
order to confirm or rule out the presence of lymphoma.
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1.6.7 Diagnosis
At the time of diagnosis the vast majority of patients tend to have widespread, 
advanced-stage disease. However, as FL is slow growing and indolent that will 
progress slowly, without any form of treatment, often showing a tendency to wax and 
wane with frequent spontaneous regressions (23%) and complete remissions 
(8%)(Horning & Rosenberg, 1984).
A diagnosis of FL is confirmed by microscopic examination of a lymph node biopsy. 
Blood tests, X-rays, computed tomography (CT) and magnetic resonance imaging 
(MRI) scans, and bone marrow samples are also taken to obtain more information 
about the type of lymphoma and the extent to which the disease has spread (staging). 
FL has 4 stages of disease progression, stage I - one group of lymph nodes (LN) is 
affected. Stage II -  more than two groups are affected. These groups are either above 
or below the diaphragm. Stage III - more than two groups are affected with locations 
both above and below the diaphragm. The spleen may also be affected. Stage IV -  The 
lymphoma has spread beyond the LN to other organs ie, bone marrow, peripheral 
blood, liver and lungs. The stage of the lymphoma is crucial in deciding the most 
effective course of treatment. It is important to note that at first presentation 40% of 
patients have spleen involvement and 60-70% have bone marrow involvement.
1.6.8 Disease progression, treatment and prognosis
Disease progression varies from patient to patient depending on the speed of tumour 
growth and the involvement of organs other than LN. Disease acceleration is often
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associated with progression to a more aggressive histological pattern and a worsening 
prognosis.
FL responds well to conventional therapies including radiotherapy, single-agent 
chemotherapy, aggressive combination chemotherapy and more recently, combination 
therapies including the monoclonal anti-CD20 (Rituximab) (Maloney et al., 1997a; 
Maloney et al., 1997b). Very high dose chemotherapy followed by autologous bone 
marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) 
is performed on patients with recurrent or refractory low-grade NHL. However, 
patients will inevitably relapse and after each relapse the trend is for shorter 
remissions until the disease becomes refractory to treatment. Allogeneic BMT has 
been shown to induce longer remissions, but transplant-associated mortality is 10-15% 
higher than with autologous BMT (Verdonck et al., 1997). Sometimes patients may 
have no symptoms for many years and as there is no evidence that early medical 
intervention can cure the disease or prolong survival a close observation "watch and 
wait" policy is generally adopted. For others, treatment may be required for alleviation 
of symptoms, such as fever, night sweats, weight loss, pain, obstructions or the 
development of anaemia or other cytopenias. However, first treatment usually results 
in complete or partial remission.
Overall the prognosis for FL patients is not good, the median survival is approximately 
10 years regardless of the therapeutic modalities employed or when treatment was 
commenced.
1.7 DNA vaccines
Vaccine development has come a long way since Edward Jenner's experiments in the
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late 18th century (Jenner, 1798). The serendipitous discovery that intramuscular 
injection of naked plasmid DNA could express protein from a gene cloned under a 
relevant promoter prompted a new era in vaccine technology. The first demonstration 
of this performed by Wolff and colleagues who coincidentally showed expression of 
cloned genes for chloramphenicol acetyltransferase, luciferase and p-galactosidase 
(Wolff et al., 1990) after intramuscular delivery of plasmid DNA (which was used as a 
negative control construct). Expression was shown to be localised to the muscle and 
persisted for over 19 months (Wolff et al., 1992). Immune responses against the 
products of such genes were demonstrated with DNA plasmids encoding luciferase 
(Tang et al., 1992) and HIV gpl20 (Feigner & Rhodes, 1991). The potential of DNA 
vaccination was realised when it was shown that protection from influenza A could be 
established in mice immunised with plasmid DNA encoding the nucleoprotein (NP) of 
influenza A (Ulmer et al., 1993; Yankauckas et al., 1993). Furthermore, it was 
demonstrated that DNA vaccination led to the generation of long-lived humoral and/or 
cellular immune responses against a range of antigens (Donnelly et al., 1994;
Donnelly et al., 1997).
Typically, DNA vaccines are bacterial plasmids carrying genes encoding pathogen or 
tumour antigens. Most vaccine plasmids share the same four basic features. Firstly, an 
origin of replication (ori) suitable for producing high yields of plasmid in E. coli. 
Secondly, an antibiotic resistance gene for selection of E. coli bearing plasmid.
Thirdly, a strong eukaryotic enhancer/promoter for high-level expression of the 
antigen gene. Finally, mRNA transcript termination/polyadenylation sequence to 
direct protein expression in mammalian cells.
These four elements are the basic requirement for replication of and expression from 
plasmid DNA. The ColEl plasmid derived bacterial origin of replication is known to
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provide high yields of plasmid DNA during bacterial growth, and antibiotic selection 
is required so that only E. coli transformed with the plasmid replicate. Several high 
level expression promoters have been used in DNA vaccination protocols, including 
human cytomegalovirus immediate/early promoter (pCMV) (Boshart et al., 1985; 
Furth et al., 1991), Rous sarcoma virus LTR (pRSV) (Gorman et al., 1982), and 
Simian virus 40 early promoter (pSV40) (Wenger et al., 1994). These have been used 
in conjunction with the SV40 or bovine growth hormone 3’-untranslated region 
transcript termination/polyadenylation sequences (Pfarr et al., 1986). Although 
promoter use differs between studies all those mentioned above give high level 
expression in vivo and comparison of promoters shows no clear differences between 
them (Wenger et al., 1994; Barnhart et al., 1998). Expression of mammalian genes 
also benefits from the inclusion of an intron between the promoter and methionine 
(AUG) start codon (Chapman et al., 1991). Other regulatory elements include a Kozak 
sequence 5’ of the AUG codon which introduces modest secondary structure (hairpin 
loop approximately 14 nucleotides upstream of AUG) and improves recognition of the 
start codon (Kozak, 1990). A signal peptide sequence may also be included to direct 
protein expression through the Golgi and endoplasmic reticulum leading to secretion. 
Using these elements the cloned genes are transcribed and translated by somatic cells 
that have either been directly transfected with or taken up plasmid DNA. Initially it 
was thought that the vaccine plasmid might integrate into the genome of a transfected 
cell or induce anti-DNA autoantibodies similar to those produced in the autoimmune 
disease, systemic lupus erythematosus (SLE). These issues posed serious safety 
concerns for the use of DNA vaccines in humans. Low affinity DNA autoantibodies 
are present ubiquitously in the human population but induction of pathological anti- 
dsDNA autoantibodies is difficult. In normal mice DNA must be denatured,
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complexed with methylated bovine serum albumin and co-administered with complete 
Freunds adjuvant in order to induce high affinity dsDNA autoantibodies (Gilkeson et 
al., 1991). Predications of the frequency of integration/insertion events leading to 
tumorigenesis are below background levels (Kurth, 1995) and no integration of either 
part or all of plasmid DNA from vaccines has been found, even after persistence of 
episomal plasmid for long periods (Nichols et al., 1995).
1.7.1 DNA vaccines in animal models
DNA vaccination has been used to raise immune responses to a number of antigens in 
a variety of species (eg chickens, mice, ferrets, cattle and non-human primates). Viral 
antigens include influenza virus haemagglutinin, matrix protein and nucleoprotein 
(Fynan et al., 1993; Ulmer et al., 1993), human immunodeficiency virus 1 (HIV-1) 
gpl20, gpl60 (Shiver et al., 1995), env, gag and pol genes (Boyer et al., 1997), bovine 
herpes virus gIV (Cox et al., 1993), rabies virus surface glycoprotein (Xiang et al., 
1994), hepatitis B virus (HBV) (Davis et al., 1985) surface antigen and hepatitis C 
virus (HCV) (Major et al., 1995). Bacterial antigens include Mycobacterium 
tuberculosis heat shock protein 65 (Hsp65) and antigen 85 (Ag-85) (Huygen et al., 
1996; Tascon et al., 1996) and tetanus toxin Fragment C (Anderson et al., 1996). 
Parasitic antigens include malaria circumsporozoite protein (Doolan et al., 1996; 
Leitner et al., 1997), Schistosoma japonicum (Yang et al., 1995) and Leishmania 
major gp63 (Xu & Liew, 1995).
48
1.7.2 Vaccination as cancer immunotherapy
Unlike most vaccines for infectious agents, cancer vaccination is therapeutic, 
involving attempts to activate immune responses against antigens of the tumour to 
which the immune system has already been exposed and tolerance may have been 
developed. Tumours are essentially self but over expression of self or modified self­
protein, eg novel fusion proteins encoded by a fusion gene antigen, may provide a 
target which can be exploited in tumour vaccine design. To the immune system these 
antigens are very close to self. For cancer immunotherapy to be effective firstly the 
tumour mass must be reduced by classic chemo/radiotherapy or modem drugs eg 
Glivec (tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia 
(CML)) or Rituximab (monoclonal anti-CD20 for the treatment of B-cell lymphomas). 
The power of the immune system can then be harnessed as a means to control minimal 
residual disease (MRD). One of the major challenges of cancer immunotherapy has 
remained the identification of suitable targets unique to the cancer cell, but with 
adequate antigenicity to elicit a clinically relevant immune response. The tumour 
target and its expression in tissues other than the tumour is therefore of primary 
importance for immunotherapy, together with an efficient method of delivering the 
antigen. Over the last two decades with the steep increase in the knowledge about the 
biology of malignant cells the list of candidate tumour antigens has increased 
exponentially. Serum antibodies in patients have also been used to identify potential 
tumour antigens by serological identification of antigens by recombinant expression 
(SEREX) profiling (Preuss et al., 2002). With the completion of the human genome
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project (Lander et al., 2001) sequencing and gene-expression profiling of malignant 
cell populations has provided additional targets.
Studies using autologous tumours, such as the murine CT26 colon carcinoma model in 
Balb/c mice (Fearon & Vogelstein, 1990) or the C57BL/6 derived murine B16-F10 
melanoma (Pardoll, 1995) have been used to induce tumour specific immune 
responses in mice. At around the same time DNA vaccination began to incorporate 
cytokines into vaccine vectors to improve antigen specific immunity, groups working 
in cancer immunotherapy began to use cytokines to enhance the immunogenicity of 
autologous tumours in vivo. Up until this point cancer vaccines consisted of killed 
tumour cells or lysates administered with Bacillus Calmette-Guerin (BCG) or similar 
adjuvants (Berd et al., 1990). Tumours transduced with vectors expressing different 
cytokines produced a distinct profile of inflammatory reaction and immune cell 
involvement. For example, administration of IL-2 expressing tumours produces an 
inflammatory infiltrate of mainly CD4+ and CD8+ lymphocytes whilst IL-4 expressing 
tumours produce an inflammatory reaction consisting mainly of macrophages and 
eosinophils (Pardoll, 1995). Experimental work in human transfer experiments has 
shown that the A20 B cell lymphoma engineered to express costimulatory molecules 
CD80, CD86 and CD137L (4-1BBL), a TNF family protein expressed on activated T 
cells (Goodwin et al., 1993), can confer long lasting tumour immunity against 
challenge with parental tumour (Guinn et al., 1999).
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1.7.2.1 DNA vaccines in cancer immunotherapy
Carcinoembryonic antigen (CEA), a membrane glycoprotein, is normally expressed 
only by human colorectal, gastric, pancreatic, breast, and non-small cell lung 
carcinomas (Kantor et al., 1992), making it an excellent target for immunotherapy. 
Studies using DNA vaccines encoding CEA, in a CEA-transgenic mouse model have 
been used to prevent Lewis lung carcinoma (Niethammer et al., 2001) and co­
delivered with trimeric CD 154 (CD40L) to protect against murine colon carcinoma 
(Xiang et al., 2001). Co-delivery of CEA with Hepatitis B surface antigen (HBsAg) 
in a human clinical trial with metastatic colorectal carcinoma patients showed 
lymphoproliferative responses to CEA (Conry et al., 2002). Recombinant CEA 
expressing vaccinia virus has also been used to induce cell mediated immunity and 
specific antibodies, which protect (in the murine model) from challenge with murine 
colon adenocarcinoma expressing human CEA (Kantor et al., 1992).
By far some of the most successful antigen targets used in immunotherapy are those 
found in melanoma. Of the 14 cancer vaccines in phase 3 clinical trials (Reichert & 
Paquette, 2002) 6 are against melanoma, one of which is a DNA vaccine (Allovectin- 
7, VICAL). The melanoma antigens are attractive targets because their expression is 
restricted to skin melanocytes. Those used for vaccination are melanocyte 
differentiation antigens MART-1, MAGE, MelanA, tyrosinase, tyrosinase-related 
peptide -1, and gplOO. However vaccination with these antigens also illustrates the 
paradigm of cancer immunotherapy, since they also induce autoimmune vitiligo 
(Rosenberg & White, 1996; Steitz et al., 2002) due to the anti-tumour response also 
targeting normal healthy melanocytes.
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1.7.2.2 Vaccines as therapy for lymphoma
Another immunogenic tumour specific target is idiotype (Slater et al., 1955; Lynch et 
al., 1972). In B cell lymphomas and myelomas, the idiotypic determinants of the Ig are 
clonal and unique, thus serving as a marker for the malignant B cell clone (Stevenson 
& Stevenson, 1975). It has long been established that anti-idiotype responses can be 
induced after vaccination with idiotype, first described in animals immunised with 
myeloma proteins (Lynch et al., 1972). This led to immunisation of mice with purified 
protein from the tumour itself (Stevenson & Gordon, 1983), an approach which is still 
being assessed experimentally for lymphoma and multiple myeloma using IL-2 and 
GM-CSF as adjuvant (Stritzke et al., 2003). Later, vaccination with idiotype in the 
form of the 38C13 murine lymphoma conjugated to an immunogenic carrier such as 
keyhole limpet haemocyanin (KLH) was shown to protect from tumour challenge in 
the murine model (George et al., 1987; Kaminski et al., 1987; George et al., 1988). In 
patients with B cell lymphoma Ig protein prepared from the patients tumour by 
heterohybridoma fusion was used to induce anti-idiotypic responses. Idiotype, either 
alone (Hsu et al., 1997), chemically linked to KLH (Kwak et al., 1992) or 
administered with recombinant GM-CSF (Bendandi et al., 1999) have been evaluated 
in patients with FL. All strategies induced anti-idiotype with the latter inducing 
molecular remission in 8/11 patients (Bendandi et al., 1999). Idiotype conjugated to 
KLH or idiotype alone have also been used to pulse DCs, which were subsequently 
used as a vaccine again using the 38C13 model in mice (Hsu et al., 1996; Timmerman 
et al., 2001). These approaches demonstrated some limited success, however the 
idiotype target for each patient is unique and therefore requires the laborious and time 
consuming production of patient specific idiotype protein.
The advent of DNA vaccines made the production of patient specific idiotype vaccines 
more feasible. DNA vaccines can be constructed to express patient specific idiotype 
relatively easily and as described can readily incorporate adjuvants to boost 
immunogenicity. Fusion with fragment C (FrC) of tetanus toxoid has produced 
effective protection from challenge against the A31 B cell splenic lymphoma and 
5T33 in vitro myeloma cell line, in mice (King et al., 1998), demonstrating the 
effectiveness of using both idiotype as target, and FrC as an adjuvant to provide T cell 
help in DNA vaccination. The mechanism of tumour protection after DNA vaccination 
with idiotype has been shown to be antibody mediated and is largely accepted to be 
via antibody-dependant cell cytotoxicity (ADCC) (Syrengelas & Levy, 1999). More 
recently effective anti-tumour responses have been achieved following immunisation 
of mice with an idiotype bearing A20 tumour transduced with adenoviruses encoding 
CD 154 (Briones et al., 2002) and with adenovirus encoding idiotype fused to mouse 
kappa constant domains (Timmerman et al., 2001).
1.7.3 Clinical trials of DNA vaccines in FL
The first clinical trial using DNA vaccines encoding the patients idiotype as a 
treatment for FL was performed by the Cambridge and Southampton teams in 1997 
(Hawkins et al., 1997). The primary objective of the phase I trial CRC no. 92/33, 
protocol number PH1/027 was to establish the safety of the intramuscular delivery of 
plasmid DNA in idiotypic vaccination. The follow up to this trial was a phase I/II trial 
CRC no. 98/04, protocol number PH2/039, using the DNA plasmid, encoding idiotype 
fused to fragment C of tetanus toxoid (pVAC2) (King et al., 1998). The trial was a 
dose escalation study designed to evaluate the clinical efficacy of the plasmid pVAC2
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in eliciting an anti-id response in FL patients in first remission. The trial differed from 
phase I in two ways. Firstly, the plasmid pVAC2 versus the adjuvant free pVACl and 
secondly the disease state, first remission versus end stage. The preparation of the 
vaccines, their evaluation in the rabbit model and the assessment of the anti-idiotype 
and anti-tetanus response in FL patients are presented in chapters 3 and 4 of this thesis. 
A similar approach was attempted in FL patients by immunising with a DNA vaccine 
encoding patient derived VH/VL domains and mouse constant domains (Timmerman 
et al., 2002). The majority of patients displayed an immune response against the 
mouse immunoglobulin, however specific responses against idiotype were low, with 
only one patient displaying T-cell proliferation against idiotype.
As with infectious diseases, clinical trials of idiotype based DNA vaccines have been 
clinically less effective as in the murine models of B cell lymphoma. It is of interest to 
note that despite the extensive research in DNA vaccination not many of the clinical 
trials have made it into phase III. In fact, during the phase I/II clinical trial described in 
this thesis evidence that DNA vaccination alone was not sufficient to induce the 
necessary immune responses was reported (Hanke et al., 1998). The next phase of 
genetic vaccines is well underway combining a DNA vaccine prime immunisation, 
followed by a powerful boost immunisation delivered by a recombinant viral vector, 
eg modified vaccinia ankara (MVA) (prime-boost). Phase I/II clinical trials for malaria 
(McConkey et al., 2003; Moorthy et al., 2003) and HIV (Mwau et al., 2004; Cebere et 
al., 2005) have produced promising results. However, the first generation T cell- 
inducing DNA/MVA against a multiple epitope Plasmodium falciparum vaccine was 
ineffective at reducing the natural infection rate in semi-immune African adults 
(Moorthy et al., 2004a; Moorthy et al., 2004b). A prime-boost vaccine has been
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developed against tuberculosis (TB) and is currently entering into a phase III trial 
(personal communication with Prof Adrian Hill).
Despite the promise of prime-boost as an effective vaccination strategy it would not be 
a suitable approach as a therapeutic for FL. Each idiotype vaccine is patient specific 
and the time required to produce individual MVA makes it unviable.
1.8 Aims
A phase IMI clinical trial using DNA vaccination as a treatment for Follicular 
Lymphoma provides the central theme for my research. In the following chapters I 
will describe the modification of an Invitrogen plasmid to produce Calmodulin tagged 
recombinant scFv in Drosophila S2 cells, the production and sterility and quality 
testing of clinical grade DNA vaccines and the subsequent antibody responses 
generated in Dutch rabbits and patients post vaccination.
The final chapter, describes a single case report, bringing together all the techniques 
previously described in order to provide a set of reagents to molecularly support the 
hypothesis that a patients’ low-grade FL was responsible for their life threatening 
thrombocytopenia.
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Chapter 2 -  Materials and Methods
2.1 Materials
2.1.1 List of Equipment
The following laboratory equipment were routinely used for this work
AIC Alpha Imager 2000 gel documentation system 
ALC PK131 and 131R bench-top centrifuges 
Applied Biosystems 3100 Genetic Analyser system 
Beckman Avanti J-25I centrifuge 
Biometra Trio thermoblock 
Biorad Miniprotean III (PAGE gels)
Cambridge Electrophoresis EM100 minigel tank (DNA gels)
Dynex MRX 5000 microtitre plate reader
Equibio Easyject plus electroporator
FT Applikon ADI 1030 Bioconsole Fermentor
Grant controlled temperature water bath
Kikusui PMC350-0.2A power supply
Millipore Miliblot System
MSE Micro Centaur microcentrifuge
New Brunswick controlled temperature shaker/incubator
56
P-l peristaltic pump, Amersham Biosciences 
PROline microchef ST44 microwave 
Shimadzu UV mini 1240 UV-Vis spectrophotometer 
Techne DB-2A Dri-block
2.1.2 Reagents
Analytical grade reagents were supplied primarily by either Sigma (Poole, UK) or 
BDH (Poole, UK). Details of suppliers of other reagents are listed below
Applied Biosystems (ABI) Warrington, UK
Aldevron ND, USA
Alexis Biochemicals Nottingham, UK
Ambion Huntingdon, UK
Amersham Pharmacia Bucks, UK
Beckman Coulter High Wycombe, UK
Biorad CA, USA
Becton Dickinson (Pharmingen) Oxford, UK
Boehringer Mannheim Mannheim, Germany
Coming High Wycombe, UK
HT Biotechnology Cambridge, UK
Invitrogen Grogingen, NL
Jackson Immunoresearch Luton, UK
JRH Biosciences KS, USA
Gibco-BRL Paisely, UK
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Medicell international
NBS Biologicals
New England Biolabs (NEB)
National Blood service (NBS)
NIBSC
Pierce
Promega
Qiagen
R&D Systems
Roche
Sigma-Genosys
Stratagene
VWR International
London, UK 
Huntingdon, UK 
Hitchin, UK 
Bristol, UK 
Herts, UK 
Cheshire, UK 
Southampton, UK 
Dorking, UK 
Abingdon, UK 
IN, USA 
Cambridge, UK 
Cambridge, UK 
Poole, UK
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2.1.2.1 pVAC2-scFv constructs
The patients for the clinical trial were enrolled by three centres. Royal Bournemouth 
Hospital, Bournemouth (B), Christie Hospital, Manchester (M) and Southampton 
General, Southampton (S).
STUDY No. Heavy Chain Closest
Germline
Light Chain Closest
Germline
B01 V h4 /  Jn4b V4-59 Vx7 /J x2 14-7
B02 V h3 / Jn4a PI V k4 / J k 1 DPK24
B03 VH3 /J H6b V3-48 V k I / Jk I A30
B04 VH3 /J H3a V3-48 V k3 / Jk I DPK 221 A l l
B05 VH3 /J H6b V3-23 V k I / Jk4 A30
M01 V h4 /  JH5a V4-39 V k4  / Jk I DPK 24
M02 V h4 /  J ^ b V4-39 V k I / Jk5 DPK 8
M03 VH3 /J H6b V3-23 Vx2 /J x2/3a DPL11
M04 V Hl/J H 4 a V I-02 V k I / Jk3 DPK 1
M05 VH1/J«4b V I-02 Vxl / J x2/3a DPL 8
M06 VH3 /J H5b V3-23 V k4 / J k4 DPK 24
M08 V h3 / Jn4a V3-15 V„2/Jx2/Jx3a 2C.118D9/V1-2
SOI V h4 / J h2 V4-34 V k3 / J k2 DPK 22
S02 VH3/Jn4b V3-21 Vxl /J ,2 DPL 2
S03 V h3 / J h6 c V3-11 V k3 / J k4 V k3
S04 V h3 / Jn4b V3-21 V k3 / J k4 Vg 38K
S05 V h3 / Jn4a V3-48 V k I /  Jk5 DPK 9
S06 V h3 / Jn4b V3-30 V k I / Jk2 DPK 9
S07 V h3 / Jn4b V3-48 V k I / Jk2 DPK 9
S09 V h3 / J h3 V3-48 V k I /  Jk I DPK 9
soil V h4 / J h1 V4-34 V k4 / J k2 DPK 24
S012 V h2  / JH5b V2-05 V k I /  Jk I HK 102
SOB V h3 / Jn4b V3-48 V k 3 / Jk I DPK 221 A l l
S017 VH3 /J H3b V3-23 Vx2 /J ,2 DPL 11
S018 VH3 /J H6b V3-15 V k I / Jk4 A30/SG3
Table 2.1 Closest germlines of patient scFvs. The closest germline sequences from the 
isolated patient VH and VL genes were identified. The scFvs were constructed and 
supplied in pVAC2 from the centres in Bournemouth, Southampton and Manchester.
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2.1.3 Commonly used buffers
PBS
TBS
TBE
Borate coating buffer 
SDS PAGE buffer (5x stock)
Transblot buffer
Coomassie blue stain
Destain
Immobilised Metal chelate 
Affinity Chromatography (IMAC) 
buffer (5x stock)
DNA/RNA agarose gel loading 
bufffer
2 x laemelli loading dye
125 mM NaCl, 25 mM NaH2P04 (pH 7.0).
150 mM NaCl, 50 mM Tris-HCl (pH 7.4).
0.09 M Tris, 0.09 M borate, 2 mM EDTA 
(pH 8.0).
1 M Boric acid pH to 8.3 with NaOH.
25 mM Trizma base, 250 mM glycine, 0.1% 
SDS.
39 mM glycine, 48 mM Trizma Base,
0.037% SDS, 20% methanol.
0.25 g Coomassie brilliant blue, 10% glacial 
acetic acid, 10% iso-propanol in dH20.
20% methanol, 10% glacial acetic acid in dH20. 
0.25 M Na2HP04, 0.25 M NaH2PO4.H20,
2.5 M NaCl, pH to 7.5 with orthophosphoric 
acid.
0.25% bromophenol blue, 0.25% xylene 
cyanol FF, 30% glycerol.
10% glycerol, 0.1% bromophenol blue, 2% SDS 
in 50 mM Tris. For reducing conditions add 10% 
P-mercaptoethanol.
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2.1.4 Media for bacterial culture
Bacterial growth media 2xTY and all culture plates were routinely supplied by the 
Laboratory of Molecular Biology central facility. Bacteria transformed with antibiotic 
resistant plasmids were grown on plates and in culture with 100//g/ml.
2.1.5 Bacterial Strains
Genotypes of the bacterial strains used this work are summarised below.
TOPIO : F mcrAA(mrr-hsdRMS-mcrBC)O801acZM15 AlacX74 deoR recAl 
araD139 A(ara-leu)7697 galU galK rpsL endAl nupG 
DH5a : F  <D80dlacZAM15 A(lacZYA-argF)U169 deoR recAl endAl hsdR17 
(rk', mk+) phoA supW447.'thi-l gyrA96 relAl
2.1.6 Plasmids
The DNA vaccination vector pVAC2 was constructed in the Department of 
Haematology, University of Cambridge by Dr Ian Harmer. Based on pcDNA3 
(Invitrogen), pVAC2 (Appendix D3) contains the gene for fragment C (FrC) of tetanus 
toxoid (TT). The multiple cloning site (MCS) was designed to be compatible with the 
phage display plasmid pHenIX and the E. Coli expression plasmid pUC119-His used 
in this laboratory. Antigen was cloned as an Sfil / Notl fragment, the restriction sites 
Sfil, Ncol (5’) and Not I (3’) were routinely appended to the antigen genes by PCR.
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2.2 Methods
2.2.1 Molecular Biology
2.2.1.1 RNA Extraction
For RNA extraction from a bone marrow biopsy approximately lxlO7 cells were 
homogenized in TRIzol (Invitrogen, NL). The homogenate was incubated at room 
temperature (RT) for 5 min. 0.2 ml of chloroform was added per 1 ml homogenate.
The sample was shaken vigorously for 15 sec, and incubated at RT for 2-3 min. 
Subsequently the homogenate was centrifuged at 13000 g for 15 min at 4°C. The 
upper aqueous phase, containing the RNA, was transferred to a fresh tube and 0.5 ml 
of isopropanol was added. The samples were incubated at RT for 5-10 min before 
centrifugation at 13000 g for 10 min at 4°C. The pellet was washed by vortex 
resuspension in 1 ml of 75% ethanol. Subsequently the RNA was centrifuged at 7500 
g for 5 min at 4°C. The pellet was air dried in a laminar flow hood before resuspension 
in diethyl-pyrocarbonate (DEPC) treated water. To allow for complete resuspension 
the sample was heated to 55°C for 10 min before being quantified (Chpt 2.2.1.2). The 
integrity of the ribosomal RNA was checked by agarose gel electrophoresis (Chpt
2.2.1.3). For long-term storage the RNA was maintained at 
-70°C without significant degradation.
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2.2.1.2 Nucleic Acid Quantification
RNA and DNA were quantified by spectrophotometry at wavelengths of 260 and 280 
nm. An optical density (OD) of 1.0 corresponds to approximately 40 pig/ml of RNA, 
50 jig/ml of double stranded DNA and 20 ng/m\ of single stranded DNA. Therefore 
the concentration of nucleic acids can be calculated with the following equations:
RNA //g/ml = OD260 x 40 x dilution factor 
dsDNA piglml = OD260 x 50 x dilution factor
The 260/280 ratio for both RNA and DNA provides an estimate of the purity of the 
sample. A pure sample, without contaminants such as phenol or protein, gives a ratio 
between 1.7 and 2.0, where 2.0 is the most pure. At ratios lower than 1.6 accurate 
quantification of nucleic acid is not possible.
2.2.1.3 Agarose Gel Electrophoresis
Molecules of linear double stranded DNA migrate through gel matrices at rates that 
are inversely proportional to the log10 of the number of base pairs (Helling et al.,
1974). The amount of agarose in the gel (% [w/v]) was determined based on the size 
of the DNA in base pairs; larger molecules need less agarose to separate efficiently. A 
0.9% agarose gel has an efficient range of separation of linear DNA molecules of 0.5- 
7 kb. The appropriate amount of agarose (High pure low EEO agarose, Cambridge 
UK) was dissolved in 50 ml TBE (Chpt 2.1.3) by heating. The agarose was cooled and
2 ]A of the intercalating dye ethidium bromide (1%) was added, in order to visualise 
DNA under ultraviolet light. Gels were cast in 10 cm2 Cambridge Electrophoresis 
(model EM 100) apparatus. Samples were mixed with 2 jA of gel-loading buffer (Chpt
2.1.3) to increase the density of the sample and add colour for ease of loading. 1 ]A of 
1Kb DNA markers (NEB) were also run for approximate size calculation. The gel was 
run at approximately 60 volts, 5 volts/cm (measured as the distance between 
electrodes).
2.2.1.4 DNA purification from agarose gels
The DNA was excised from a 1% agarose gel using a sterile scalpel under UV light. 
The gel slice was treated following the Qiagen protocol for QLAquick gel extraction. 
Briefly the gel slice was weighed and 3 volumes of Qiagen Buffer QG (Appendix C) 
was added and incubated at 50°C for 10 min until the agarose had dissolved. 1 volume 
of isopropanol was added and the DNA solution added to a QLAquick spin column and 
centrifuged at 13000 rpm for 1 min. The column was then washed with 0.75 ml of 
Buffer PE and centrifuged as before, the flow through was discarded and the column 
re-centrifuged as before to remove all traces of ethanol. To elute the DNA 30 pi of 
water was added to the column and incubated at RT for 1 min, followed by 
centrifugation as before.
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2.2.1.5 Preparation of cDNA
Complementary DNA (cDNA) was prepared from total RNA, extracted as in Chpt 
2.2.1.1, using oligo dT (Promega) in a 50 jA reaction. 5 jig of total RNA was diluted to 
a final volume of 9.5 ji\ in DEPC treated water. At this stage if required RNA can be 
DNAse treated to remove contaminating DNA by the addition of 1 jA of RNAse free 
DNAse (HT Biotechnology) and incubation at 37°C for 10 min, followed by heat 
inactivation at 75°C for 5 min. 2 jA of oligo dT 10 pM//d (Promega) was added to the 
treated RNA and the sample incubated at 65°C for 5 min, to anneal the oligo dT to the 
polyA region of the RNA target, before cooling to RT. Following this incubation, lx 
Reverse Transcriptase (RTase) buffer, 20 mM each of dATP, dTTP, dCTP and dGTP, 
50 U of super RT (HT Biotechnology) and 50 U RNAsin (Promega) were added and 
incubated at 37°C for 1 hour. The synthesis was stopped by heating the reaction 
mixture to 94°C for 3 min. This produced a double stranded RNA/DNA hybrid for use 
in PCR.
2.2.1.6 Standard Polymerase Chain Reaction (PCR)
PCR reactions were routinely set up in 50 jA reaction volumes. Each reaction included 
lx polymerase buffer, 2 mM magnesium chloride and 0.5 mM each dNTP, 10 pmole 
of each primer, 5 U of DNA polymerase, and required DNA target made up to a final 
volume with Millipore water. Reactions were cycled on a thermal block 94°C 5 min, 
followed by 30 cycles of 94°C for 1 min (denaturation), x°C for 1 min (annealing) and 
72°C for 1 min 30 sec (extension) and a final 5 min extension at 72°C; where x is the
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lowest theoretical annealing temperature of the primers used. PCR products were 
routinely cloned into pCR2.1 (Chpt 2.2.1.7).
2.2.1.6.1 Addition of deoxyadenosine to the 3’ ends of PCR products
In a 30 fxl reaction volume, 23 \x\ of PCR product was added to 25 mM MgCl2, 5 mM 
dNTPs, 10 x Taq reaction buffer and 1U Taq DNA polymerase and incubated at 72°C 
for 10 min, the product was used immediately for TA cloning (Chpt 2.2.1.7).
2.2.1.7 TA Cloning (Invitrogen)
PCR fragments were cloned into the plasmid pCR2.1 (Appendix D4) for replication in 
bacteria and subsequent manipulation, using the TA cloning kit (Invitrogen), following 
the manufacturers protocol. If a proofreading polymerase had been used for PCR, 
adenosine was first added to the 3’ ends of the product (Chpt 2.2.1.6.1).
PCR products were ligated into 50 ng pCR2.1 TA vector according to the equation 
below:
size of insert (bp) ^ am0unt of vector (ng) = amount of insert (ng) 
size of vector (bp)
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2.2.1.7.1 DNA Ligation Reaction
The required amount (vector:insert ratios of 1:1 and 1:3) of PCR product or DNA was 
ligated into the appropriate plasmid. Briefly 400 U of T4 DNA ligase (NEB), lx T4 
DNA ligase buffer, approximate amounts of cut vector (approx 50 ng) and insert (Chpt 
2.2.1.7) were mixed with water to a final volume of 10 jA and incubated overnight 
(O/N) at 14°C. Controls were set up using vector only and vector/enzyme ligations to 
assess digestion efficiency and background religation of the plasmid.
2.2.1.8 Preparation of Electrocompetent Bacteria
Bacterial colonies (TOPIO) were maintained on minimal agar plates with no antibiotic. 
A single colony was picked into 10 ml of 2xTY in a 50 ml tube and grown O/N (16-20 
hrs) at 37°C with shaking (225 rpm). Subsequently two sterile 2 L conical flasks each 
containing 500 ml 2xTY were inoculated with 5 ml of the overnight culture and grown 
at 37°C with shaking to an OD at 600 nm of 0.5-0.6 (approx. 2-3 hrs). The cultures 
were chilled on ice for 30 min and then centrifuged at 3700 g for 20 min (Beckman 
Avanti J25-I) at 4°C. All subsequent steps were performed at 4°C. Supernatants were 
decanted and the cell pellet from each flask resuspended in 500 ml of cold 1 mM 
HEPES (Sigma). After centrifugation as above the pellets were pooled and 
resuspended in a total of 500 ml 1 mM HEPES. The pooled sample was centrifuged 
and resuspended in 20 ml of 10% glycerol/1 mM HEPES and transferred to a 50 ml 
tube before further centrifugation at 4100 rpm for 20 min (ALC PK131R) at 4°C.
67
Finally, the pellet was resuspended in 10% glycerol, and aliquoted into pre-chilled 
(dry ice) 1.5 ml Eppendoifs. Aliquots were stored at -70°C until required.
2.2.1.9 Transformation of Electrocompetent Bacteria
0.5-1 ]A of ligation reaction or plasmid DNA was used to transform a 50 jA aliquot of 
previously prepared electrocompetent bacteria. DNA and bacteria were mixed in a pre­
chilled 1.5 ml Eppendorf (wet ice) and subsequently transferred to a 0.2 //m 
electroporation cuvette (Equibio) on ice. Electroporation settings for bacterial 
electroporation were 2500 volts, 25 piF, and 201 Q using an Easyject plus 
electroporator (Equibio). Transformations were repeated if time constants were below 
4.0 msec. Following electroporation the bacteria was transferred from the cuvette into 
a sterile 15 ml snap top tube with 1 ml of 2xTY. This culture was incubated at 37°C 
with shaking for lhr and subsequently 50-200 jA was plated onto 2xTY plates with the 
appropriate antibiotic selection. The plates were incubated overnight in a 37°C 
incubator.
2.2.1.10 Glycerol Stocks
A 3 ml culture (2xTY and appropriate antibiotic) was inoculated with a single 
bacterial colony, and grown O/N at 37°C with shaking. 700 jA of the culture was 
aliquoted into pre-labelled 1.5 ml Eppendorf tubes containing 300 jA of sterile 50% 
glycerol. The solution was mixed and snap frozen on dry ice before transferring to a 
-70°C freezer.
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2.2.1.11 PCR Screening of bacterial colonies
10 to 20 bacterial colonies were routinely screened for gene insertion into the vector 
backbone. The PCR reaction was performed in 10 ]A reaction volumes, for 10 
reactions a stock of PCR reaction mix was prepared as follows:
10 jA 10 x PCR buffer 
10 jA dNTP mix (5mM each)
1 jA forward primer (10//M)
1 jA reverse primer (10//M)
10 jA MgCl2 (25 mM)
1 jA Taq polymerase (Promega)
Water to 100 j41
A single colony was picked from a 2xTY plate using a 1 ]A inoculating loop (NUNC) 
into a 10 ]A aliquot of reaction mix followed by streaking onto a fresh 2xTY plate. 
PCR reactions were cycled on a thermal block, 95°C 1 min, 45°C 1 min, and 72°C 1 
min for 30 cycles. 4 }A of each reaction was run on an agarose gel (Chpt 2.2.1.3). The 
2xTY plates were incubated O/N at 37°C.
2.2.1.12 Preparation/purification of plasmid DNA
A single colony from an O/N 2xTY plate was used to inoculate 2xTY. The liquid 
cultures were grown O/N at 37°C with shaking.
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The plasmid DNA was isolated from the bacteria using Qiagen column anion 
exchange resin following manufacturers instructions.
A Qiagen Miniprep kit (yielding up to 20 pig plasmid DNA) was routinely used to 
prepare DNA for cloning. For larger amounts of DNA either a Qiagen Midiprep 
(yielding up to 100 pig of plasmid DNA) or Qiagen Mega/Gigaprep (yielding up to 
2.5/10 mg of plasmid DNA) was used. Composition of buffers can be found in 
Appendix C.
2.2.1.13 Ethanol precipitation
To the resuspended DNA three volumes of 70% ethanol (-20°C) and 3 M sodium 
acetate pH 5.2 to a final concentration of 0.3 M was added, mixed vigourously and 
incubated at -20°C for a minimum of 2 hours. The DNA was centrifuged at 10000 rpm 
for 15 min and the pellet washed with 70% ethanol and centrifuged as before. The 
DNA pellet was air dried at RT for 5-10 min. The DNA can then be resuspended in the 
appropriate volume of water or sterile saline.
2.2.1.14 DNA Sequencing
Sequencing reactions were set up with big Dye terminator v l.l cycle sequencing kit 
(Applied Biosystems). Reactions were set up in 10 pi\ reaction volumes. Each reaction 
included 2 pi\ of pre-mix (containing polymerase and dNTP flurochromes), lx 
sequencing buffer, 0.16 pmol primer and 100 ng of plasmid DNA or 10 ng of PCR 
product. Reactions were cycled on a thermal block for 25 cycles of 96°C 10 sec, 48°C,
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5 sec, 60°C, 4 min. Samples were precipitated by vigorous mixing of the reaction with 
1 ji\ of 3 M sodium acetate pH 5.2 in a 1.5 ml Eppendorf tube, before the addition of 
25 ]A of 100% ethanol and incubation at RT for 15 min. The precipitated DNA was 
harvested by centrifugation at 15000 g for 20 min and the pellet was then washed with 
0.2 ml of 70% ethanol and air dried for approx. 10 min. Pellets were resuspended in 10 
\A of HiDi formamide (Applied Biosystems) and transferred to a 96 well plate 
(Applied Biosystems). All sequencing was undertaken in the Division of Transfusion 
Medicine on a 3100 ABI prism genetic analyzer following manufacturers instructions.
2.2.1.15 Restriction Enzyme Digest
Restriction digests were routinely performed at the temperature recommended by the 
supplier for 1.5-4 hours. To an appropriate amount of DNA in water, l/10th of the 
volume of the recommended buffer and l/10th volume of enzyme were added. For 
double digests the total amount of enzyme did not exceed l/10th of the final volume to 
avoid non-specific activity. Following digestion fragments were visualised on a 1% 
agarose gel. Appropriate fragments were purified using Qiagen Qiaquick gel 
extraction kit (Chpt 2.2.1.4).
2.2.1.16 Filling of 5’ overhangs (Polymerase reaction)
To an appropriate amount of DNA with restriction enzyme cut overhangs, 3 U T4 
DNA polymerase (NEB), 1 x T4 DNA polymerase buffer, and a final concentration of 
1.25 mM dNTP’s was added and made up to a final volume of 50 y\ with water. The
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reaction was incubated at 37°C for 30-60 min. Samples were heat inactivated at 75°C 
for 10 min.
2.2.1.17 Site Directed Mutagenesis
Mutagenesis was performed using the QuikChange XL site-directed mutagenesis kit 
(Stratagene). Oligos were designed to anneal to the same sequence on opposite strands 
of the plasmid and incorporate the desired mutation. Oligos were between 25 and 45 
nucleotides long with a melting temperature of ^ 78°C. PCR was performed to amplify 
the entire plasmid using 10 ng template in pMT/BiP/CaM, lx reaction buffer, 125 ng 
of each oligo, 1 pi dNTP mix, 3 pi Quik solution and 1 pi PfuTurbo DNA polymerase 
in a 50 pi reaction. Reactions were cycled on a thermal block 95°C 1 min, followed by 
18 cycles of 95°C for 50 sec (denaturation), 60°C for 50 sec (annealing) and 68°C for 
1 min/kb of plasmid length (extension) and a final 7 min extension at 68°C. 1 pi of 
Dpnl was added to the reactions and incubated at 37°C for 1 hour to digest the 
parental DNA. 1 pi of the digested template was used to transform electrocompetent 
TOP10 bacteria (Chpt 2.2.1.9). Minipreps (Chpt 2.2.1.12) were made from the 
resulting colonies and sequenced (Chpt 2.2.1.14) to confirm nucleotide substitution.
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Restriction
Endonuclease
Restriction Site NEB reaction 
buffer
Reaction 
Temperature (°C)
ApaL I GTGCAC
CACGTG
NEBuffer 4 37
Bglll AGATCT
TCTAGA
NEBuffer3 37
Dpnl
(methylated DNA only)
GATC
CTAG
NEBuffer 4 37
Hind III AAGCTT
TTCGAA
NEBuffer 2 37
Nco I CCATGG
GGTACC
NEBuffer 4 37
Not I GCGGCCGC
CGCCGGCG
NEBuffer 3 37
SacI GAGCTC
CTCGAG
NEBuffer 1 37
Sail GTCGAC
CAGCTG
NEBuffer 3 37
Sfil GGCCNNNNNGGCC
CCGGNNNNNCCGG
NEBuffer 2 5 0
Xho I CTCGAG
GAGCTC
NEBuffer 2 37
Table 2.2 Commonly used restriction endonucleases. The DNA recognition sequence 
for each enzyme is shown with red type distinguishing the overhangs generated. N is 
any base. The optimum reaction buffers and temperatures are shown for each enzyme.
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2.2.2 Recombinant Protein Expression
2.2.2.1 Maintenance of Schneider 2 (S2) cell line
S2 cells were maintained in Schneiders Drosophila medium (Gibco), supplemented 
with 10% heat inactivated Foetal Bovine Serum (FBS) (Gibco) at 26°C (complete 
media). Cells were cultured in sterile conditions.
2.2.2.2 Calcium Phosphate Transfection of S2 cells
On the day of transfection 3xl06 S2 cells were seeded in 3 ml of complete media into 
each well of a 6 well plate (Costar), and incubated at 26°C for approx. 9 hours until 
they reached a density of 2xl06/ml. Plasmid DNA was prepared using Qiagen 
midiprep kit and resuspended in Millipore water to approx 2 pgIpi. For each 
transfection 2 tubes were prepared one with 300 pi of 2xHEPES buffered saline (HBS) 
and one with 19 pg DNA, 0.24 M calcium chloride, and tissue culture grade water to 
300 p\. Over a gentle vortex the DNA containing mixture was slowly titrated into the 
HBS, followed by incubation for 40 min at RT. The calcium phosphate DNA mixture, 
which should be cloudy in appearance, was slowly added drop wise to the cells, which 
were subsequently incubated overnight at 26°C. At 16-24 hour post-transfection the 
cells were washed three times with complete media and resuspended in 3 ml of fresh 
complete media. Expression was induced by the addition of copper sulphate to a final 
concentration of 500 pM; supernatants and cells were harvested 5-7 days post-
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induction. The cell pellet and supernatant were assayed for the presence of the protein 
by Western blot (Chpt 2.2.2.8.2).
2.2.2.3 Stable Transfection of S2 cells
Cells were treated as for transient transfection except 1 pig of pCoBlast vector 
(Invitrogen) was co-transfected with the cloned pMT plasmid. This vector confers 
resistance to Blasticidin. Stable cell lines were not induced but were incubated for a 
further 2 days and then selected for resistance to blasticidin by the addition of 25 
pig/m\ of Blasticidin for 2 weeks. During selection cells were washed every 5 days into 
3 ml of complete media with selection and replated into the same wells. After the 
selection period cells were split 1:2 into a new 6 well plate and half induced as before 
to check for expression of the protein. Once expression was confirmed cells were 
grown up for large-scale production in Ex-Cell 420 serum free media (JRH 
Biosciences, Kansas, USA). Cells were passaged in serum free media to a final density 
of 2-4xl06/ml; this process was repeated until a large volume was reached (usually 
approx. 200ml). Once the required volume was obtained the cells were incubated O/N 
at 26°C with shaking (100 rpm) and then protein expression was induced by the 
addition of 500 pM copper sulphate. Cells were grown for a further 5-7 days following 
which the supernatant was harvested, cleared by centrifugation at 18000 g for 20 min 
at 4°C and then passed through a 2 pim stericup filter (Millipore).
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2.2.2A Purification of Calmodulin tagged proteins expressed from S2 cells
To purify calmodulin tagged proteins NHS-activated HiTrap columns (Amersham 
Pharmacia Biotech) were prepared using N-(6-Aminohexyl)-5-chloro-l-naphthalene 
sulfonamide (W7) (Sigma)(Figure 2.1).
2.2.2.4.1 Preparation of W7 column
W7 resin is a chemical compound, which has been shown to bind specifically to the 
hydrophobic pocket of calmodulin, in the presence of calcium, via the naphthalene 
ring (Osawa et al., 1999).
NHCH2(CH2)4CH2NH2
o=s=o
Figure 2.1 -  Chemical structure of N-(6-Aminohexyl)-5-chloro-l-naphthalene 
sulfonamide (W7).
A 5 mM solution of W7 was prepared by dissolving 20 mg of W7 in 20 ml of 19:1 
ethanol: isopropanol mix. The W7 was allowed to dissolve overnight at RT before 
being mixed with an equal volume of 50 mM borate buffer pH 8.3-5 whilst vortexing 
to ensure complete mixing. This yielded a clear solution. A 1 ml NHS-activated 
HiTrap column was connected to a peristaltic pump and the storage buffer washed out 
using 10 ml freshly prepared 1 mM HC1 at a flow rate of 1 ml/min. 10 ml of W7/
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Borate solution was then recycled through the column for at least 3 hours (or O/N). 
The column was washed with 10 ml 70% ethanol and then blocked with equilibration 
buffer (0.5 M NaCl, 50 mM Tris, 1 mM CaCl2) at a flow rate of 1 ml/min for 30 min. 
Finally, 10 ml of elution buffer (0.15 M NaCl, 50 mM Tris, 10 mM EDTA) followed 
by 10 ml of equilibration buffer were passed over the column. Columns were stored 
closed at 4°C in elution buffer. Before use stored columns were re-equilibrated by 
washing out the elution buffer with 10 ml of equilibration buffer. All steps were 
performed at 4°C.
2.2.2.5 Preparation of supernatants and purification of CaM tagged proteins
Filtered supernatants were supplemented with NaCl, Tris and CaCl2 to final 
concentrations of 0.3 M, 50 mM, and 1 mM respectively. This supplemented 
supernatant was loaded onto a W7 column at a flow rate of 1 ml/min in approx 200 ml 
batches. The column was subsequently washed with 30 ml of equilibration buffer and 
the purified protein eluted in 1 ml fractions with elution buffer. The major peak of the 
protein was eluted in fractions 2-4. The column can be re-equilibrated with 
equilibration buffer or stored in elution buffer. Each eluted fraction was quantified by 
BCA assay (Chpt 2.2.2.10), and visualised by SDS-PAGE with subsequent Coomassie 
staining (Chpt 2.2.2.8.1).
2.2.2.6 Purification of Histidine tagged proteins expressed from S2 cells
Histidine tagged proteins were purified using HiTrap Nickel chelating columns 
(Amersham Pharmacia Biotech).
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2.2.2.6.1 Preparation of Nickel chelating column
For purification using HiTrap Nickel columns, a 1 ml chelating column was washed 
out with 5ml of distilled water, and 0.5 ml of 0.1 M Nickel sulphate was loaded at a 
flow rate of lml/min. The column was washed again with 5ml of water followed by 5 
ml of 250 mM Imidazole/IMAC (elution buffer) and 5 ml of 100 mM 
imidazole/IMAC (equilibration buffer).
2.2.2.6.2 Preparation of supernatants for purification
Supernatants containing histidine tagged proteins were dialysed into 1 x IMAC buffer 
(Chpt 2.1.3) with at least 3 changes at 4°C. The dialysed supernatant was 
supplemented with 500 mM imidazole/lx IMAC to a final concentration of 25 mM 
imidazole and filtered through a 2 pim stericup filter. Supernatants were applied to the 
column at a flow rate of 1 ml/min, which was then washed with 100 mM 
Imidazole/IMAC. Histidine tagged proteins were eluted in 1 ml fractions in 250 mM 
Imidazole/IMAC. 10 jA of each fraction was run on reducing SDS-PAGE gel and 
Coomassie stained (Chpt 2.2.2.8.1).
2.22.1 Preparation of conjugated calmodulin binding peptide (N9A)
N9A peptide (CAAARWKKAFTAYSAANRFKKIS) was synthesized by C. Graham 
Knight (Department of Biochemistry, University of Cambridge). The synthesised N9A 
peptide was conjugated to BSA (Bernatowicz & Matsueda, 1986) and peroxidase (Dr
Peter Smethurst). Polymerised, maleimide-activated peroxidase (HRP; Sigma) was 
used for the production of HRP-N9A following manufacturers instructions. SDS- 
PAGE analysis of molecular weight post-conjugation indicated that 2-6 N9A 
molecules were conjugated per BSA molecule. 1-4 N9A molecules per HRP polymer 
were estimated from molar ratio of peptide to polymer used.
2.2.2.8 SDS PAGE gels and immunoblotting
2.2.2.8.1 Preparation, running and staining of reducing SDS PAGE gels
SDS PAGE gels were prepared at the appropriate percentage for linear separation of 
proteins. 10% gels provide clear separation of proteins of 16-68 kDa, 12% proteins of 
12-43 kDa (Table 2.2). Gels were stored at 4°C.
SDS PAGE gels were prepared and run using the Protean III system (Biorad).
Gels were placed in the electrode of the Protean III apparatus and lx SDS PAGE 
running buffer (Chpt 2.1.3) poured into the interior and exterior chambers. Samples 
were diluted in an equal volume of 2x laemelli sample buffer (Chpt 2.1.3) and 
incubated at 99°C for 3 min before loading. SDS gels were run at 25 volts/cm for 
approx. lhour, or until the dye front reached the bottom. Gels were immunoblotted 
(Chpt 2.2.2.8.2) or stained with Coomassie blue (Chpt 2.1.3) followed by incubation 
with destain (Chpt 2.1.3) with shaking at RT.
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Component
Percentage of gel
5% stack 10% 12%
Sterile H20 3.7 1.9 1.6
30% acrylamide 0.5 1.7 2.0
1.5 MTris-HCl pH 8.8 na 1.3 1.3
1.0 MTris-HCl pH 6.8 0.62 na na
10% SDS 0.05 0.05 0.05
10% APS 0.05 0.05 0.05
TEMED 0.005 0.002 0.002
Table 2.3 Recipes for making SDS-PAGE gels. The components (ml) needed to make 
one 10% and 12% resolving gel and 5 ml of 5% stacking gel are listed.
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2.2.2.8.2 Western Blot
Western blotting was performed using a semi-dry transblot apparatus (Atto). Six-gel- 
sized pieces of 3 MM paper and one piece of nitrocellulose (Protran, Schleicher and 
Schuell, Dassel, USA) were soaked in transblot buffer for approx. 10 min prior to 
blotting. SDS gel and nitrocellulose were carefully sandwiched between the six pieces 
of 3 MM paper and placed on the transblotter with the nitrocellulose toward the 
positive electrode. The gel was blotted for approx. 75 min at 0.1 mA/cm2.
2.2.2.8.3 Detection of Calmodulin tagged proteins by Western blot
Following protein transfer to a nitrocellulose membrane, CaM tagged proteins were 
detected with HRP-N9A. Membranes were blocked for 1 hour in TBS containing 1% 
BSA, 0.1% Tween 20 and 1 mM CaCl2 (TBS-BC). Following blocking, the 
membranes were incubated for 20 min at RT with HRP- N9A (0.05 p-g/ml) diluted in 
TBS-BC. After extensive washing with TBS-BC, the binding of HRP-N9A was 
detected by enhanced chemiluminescence (ECL) (Chpt 2.2.2.9).
2.2.2.8.4 Detection of Histidine or V5 tagged proteins by Western blot
Following protein transfer to a nitrocellulose membrane, His tagged proteins were 
detected with mouse monoclonal IgG 2b anti-His HRP (Invitrogen) and the V5 epitope 
were detected with mouse monoclonal IgG 2b anti-V5 HRP (Invitrogen). Membranes 
were blocked for 15 min in PBS containing 2.5% casein and 0.05% Tween 20.
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Following blocking, the membranes were incubated for 90 min at RT with the mouse 
monoclonal HRP, 1:5000 dilution in PBS containing 0.05% Tween (PBS-Tw). After 
extensive washing with PBS-Tw, the binding of the HRP antibody was detected by 
enhanced chemiluminescence (ECL) (Chpt 2.2.2.9).
2.2.2.9 Enhanced Chemiluminescence (ECL)
Immunoblots probed with HRP conjugated antibodies were developed using ECL 
detection reagents (Amersham Pharmacia Biotech, UK). Blotted and probed 
nitrocellulose was washed with the appropriate buffer. After final washing an equal 
volume of reagents 1 and 2 were mixed (total volume of 3 ml/60 cm2), gently applied 
to the nitrocellulose and incubated for lmin at RT, no agitation. The ECL reagent was 
removed and the nitrocellulose dabbed with tissue to remove excess reagent. Finally 
the nitrocellulose was wrapped in Saran wrap, exposed to photographic film (Fuji 
medical X-ray film, Japan) for between 30 sec and 5 min and developed using a RP X- 
OMAT processor (model M6B).
2.2.2.10 Quantification of purified protein by BCA Assay
10 ]A samples of eluted column fractions or other recombinant proteins were assayed 
in triplicate in 96 well plates (NUNC) using a bicinchoninic acid (BCA) assay kit 
(Pierce). BSA (Bovine Serum Albumin) standards of 2, 1, 0.5,0.25, 0.125, 0.06 mg/ml 
were used. Elution buffer alone or sample diluent was used as a blank. BCA 
containing buffer was mixed with 4% cupric sulphate, 50 parts to 1, and 200 jA was
added to each well containing 10 jA of protein solution. The plate was incubated at 
37°C for 30 min. A purple colour developed in wells containing protein, and the 
optical density was measured at 562 nm. Protein concentration was determined from 
the BSA standard curve.
2.2.3 Production of Immune serum
2.2.3.1 Rabbit Immunisation by i.m. needle injection
Rabbits were immunised according to Home Office guidelines under a project license 
at the National Institute for Biological Standards and Control (Herts, UK). Dutch 
Rabbits were vaccinated with 200 pig of pVAC2-scFv plasmid DNA in sterile PBS 
injected into two sites in the quadriceps muscles, i.m. injections were given at days 0 , 
14 and 28. Bleeds were taken at days 0 and 35 to measure antibody responses.
2.2.3.2 Human Vaccination under LIFTT clinical trial
Patients with Follicular Lymphoma enrolled on the LIFTT clinical trial were 
immunised with their corresponding pVAC2-scFv. The vaccine was administered at 
weeks 0 , 1 , 2 ,4, 8  and 1 2 .
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2.2.4 ELISA Assays
2.2.4.1 IgG ELISA for anti-tetanus
Tetanus Toxoid for flocculation (NIBSC) was coated at 10 pg/ml in PBS onto a 96- 
well ELISA plate (NUNC maxisorp) at 37°C for 2 hours. The wells were blocked with 
100 pi 2.5% BSA in PBS containing 0.05% Tween-20 at room temperature for 1 hour. 
Next, the wells were incubated with 100 pi of serial dilutions of anti-sera (prepared in 
blocking buffer). All washings were performed with 200 pi of wash buffer (PBS, 
0.05% Tween). Bound immunoglobulins were detected by incubation with 100 pi of 
peroxidase-conjugated goat anti-rabbit IgG (Sigma) or peroxidase-conjugated goat 
anti-human (Jackson), 1:4000 dilution in blocking buffer and visualised using 100 pi 
3,3’,5, 5’ tetramethylbenzadine (TMB) substrate (Sure-blue, KPL, Guilford, UK). The 
plates were incubated for 5 min at RT and the reaction was stopped with 25 pi 2M 
H2 S04. The O.D. value at 450 nm was taken for each sample (Dynatech MRX 500).
2.2.4.2 IgG ELISA for anti-idiotype
N9A cross-linked to BSA (BSA-N9A) was coated at 5 pg/ml in 0.05 M Borate onto a 
96-well ELISA plate (NUNC maxisorp) at 4°C overnight. The wells were blocked 
with TBS containing 10% BSA and 1 mM calcium chloride (blocking buffer) at 37°C 
for 2 hours before the addition of 5 pg/ml of purified scFv-CaM. Next, the wells were 
incubated with 100 pi of serial dilutions of anti-sera, prepared in blocking buffer. All
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washings were performed with 200 pi of wash buffer (TBS containing 0.1% Tween
and 0.1 mM CaCl2). Bound immunoglobulins were detected as before (Chpt 2.2.4.1).
2.2.4.3 Inhibition ELISA
B2 IgGl (gift from Dr K Armour) was coated at 10 pg/ml in PBS onto a 96-well 
ELISA plate (Falcon, 353912 PVC) at 37°C for 2 hours. The wells were blocked with 
2.5% BSA in PBS containing 0.05% Tween-20 at room temperature for 1 hour. Prior 
to blocking the serum samples (at a dilution determined by a prior titration) were 
incubated with doubling dilutions of inhibitor (Drosophila and E. coli derived 
recombinant scFv) and incubated at RT for 1 hour, equal volumes of serum and 
inhibitor were used. A no inhibitor control was also set up, serum plus equal volume 
of PBS. 100 pi of the serum, inhibitor mix was added to the plate in duplicate and 
incubated at RT for 1 hour. All washings were performed with 200 pi of wash buffer 
(PBS, 0.05% Tween). Bound immunoglobulins were detected as before (Chpt 2.2.4.1).
2.2.4.4 ELISA for detection of N-linked glycosylation
N9A cross-linked to BSA (BSA-N9A) was coated at 5 pg/ml in 0.05 M Borate onto a 
96-well ELISA plate (NUNC maxisorp) at 4°C overnight. The wells were blocked 
with TBS containing 10% BSA and 1 mM calcium chloride (blocking buffer) at 37°C 
for 2 hours before the addition of 5 pg/ml of purified scFv-CaM. N-linked 
glycosylation was detected by incubation with 1 pg/ml of HRP labelled Concanavalin 
A (Con A) diluted in TBS/0.1% Tween (wash buffer) and incubated for at RT for 1
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hour. All washings were performed with 200 pi of wash buffer. Bound
immunoglobulins were visualised as before (2.2.4.1).
2.2.5 Resonant Mirror Technology
An IAsys Auto + resonant mirror biosensor (Labsystems Affinity Sensors, Cambridge, 
UK) was used to study the binding of purified glycoprotein Ilbllla (GPIIbllla) to the 
purified scFv, B2-CaM fusion protein. The BSA-N9A was coupled to the 
carboxymethylated dextran surface of the cuvette in 50 mM sodium acetate, pH 4, 
according to manufacturer’s instructions. This coupling allowed the capture of the 
CaM tagged scFv in the presence of calcium. All experiments were performed in the 
presence of TBS (2.1.3) containing lOmM calcium and 0.1% Tween (wash buffer). 
Two alleloforms of purified GPIIbllla were added to the cuvette, HPA-lala and - 
lb lb. The binding of the sample was measured in arc seconds after repeated washes 
with wash buffer. Regeneration of the cuvette was performed by the addition of 20 
mM EDTA.
2.2.6 Platelet Immunofluorescence Test (PIFT)
2.2.6.1 Drosophila supernatant
1 x 107  platelets in 50 pi wash buffer (0.25% BSA, 0.01 M EDTA, pH 6 . 8  in PBS, 
filtered) were incubated with 50 pi of Drosophila supernatant containing scFv for 1 
hour at RT, the samples were washed with 4 ml wash buffer and centrifuged at 1200 g 
for 6  min, repeated three times. The pellet was then resuspended in 100 pi of mouse 
monoclonal IgG2b anti-His (Invitrogen), diluted 1:100 and incubated at RT for 1 hour. 
The samples were washed as before and the pellet resuspended in 100 pi of
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fluorescein isothiocyanate (HTC) -conjugated F(ab’ ) 2  fragment of goat anti-mouse 
immunoglobulins (Dako), 1:20 dilution and incubated at RT for 30 min, the samples 
were washed as before and the pellet resuspended in 500 pi of wash buffer. All 
dilutions were performed in wash buffer. The samples were then analysed using a 
Beckman-Coulter flow cytometer.
2.2.6.2 Human plasma
Plasma collected with both EDTA and citrate was tested for platelet antibodies by the 
indirect PIFT using a panel of HP A genotyped donor platelets. Briefly, platelets were 
incubated with the patients' plasma then washed and resuspended with FITC- 
conjugated isotype and light chain specific conjugates (Dako Cytomation, Ely, UK). 
Normal human group AB plasma from a non-transfused male was used as a negative 
control. For investigation of temperature dependence all reagents and samples were 
brought to a temperature of 4,18, 25, 30 or 37°C prior to commencing the assay.
These temperatures were maintained at all stages of the assay until immediately before 
examination for bound FITC by flow cytometry. The fluorescence for the negative 
control (FITC-conjugated antibody alone) obtained with each sample was subtracted 
from that obtained with each test antibody to give the corrected MFI (MFI Corr).
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Chapter 3
Recombinant scFv expression in Drosophila S2 Cells
3.1 Introduction
Human antibody molecules and their fragments are increasingly being exploited for 
various scientific and clinical applications. One of the limitations to the widespread 
use of these technologies is the ability to express large amounts of active protein 
(Verma et al., 1998). An ideal expression system would provide milligram quantities 
of pure protein without the need for time-consuming downstream processing such as 
multiple rounds of purification, re-folding and dialysis. Furthermore, such a system 
needs to be cheap, easy to manipulate and produce active recombinant protein from 
the majority of sources with little modification.
A Cancer Research UK (CR-UK) clinical trial has been completed using DNA 
vaccines encoding the single chain variable domain antibody fragment (scFv) derived 
from the surface immunoglobulin (slg) of patients with low-grade follicular lymphoma 
(LIFTT) (CRC code: 98/04, protocol No: PH2/039). Serum samples taken from the 
patients pre- and post-vaccination need to be analysed for the presence of antibodies 
against the scFv, anti-idiotypic response. In order to measure this response a source of 
antigen is required. Although it is possible to isolate the antigen (slg) from the B-cells 
(Kwak et al., 1992) the yields are poor. Recombinant protein provides an excellent 
alternative, providing a reliable expression system can be found.
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The scFv comprising both variable domains is regarded as the minimal structural 
component of an antibody required for antigen-binding activity. Immunoglobulins 
express three types of antigenic determinants or epitopes; these are classified as 
isotypes, allotypes and idiotypes. The idiotype is a set of one or more epitopes specific 
to the variable regions of the immunoglobulin molecule; the idiotype can be recreated 
by construction of the scFv. The aim of the DNA vaccination strategy in the LIFTT 
clinical trial is to induce a clinically relevant immune response in the patients; this 
response will be measured by ELISA using recombinant scFv (Chapter 4) and by T 
cell proliferation assays. For a successful ELISA; firstly milligram quantities of 
correctly folded pure scFv need to be produced and secondly a versatile affinity tag for 
purification and capture of the scFvs onto the solid phase is required. Earlier studies 
from our laboratory have revealed that the commonly used hexa-histidine tag when 
fused to the carboxy terminus of the VL domain is susceptible to cleavage. This affects 
the overall yield, purification ability, detection and potential capture of any 
recombinant antibody. In this chapter studies are described on the evaluation of a 
robust recombinant expression system in Drosophila of human scFv fused to 
calmodulin (CaM).
3.1.1 Review of expression systems
Cell based in vitro protein expression systems can be classified into two categories, 
prokaryotic, the E. coli systems and eukaryotic, mammalian, yeast and insect cell 
expression systems. Each of these systems has been used effectively to express 
antibody fragments, each with their own advantages and disadvantages (reviewed in 
Verma et al (Verma et al., 1998)).
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3.1.1.1 Escherichia coli (E. coif)
Escherichia coli (E. coli) is probably the cheapest, fastest and most widely used 
expression system available to research laboratories. The cell growth is typically 
exponential allowing detection of expressed protein in a minimum culture time of 
eight hours. Relatively small amounts of DNA are needed for transfection of the 
bacteria and the yields are substantial. Fermentation of E. coli has successfully 
produced yields of 100-130 mg/L of active scFv (Huston et al., 1995). Although the 
yields are substantial fermentation requires large volumes of bacterial culture, which 
are difficult to manipulate in average research laboratories. Other disadvantages to E. 
coli expression systems include production of inactive and insoluble protein located 
inside inclusion bodies; in this case protein refolding protocols must be applied, which 
require a functional assay in order to monitor activity. E. coli lacks the ability to 
provide the post-translational modifications found in eukaryotic cells, for example, 
glycosylation of the mature protein; this will have an effect on the properties and 
activity of some proteins. In addition E. coli systems are less suitable for proteins with 
multiple disulfide bonds and refolding of these proteins is cumbersome. Finally E . coli 
produced proteins contain high concentrations of endotoxins, which need careful 
removal if the recombinant proteins are to be used in cell biology assays or in vivo 
experiments.
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3.1.1.2 Mammalian
Mammalian expression systems, for example Chinese hamster ovary (CHO) cells are a 
widely used system with many advantages (Geisse et al., 1996). CHO cells have the 
required molecular machinery to synthesise active protein directly. Proteins are 
appropriately folded, glycosylated and secreted, the latter simplifying purification. 
Therefore, mammalian cells inevitably produce the best materials for almost all 
applications including human therapeutics and diagnostics (Morrison, 1992). 
Mammalian hosts have limited tolerance for certain proteins especially intracellular 
and membrane proteins, at least 50% of chosen proteins are poorly or never expressed 
and are sometimes toxic to the host (Geisse et al., 1996). Working with mammalian 
cells in culture is demanding and specialised cell culture techniques and equipment are 
required. Yields may be disappointing and extensive rounds of clone selection are 
often needed to achieve reasonable expression levels in the p,g/ml range. The overall 
yields are reportedly not as high as from E. coli (Dorai et al., 1994).
3.1.1.3 Yeast
Compared to other eukaryotic expression systems, Pichia pastoris offers many 
advantages, because it does not have the problems of endotoxin associated with 
bacteria or viral contamination of proteins produced in animal cell culture. Yeast can 
provide some post translational modification, although not as advanced as mammalian 
cells. Pichia can be grown rapidly in simple growth medium and it has been
91
demonstrated that yeast is capable of producing higher levels of recombinant antibody 
fragments than E. coli (Eldin et al., 1997 and Ridder, 1995 #28).
3.1.1.4 Insect
Insect cells can easily be maintained in suspension cultures at room temperature, they 
can produce higher levels of protein than both mammalian and E. coli expression 
systems and most of the post-translational modifications used by higher eukaryotes are 
present (Miller, 1988; Maeda, 1989). The most common insect expression system uses 
baculovirus to infect insect cells of the order Lepidoptera, for example ovarian cell 
lines from Spodoptera frugiperda (Sf9, Sf21). Functionally active antibody fragments 
have been produced in this system (Hasemann & Capra, 1990; zu Putlitz et al., 1990). 
The N-linked glycosylation sites are the same as in mammalian cells but they differ in 
the nature of the oligosaccharide chains, insect cells are not capable of processing 
mature oligosaccharides to the forms found in mammalian cells (Hsieh & Robbins, 
1984). Baculovirus have a highly restricted host range and are therefore considered 
safer than mammalian expression systems for use in the laboratory (Groner, 1986). 
Disadvantages include the maintenance of a viral stock, which is time consuming; 
expression is under the control of a very late viral promoter such that expression peaks 
when the cells are dying. The inherent problems with this include no stable cell lines 
and the possibility of proteolysis occurring as the protein is expressed.
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3.1.1.4.1 Drosophila Expression System
An alternative insect cell system is the Drosophila expression system which uses a cell 
line derived from a primary culture of late stage Drosophila melanogaster embryos, 
Schneider 2 (S2) cells (Schneider, 1972) and a simple plasmid vector. The Drosophila 
system has the same advantages as baculovirus but expression can be controlled using 
an inducible promoter. Several groups have shown that high-level transcription can be 
achieved with a metallothionein promoter when induced by heavy metal such as 
cadmium and copper (Maroni et al., 1986; Otto et al., 1987). Co-transfection of a 
second plasmid carrying a gene conferring resistance to antibiotics like hygromycin or 
blasticidin provides a simple method of selection (van der Straten, 1989) of stable cell 
lines in two weeks. Surprisingly this system has not been widely used although reports 
indicate good yields of a variety of proteins (Culp et al., 1991; Johanson et al., 1995; 
Kirkpatrick et al., 1995; Li et al., 1996).
3.1.2 Glycosylation of Human Immunoglobulin G (IgG) and scFv
Higher eukaryotes perform a variety of post-translational modifications, including 
methylation, sulfation, phosphorylation, lipid addition, and glycosylation. Such 
modifications may be of critical importance to the function of an expressed protein. 
Secreted proteins, membrane proteins, and proteins targeted to vesicles or certain 
intracellular organelles are likely to be glycosylated. The most common and best 
studied is N-linked glycosylation, where oligosaccharides are uniquely added to 
specific asparagine residues. The tripeptide sequence (or sequon), asparagine-X-
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serine/threonine (Asn-X-Ser/Thr) is generally required for N-linked glycosylation 
(Marshall, 1974). In this sequon, X can be any amino acid, although proline, glutamic 
acid and aspartic acid are rarely found at this position (Marshall, 1972, 1974;
Mononen & Karjalainen, 1984). Only rare examples of N-linked glycosylation at other 
sequences (eg Asn-X-Cys and Asn-Gly-Gly-Thr) have been described (Gavel & von 
Heijne, 1990). One of the major differences between mammalian and insect 
expression systems is the types of glycosylation added. Mammalian cells add more 
complex, branched glycan moieties, which are composed of mannose, galactose, N- 
acetylglucosamine (GlcNAc) and neuramic acids (Komfeld & Kornfeld, 1985). Insect 
cell glycosylation is generally of the high-mannose type as they are not trimmed and 
sialylated. Human IgG is glycosylated on asparagine residue 297, on each of the CH2  
domains and this residue is conserved in all of the IgG subclasses. Glycosylation 
within the variable domains is rare, of the 52 human germline VH genes; only three 
encode a naturally occurring glycosylation site (V^g, V4 . 3 4  and V5a) (Zhu et al., 2002). 
Interestingly the V domains expressed on the membrane of the malignant B cells in 
patients with low-grade FL are frequently glycosylated. A recent study has shown that 
glycosylation sites are present in the immunoglobulin V domains of 79% of patients 
with FL compared with 9% of B cells in healthy individuals (Zhu et al., 2002). Studies 
of monoclonal immunoglobulins have shown that binding to antigen can be increased 
(Wallick et al., 1988; Leibiger et al., 1999) or decreased (Fujimura et al., 2000) by the 
presence of a carbohydrate moiety in the V region. The question whether naturally 
occurring IgG antibodies against the less complex glycosylation moieties of the 
expressed scFv masks the specific binding of the human anti-idiotype IgG to the 
recombinant scFv is addressed in chapter 4 of this thesis.
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3.1.3 Tagging of recombinant proteins
For the purposes of detection, purification and immobilization tagging of recombinant 
proteins is important. The size of the tag can vary considerably from a small number 
of amino acids to complete independently folded protein domains. The selection of the 
tag is dependant on the functional requirements and the expression systems (Terpe, 
2003). scFv were initially tagged with the c-myc tag (Ward et al., 1989) and the 
monoclonal antibody 9E10 has been widely used for scFv detection. Purification of 
scFvs using affinity chromatography with 9E10 columns (Evan et al., 1985) has 
proven cumbersome and results in poor yields. The hexa-histidine (His) tag is 
increasingly being selected as an alternative tag for purification. However, in the 
context of scFvs the His tag does have some drawbacks. Firstly the His tag is 
susceptible to cleavage. Secondly the nickel agarose columns used for purification are 
costly. Finally the purification is not single step, requiring pre and post purification 
dialysis substantially reducing the yields.
3.1.4 Calmodulin
Calmodulin (CaM) has been described as a tag for bacterial expression of scFvs (Neri 
et al., 1995a; Melkko & Neri, 2003) with the result of better yields and no cleavage of 
the tag. In this chapter I describe its use in an insect cell system. Calmodulin is a 
ubiquitous, calcium-binding protein that can bind to and regulate a multitude of 
different protein targets, thereby affecting many different cellular functions. It is 
abundant in the cytoplasm of all higher cells and has been highly conserved during 
evolution. It is a small (17 kDa) dumbbell-shaped protein composed of two globular
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domains connected by a flexible linker (Chattopadhyaya et al., 1992). Each globular 
domain has two calcium binding sites. In the presence of calcium the molecule adopts 
a constrained configuration and in the absence of calcium it adopts a more elongated 
and relaxed state (Figure 3.1).
Calmodulin (CaM) is a crucial intracellular calcium regulated switch and a substantial 
number of intracellular proteins such as kinases and phosphatases have CaM binding 
domains. The CaM binding protein is trapped between each domain; this binding is 
calcium dependant and high affinity (Ka > 10'9). The CaM binding domain of myosin 
light-chain kinase was used as a template to engineer a short oligopeptide with high 
affinity for CaM in the presence of calcium and no affinity in the absence of calcium. 
The NMR structure of the complex between calcium-bound CaM and a 26-residue 
synthetic peptide comprising the CaM binding domain (residues 577 to 602) of rabbit 
skeletal muscle myosin light chain kinase has shown that only amino acids 580 to 598 
of the myosin light-chain kinase, sequence RWKKNFTAVSAANRFKKIS contact 
CaM (Ikura et al., 1992). Alanine mutant scanning was applied to this oligopeptide 
extended at the amino terminus producing the 23-mer
CAAARWKKAFIAVSAANRFKKIS (N9A mutant) that showed surprisingly higher 
affinity (Ka 10'12) for CaM than the wild type (Montigiani et al., 1996).
In our laboratory this CaM was used for the expression and purification of the leucine 
rich repeat domain of glycoprotein (GP) Iba in Baculovirus (Li et al., 2001) and the 
two Ig-like domains of platelet GPVI (Smethurst et al., 2004). Making use of the high 
affinity binding of calmodulin to the organic compound 
N-(6-Aminohexyl)-5-Chloro-l-Naphthalenesulfonamide (W7) a simple one step 
purification removes all contaminating proteins enabling the CaM tagged scFvs to be 
eluted under mild conditions by calcium chelation with 10 mM EDTA. Not only is the
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CaM an excellent tag for purification of the recombinant protein but it also provides a 
reusable method for capture and immobilization of the protein onto a solid surface. For 
immunoassays (eg ELISA) or protein interaction studies using mirror resonance 
technology. The 23-mer alanine mutant (N9A) is linked to BSA and bound directly to 
the solid phase allowing the fusion protein to be directly captured by means of the 
CaM tag (Smethurst et al., 2004). This enables orientation of the protein of interest 
with optimal exposure of the epitopes and excellent access to the active site.
3.1.5 Model scFv
scFv-B2 is a human anti-GPIIbllla specific for the leucine 33 alleleoform of the |33 
integrin (Griffin & Ouwehand, 1995). The single amino acid substitution at position 
33 in GPIIIa from a leucine (a alleleoform) to a proline (b alleleoform) is at the basis 
of the Human Platelet Antigen 1 (HPA-1) system (Newman et al., 1989). scFv B2 will 
bind HPA-la positive but not la negative platelets (Griffin & Ouwehand, 1995). The 
allele restricted specificity of scFv B2 is retained when tested with GPIIbllla 
alleleoforms purified from HPA-1 genotyped platelets. B2 is a well-characterised scFv 
and has previously been expressed in E. coli with c-myc and His tags (Griffin & 
Ouwehand, 1995) and in a rat myeloma cell line as a recombinant IgGl (Watkins et 
al., 1999).
The work in this chapter compares the characteristics of scFv B2 produced in E. coli 
and in Drosophila. Based on these results scFvs encoded by V genes from the 
malignant B cells of patients with FL were expressed as CaM fused scFvs in 
Drosophila, followed by purification.
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AFigure 3.1 Ribbon structure of calmodulin in its resting (A) and active state (B). The 
four calcium-binding sites (yellow dots) are shown in A. In the absence of calcium the 
structure is elongated with domain 1 (red) and domain 2 (green) separated by a 28 
amino acid long a-helix (A). In the presence of calcium and a calmodulin binding 
peptide (blue) (B) the separating a-helix is disrupted into two shorter helices joined by 
a flexible loop. The globular domains are able to come closer together forming a box 
like structure around the peptide. Modelled from www.rcsb.org/pdb.
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3.2 Experimental Design
3.2.1 Plasmid Construction
The pMT/BiP/V5 His C inducible / secreted expression plasmid (Invitrogen) was 
modified in order that the cloning sites were compatible with the bacterial expression 
plasmids and the DNA vaccination plasmids used in our laboratory. The cloning sites 
are 5’, Ncol, such that the ATG of the restriction site encodes for a methionine residue 
in the mature protein, whilst remaining in frame with the BiP signal sequence and 3’, 
Notl, such that the affinity tags are in frame. The Notl restriction site encodes for a 
three-alanine spacer. pMT/BiP/V5 His C was chosen for modification as the V5 and 
His tags are in frame with the Notl site. The Ncol site, although already present in the 
multiple cloning site (MCS) of pMT/BiP/V5 His C, was in a different reading frame to 
our other plasmids (Figure 3.2 A). To change the reading frame of the Ncol site a 
double digest with Bglll and Ncol (Chpt 2.2.1.15) was performed giving rise to the 
overhangs (Figure 3.2 B). This double digest has removed a thymine (T) from the 3’ 
end of the Bglll site and a cytosine (C) from the 5’ end of the Ncol site. The Ncol site 
was recreated by the plasmid being re-annealed by end filling the overhangs using 
DNA polymerase (Chpt 2.2.1.16) followed by ligation (Chpt 2.2.1.7.1) and 
transformation into TOP 10 electrocompetent bacteria (Chpt 2.2.1.9). The sequence of 
the new cloning site is shown in Figure 3.2 C. The new plasmid pMT/BiP/V5 His D 
has lost the Bglll site and retained the Ncol site. The removal of the two bases, C and 
T, has changed the reading frame so the Ncol site now encodes for methionine.
(Figure 3.2 D). Cloning of gene sequences into this plasmid by means of the Ncol site 
add an extra four N-terminal residues, arginine, serine, methionine and alanine.
A5' TCG CTC GGG AGA TCT CCA TGG CCC GGG GTA CCT ACT 3'
A
0RF1 Ser Leu Gly Arg Ser Pro Trp Pro Gly Val Pro Thr 
0RF2 Ser Arg Glu lie Ser Met Ala Arg Gly Thr Tyr
Last 3 aa of BiP signal sequence Bglll site Ncol site 
Multiple cloning site
B
5' TCG CTC GGG A CATGG CCC GGG GTA CCT ACT 3'
3' AGC GAG CCC TCTAG C GGG CCC CAT GGA TGA 5'
c
5' TCG CTC GGG AGA TCC ATG GCC CGG GGT ACC TAC T 3'
3' AGC GAG CCC TCT AGG TAC CGG GCC CCA TGG ATG A 5'
D
5' TCG CTC GGG^AGA TCC ATG GCC CGG GGT ACC TAC T 3'
Ser Leu Gly Arg Ser Met Ala Arg Gly Thr Tyr
Last 3 aa of BiP signal sequence Ncol site
Figure 3.2 Sequential modifications to the pMT/BiP/V5 His C plasmid to obtain 
pMT/BiP/V5 His D. A) Nucleotide and amino acid sequence of pMT/BiP/V5 His C, 
open reading frame (ORF) 1 denotes the amino acid sequence of pMT/BiP/V5 His C, 
ORF 2 denotes the required amino acid sequence to obtain the correct ATG reading 
frame of Ncol (bold). The position of signal peptide cleavage is indicated^ . B) 
Nucleotide sequence of pMT/BiP/V5 His C after Bglll and Ncol digest. C) Nucleotide 
sequence of pMT/BiP/V5 His D, the ATG is in bold and the bases added by DNA 
polymerase are in red. D) Nucleotide and amino acid sequence of pMT/BiP/V5 His D, 
the ATG of the Ncol site encodes for Methionine (bold) in frame with the BiP signal 
sequence. The position of signal peptide cleavage is indicated^ .
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A 134 bp fragment containing the V5 epitope and polyhistidine tags were removed 
from pMT/BiP/V5 His D by restriction enzyme digest using Notl and SacI without 
altering any of the regulatory elements. The CaM gene was amplified by PCR using 
pWIbawt (Li et al., 2001) as template and the primers 5’-GCC AT A GCG GCC GCT 
GAC CAA CTG ACA GAA GAG CA-3’ and 5’-CGA CAT GAG CTC TTA TCA 
CTT TGA TGT CAT CAT-3’, encoding Notl and SacI restriction sites respectively 
(underlined). Amplification was performed over 30 cycles consisting of 1 min at 94°C, 
1 min at 60°C and 2 min at 72°C. The PCR product was gel purified, digested with 
Notl and SacI, and cloned into the Notl/SacI digested pMT/BiP/V5 His D to generate 
pMT/BiP/CaM (Figure 3.3).
3.2.2 Testing recombinant scFvs
To assess the activity of the recombinant scFv derived from expression in the S2 cells 
the well-characterised scFv-B2 against the leucine 33 alleleoform of the p3 integrin 
was used. scFv-B2 was expressed in the Drosophila expression system with both the 
His and CaM tags and compared with recombinant B2 expressed from E. coli TGI 
cells with a c-myc / His tag. The functional activity of B2 was defined by its ability to 
bind to native GPIIbllla on platelets by the platelet immunofluorescence test (PIFT) 
(Chpt 2.2.6) and by measuring binding to purified GPIIbllla by mirror resonance 
technology (Chpt 2.2.5).
The folding and tertiary structure of scFv-B2 was further investigated by its ability to 
inhibit the binding of polyclonal anti-idiotype B2 to B2 IgGl (Watkins et al., 1999) 
(Chpt 2.2.4.3). The amount of protein required to inhibit the binding by 50%, the IC50 
value, was determined in this assay and compared between the two different His
tagged preparations. Polyclonal anti-B2 rabbit serum was produced by immunising 
Dutch rabbits with the DNA plasmid based vaccine pVAC2-B2 (Chpt 2.2.3.1). Further 
information regarding rabbit immunisations is provided in chapter 4.
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Figure 3.3 Map of pMT/BiP/CaM. Expression of the C-terminal CaM fusion protein is 
under the control of the metallothionein promoter. Protein secretion is directed by the 
signal sequence of Drosophila BiP protein. DNA encoding the protein of interest is 
cloned as an Ncol/Notl fragment.
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3.3 Results
3.3.1 Construction of expression plasmid
The expression plasmid pMT/BiP/V5 His D (Invitrogen) was modified by the 
insertion of the gene for CaM. The V5 epitope and the His-tag can be detected with 
polyclonal antibodies against V5 and His respectively. Proteins can only be purified 
via the His tag. The alternative tag for scFv was the 17 kDa protein CaM. For this the 
plasmid pMT/BiP/CaM was constructed and the V5/His sequence was replaced with 
the CaM gene sequence. The CaM gene used is derived from Xenopus laevis (Chien & 
Dawid, 1984) and encodes the same amino acid sequence as the human gene.
3.3.2 Expression and characterisation of B2-His in Drosophila S2 cells
scFv-B2 was expressed with the V5 and His tags using pMT/BiP/V5 His D. The 
nucleotide and amino acid sequences of B2 are in Appendix A. The level of expressed 
scFv in the supernatant was monitored by Western blotting over a 7-day period 
(Figures 3.4) following induction. scFv expression reached a maximum at day 4 and 
remained stable for at least 3 days (Figure 3.4). Based on these results supernatant was 
harvested at any day between days 4 and 7.
The S2 stable lines of scFv-B2 were expanded to a 200 ml culture in serum free 
media. Following a 5-day induction protein was purified from the supernatant and 
analyzed on a 12% SDS-PAGE gel (Figure 3.5). The recombinant protein was eluted
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in fractions 2 and 3. The concentration of protein in these fractions was determined by 
BCA assay (Table 3.1), the overall yield of B2-His was 3 mg.
Binding of scFv-B2 His to platelets was determined by flow cytometry using HPA-1 
genotyped platelets. Drosophila supernatant containing scFv-B2 His was incubated 
with platelets and bound scFv was revealed by incubation with mouse anti-His 
(Invitrogen), followed by goat anti-mouse immunoglobulin FITC (Dako) (Chpt 
2.2.6.1). The scFv-MHll that has activity against human factor VIII and the scFv-2F2 
recognising GPIIbllla, but binding an epitope distinct of HPA-1 a were used as 
negative and positive controls respectively. A median fluorescence intensity (MFI) of
20.2 and 23.3 was observed with scFv-2F2-His binding to HPA-lala and -lb lb  
platelets respectively (Figure 3.6). scFv-B2-His produced a MFI of 71.5 and 1.41 
when reacted with HPA-lala and -lb lb  platelets respectively. The latter is equivalent 
to the MFI of the negative control (scFv-MHll) of 1.31 and 1.39 respectively. Data 
shown is representative of n=2 .
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Figure 3.4 Detection of scFv-B2-His by immunoblot. A stable S2 cell line expressing 
B2-His was scaled up in 200 ml serum free medium before induction with 500 p,M 
CuS04. 1 ml samples were taken at days 1-7 post induction and 10 pi of cleared 
supernatant analysed on a 12% SDS-PAGE gel. His tagged proteins were detected 
with peroxidase labelled mouse anti-His and visualised by enhanced 
chemiluminescence. Lanes 1-7, days 1-7.
Figure 3.5 Coomassie stained SDS-PAGE gel of purified histidine (His)-tagged scFv- 
B2. A stable S2 cell line expressing B2-His was scaled up in 200 ml of serum free 
medium before induction with 500 pM CuS04. On day 5 post induction the 
supernatant was harvested, dialysed with IMAC buffer and then supplemented with 25 
mM imidazole. B2-His was purified over a Nickel chelating column and eluted in 1 ml 
fractions with IMAC containing 100 mM imidazole, 10 pi of each fraction as analysed 
on a 12% SDS-PAGE gel and visualised with Coomassie. Lanes 1 and 7 -  broad range 
molecular weight marker, lanes 2-6 fractions 1-5.
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3.3.3 Comparison of B2-His expressed from Drosophila S2 cells and E. coli TGI
3.3.3.1 Yields
His tagged scFv-B2 was expressed simultaneously in S2 cells and E. coli and purified 
over Ni-agarose columns. Yields of scFv after purification were determined by BCA 
assay. Drosophila supernatant produced approximately 15 mg/L of cell suspension 
compared with 1 mg/L of E. coli bacterial broth. Equal amounts of the purified scFv- 
B2 from both sources were analyzed on a 12% SDS-PAGE gel (Figure 3.7). scFv-B2 
has an approximate molecular weight of 26 kDa, this is increased by the presence of c- 
terminal tags (Figure 3.7). There is also a minor difference in molecular weight 
between the scFv-B2 expressed from E. coli and that from Drosophila S2 cells due to 
differences in molecular weight of the c-terminal tags used in each system.
3.3.3.2 Activity
Polyclonal rabbit antibodies against the B2 idiotype were generated by DNA based 
vaccination of Dutch rabbits (Chpt 2.2.3.1). The majority of antibodies present in the 
rabbit sera will recognise tertiary structures. Inhibiting the binding of the serum IgG 
antibodies to B2-IgGl will give an idea of how well folded each protein is. The 
potency of His tagged scFv-B2 produced from Drosophila S2 cells and E. coli was 
determined by inhibiting the binding of these polyclonal rabbit antibodies to the B2 
idiotype (Figure 3.8). IgGl B2 was used as a positive control. In short, B2 IgGl was 
immobilized on the solid phase and the signal of the rabbit antiserum was determined
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in the presence of increasing amounts of scFv-B2 from either source. The amount of 
each inhibitor required to reduce the binding of the rabbit serum to B2 IgG by 50% 
(IC50) was extrapolated from the graph using GraphPad Prism®. The IC50 value was 
calculated for Drosophila B2-His at 3.8 [xg/ml, E. coli B2-His at 7.7 pg/ml and B2 
IgGl at 1.3 [ig/ml.
3.3.4 Expression and validation of B2-CaM in Drosophila S2 cells
scFv-B2 was expressed with a CaM tag using pMT/BiP/CaM. The level of expressed 
scFv in the supernatant was monitored by Western blotting over a 7-day period 
(Figures 3.9) following induction. scFv expression reached a maximum at days 3 to 5 
(Figure 3.9). After day 5, the level appeared to reduce.
The S2 stable lines of scFv-B2 were expanded to a 200 ml culture in serum free 
media. Following a 5-day induction protein was purified from the supernatant and 
analyzed on a 12% SDS-PAGE gel (Figure 3.10). The recombinant protein was eluted 
in fractions 2 and 3. The concentration of protein in these fractions was determined by 
BCA assay (Table 3.1). The overall yield of purified B2-CaM from 200 ml of culture 
supernatant was 4 mg.
The CaM tagged scFv-B2 was validated for functional activity using mirror resonance 
technology (Figure 3.11). The CaM binding peptide N9A was immobilized onto the 
surface of the cuvette and scFv B2-CaM was captured on the BSA-N9A to 1200 arc 
seconds (Figure 3.11 A). Purified GPIIbllla from HPA-lala and -lb lb  platelets was 
added in turn to the cuvette and binding was allowed to take place (Figure 3.11 B and
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3.11 C). As expected the GPIIbllla from the -la la  platelets associated strongly to 
scFv-B2 and on washing dissociated slowly (Figure 3.11 B). Any binding to scFv-B2 
by the GPIIbllla from the -lb lb  platelets was removed immediately after the addition 
of wash buffer (Figure 3.11 C).
I l l
Figure 3.7 Coomassie stained SDS-PAGE gel of purified His tagged scFv-B2. A stable 
S2 cell line expressing B2-His was induced to express as in Figure 3.5. E. Coli TGI 
were induced with IPTG to express B2-His. Osmotic and periplasmic preparations 
were isolated from the bacterial pellets and pooled. This along with the Drosophila 
supernatant were dialysed with IMAC buffer and supplemented with 25 mM 
imidazole. B2-His was purified over a Nickel chelating column and eluted in 1 ml 
fractions with IMAC containing 100 mM imidazole, 10 \x\ of each fraction as analysed 
on a 12% SDS-PAGE gel and visualised with Coomassie. Lane 1, Drosophila scFv- 
B2-His; Lane 3 E. coli scFv-B2-His; Lane 2 broad range molecular weight marker.
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Figure 3.8 Inhibition of the binding of polyclonal anti-idiotype B2 (rabbit sera) to B2 
IgGl with Drosophila S2 and E. coli derived B2-His and with B2 IgGl. Each line 
represents a titration of inhibitor. Minimum and maximum inhibition concentrations 
are 20 ng and 80 pg/ml respectively. The IC50 values were extrapolated from the 
graph using GraphPad Prism®.
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Figure 3.9 Detection of scFv-B2-CaM by immunoblot. A stable S2 cell line expressing 
B2-CaM was scaled up in 200 ml serum free medium before induction with 500 pM 
CuS04. 1 ml samples were taken at days 1-7 post induction and 10 pi of cleared 
supernatant analysed on a 12% SDS-PAGE gel. CaM tagged proteins were detected 
with peroxidase labelled N9A and visualised by enhanced chemiluminescence. Lanes 
1-7, days 1-7.
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Figure 3.10 Coomassie stained SDS-PAGE gel of purified scFv-B2-CaM. S2 cells 
were treated as for Figure 3.5. On day 5 post induction 200 ml of supernatant was 
harvested and supplemented with 1 mM CaCl2. scFv B2-CaM was purified over a W7 
column and eluted in 1 ml fractions with TBS containing 10 mM EDTA. 10 pi of each 
fraction analysed on a 12% SDS-PAGE gel and visualised with Coomassie blue (Chpt 
2.2.2.8.1). Lane 1- broad range molecular weight marker, Lanes 2-4 -  fractions 2-4.
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Figure 3.11 Binding of both HPA-1 alleloforms of GPIIbllla to B2-CaM measured by 
resonant mirror technology. The arrows at position 1 indicate the addition of GPIIbllla 
and the arrows at position 2 indicate the addition of wash buffer. A) Addition of 
recombinant B2-CaM to BSA-N9A in the presence of calcium, the baseline was re-set 
to zero after the removal of excess B2-CaM, B) Addition of purified GPIIbllla-Leu 33 
alleloform (HPA-la). C) Addition of purified GPIIbllla-Pro 33 alleloform (HPA-lb). 
Representative of n=2.
115
3.3.5 Expression of patient scFvs in Drosophila S2 cells
Twenty-five patients with low-grade follicular lymphoma were enrolled in the phase 
I/IILIFTT clinical trial (CRC code: 98/04, protocol No: PH2/039). The Vj/VL gene 
cassettes were assembled in pVAC2 by our collaborators in Southampton, Manchester 
and Bournemouth. In short, RNA was recovered from biopsy material and reverse 
transcribed to cDNA with isotype and kappa or lambda specific forward primers. The 
VH and VL genes were amplified with the appropriate sets of V gene and J gene 
primers. The amplified VH and VL genes were cloned and at least ten clones each for 
VH and VL were sequenced. The dominant sequence, assumed to be derived from the 
malignant clone, was selected for the construction of the VH /VL gene cassette. The 
nucleotide and amino acid sequences of all 25 are shown in Appendix A. The V gene 
cassettes from the first three patients (B02, M01 and SOI) enrolled in the trial were 
removed from the pVAC2 plasmid by restriction enzyme digestion with Ncol and Notl 
and sub-cloned into the pMT/BiP/V5 His D and pMT/BiP/CaM expression plasmids. 
Confirmation of V gene insertion was by sequence analysis.
3.3.5.1 Transient expression of patient scFvs with His and CaM tags
The pMT plasmids containing patient B02, M01 and SOI (Table 2.1) V gene cassettes 
were transfected into S2 cells. The level of expressed scFvs in the supernatant 5 days 
post induction was monitored by Western blotting (Figures 3.12 A and B, Figure 
3.13). There appeared to be no expression of the scFvs from pMT/BiP/V5 His D as 
detected by C-terminal anti-His (Figure 3.12 A), however the anti-V5 antibody
116
produces a clear band at approximately 32 kDa (Figure 3.12B) indicating that the scFv 
is expressed and secreted but the C-terminal His tag has been removed. scFv-SOl 
appears smaller than the other three, which is compatible with their calculated 
molecular weights (MW) (Appendix B), M01, B01 and B2 are approximately 1 kDa 
heavier than SOI. Also the potential for glycosylation will have an affect on the 
apparent MW (Table 3.1), the presence of glycosylation for the V5/His tagged proteins 
was not tested. The expression of the three scFvs with a CaM tag was successful and 
appropriate MW bands (~42 kDa) are detected with N9A-HRP (Figure 3.13). Again 
scFv-SOl is smaller than the other two. Based on these results the decision was taken 
to express the scFvs from the remaining 22 patients enrolled in the study as CaM 
tagged scFvs only.
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Figure 3.12 Detection of patient scFv-His by immunoblot. Transient S2 cell lines 
expressing V5/His tagged scFv-MOl, SOI, B02 and B2 were induced with 500 pM 
CuS04. Supernatants were harvested on day 5 post induction and 10 pi of cleared 
supernatant analysed on a 12% SDS-PAGE gel. A) V5/His tagged scFvs were detected 
with peroxidase labelled mouse anti-His and visualised by enhanced 
chemiluminescence. B) V5/His tagged scFvs were detected with polyclonal anti-V5 
and visualized as in A). Lanes 1-4, M01, SOI, B02 and B2 respectively.
118
Figure 3.13 Detection of patient scFv-CaM by immunoblot. Stable S2 cell lines 
expressing scFv-CaM B02, M01 and SOI were treated as in Figure 3.7. On day 5 post 
induction a 1 ml sample was taken and 10 p-1 of cleared supernatant analysed on a 12% 
SDS-PAGE gel. CaM tagged scFvs were detected with peroxidase labelled N9A and 
visualised by enhanced chemiluminescence. Lanes 1-3 scFv-CaM M01, SOI and B01.
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3.3.5.2 Stable expression of twenty-five patient scFvs with a CaM tag
The VH/VL gene cassettes of 25 FL patients (Table 2.1) were sub-cloned from pVAC2 
into pMT/BiP/CaM; confirmation of correct gene insertion was by sequence analysis. 
The level of expressed scFvs in the supernatant 5 days post induction was determined 
by Western blotting (Figure 3.14). The expression levels of the scFvs in the 
supernatant appear to vary, for example M05 is barely detectable by this method 
(Figure 3.14 A).
The 25 stable lines were grown up in 200 ml of serum free medium and expression 
induced for 5 days. The supernatants were harvested on day 5 and purified over W7 
columns; the eluted fractions were analyzed on a 12% SDS-PAGE gel and stained 
with Coomassie blue (Figure 3.15). The concentration of protein in the purified 
fractions was determined by BCA assay (Table 3.1).
Coomassie blue staining revealed the purified protein; the bands are shown in Figure 
3.15 A-M. Purification of the scFv-CaM proteins should yield one band corresponding 
to the molecular weight of the scFv when analysed by SDS-PAGE gel and coomassie 
staining. However, analysis of the purified protein revealed several features. Firstly, as 
expected the molecular weight (MW) of the dominant band varied between clones.
The MW of each scFv was calculated from the amino acid sequences, 10 of the 25 
samples had a single band at the predicted MW. Secondly, for some clones there is an 
additional band at approximately 25 kDa (clones M01, SOI, S05, B01 and B03). This 
fragment does not bind the N9A peptide as it was not revealed on the immunoblots in 
Figure 3.14. The nature of this band was investigated by N-terminal sequencing
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(performed by the PNAC facility, Department of Biochemistry), which revealed that it 
was FK (Fujisawa Kaihatsu) binding protein 13 (FKBP13). FKBPs are a family of 
proteins that bind the immuno-suppressive drug FK 506. FKBP13 (Genbank accession 
NP 476973) is encoded in the Drosophila genome (Bryant et al., 1999). The amount 
of FKBP13 seems to be associated with cell viability. The expression level of FKBP13 
is particularly high in the B03 clone (Figure 3.15 K) this culture only had 50% viable 
cells, as determined by trypan blue staining and FKBP13 accounts for approximately 
50% of the total purified protein. A repeat culture and purification of B03 (Figure 
3.16) where the cells were >98% viable at harvest shows a substantial reduction of the 
contaminating FKBP and conversely a substantial increase in the yield of scFv.
Thirdly, for several clones two bands are observed in the expected MW range. This is 
most prominent for clones M04, M06, B04, S011, S013, S017 and S018. The doublet 
is most likely caused by glycosylation of the V domains. This observation is consistent 
with the presence of one or more putative N-linked glycosylation sites (Table 3.1) 
except for M04 and S017, which contain none. All purified scFvs were subsequently 
assayed for the presence of N-linked glycosylation. ELISAs were performed using 
HRP labelled Concanavalin A (Con A) (Chpt 2.2.2 A). Of the purified scFvs 11 are N- 
glycosylated (Figure 3.17) as detected by Con A-HRP. A sample was negative for 
glycosylation if the binding was less than 20% of the strongest Con A binder. Finally, 
the amount of scFv-CaM obtained varied widely between clones. This was calculated 
by measuring the concentration of protein in all preparations (Table 3.1).
There was no detectable protein from the 200 ml cultures of clones M05, M02 and S06 
(data not shown). The results for M02 and S06 were surprising as there was expression 
present in the 3 ml transient cultures as detected by Western blotting (Figure 3.14 D).
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The difference between the test cultures and the 200 ml cultures is that the latter is in 
shake-flasks and ‘serum free’ conditions. To investigate whether the failure of 
expression was associated with the absence of foetal calf serum (FCS) parallel test 
cultures were set up in complete Drosophila Expression System (DES) medium and 
serum free medium for clones M02 and S06. This confirmed our assumption that the 
loss of expression was associated with the withdrawal of FCS. To further verify this a 
400 ml culture of clones M02 and S06 in shake-flasks was maintained for 5 days in 
complete medium with 10% FCS, supplemented with 0.1% Pluronic F- 6 8  solution 
(Sigma). Supernatants were harvested and purified over W7 columns and the eluted 
fractions were analyzed on a 12% SDS-PAGE gel and stained with Coomassie blue 
(Figure 3.18 A and B). The absence of expression of scFv-CaM was associated with 
the lack of FCS for two of the three clones (M02 and S06). This could be resolved by 
growing the cells in the presence of FCS. An obvious disadvantage of this approach is 
that the purity of scFv-CaM after a single purification step is substantially lower and 
significant amounts of albumin is co-purified. Expression of M05 was never achieved.
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Patient Amount of Number of Predicted N- Detected N-
number protein
(mg)
N-X-S/T sites glycosylation* glycosylation#
B01 5.0 2 2 X
B02 6 . 0 1 0 X
B03 1.7 2 1 X
B04 2 . 2 1 1 ✓
B05 1.5 1 1 X
M01 3.0 4 3 X
M02 0 . 2 1 1 ✓
M03 3.2 4 4 X
M04 1 . 1 0 0 ✓
M05 0 1 0 nt
M06 0.3 2 2 ✓
M08 1 . 2 2 2 X
SOI 3.4 2 2 X
S02 0.4 1 1 ✓
S03 0.3 3 3 ✓
S04 1 . 0 2 2 X
S05 2.3 2 1 X
S06 0 . 8 1 0 ✓
S07 2 . 2 1 1 X
S09 17.0 5 3 X
S011 2 . 0 2 1 ✓
S012 0 . 1 4 3 ✓
S013 1.4 1 1 X
S017 0.5 0 0 ✓
S018 0.5 2 1 ✓
B2 4.0 0 0 X
CaM nt 1 1 nt
B2-His 3.0 0 0 X
Table 3.1 scFv protein yields as determined by bicinchoninic acid (BCA) assay. The 
concentration of the purified scFv in each of the fractions was determined by BCA 
assay, yields are expressed as the total amount of purified protein obtained from a 2 0 0  
ml culture supernatant. * as determined by NetNGlyc server (.R. Gupta, E. Jung and S. 
Brunak. In preparation, 2004). # As detected by Con A ELISA, nt -  not tested, t /  - 
glycosylation detected, X - no glycosylation detected.
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Figure 3.14 Detection of patient scFv-CaM by immunoblot. 22 Stable S2 cell lines 
expressing scFv-CaM fusion proteins were treated as in Figure 3.9. On day 5 post 
induction 1 ml sample was taken and 10 \x\ of cleared supernatant analysed on a 12% 
SDS-PAGE gel. CaM tagged proteins were detected with peroxidase labelled N9A and 
visualised by enhanced chemiluminescence. The patient identifiers are presented 
above the corresponding lane. Molecular weight markers (M) are drawn on the blots 
and the sizes are indicated by arrows.
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Figure 3.15 A-M Coomassie stained SDS-PAGE gels of purified scFv-CaM.
S2 cells were treated as for Figure 3.5. On day 5 post induction 200 ml of supernatant 
was harvested and supplemented with 1 mM CaCl2. scFvs were purified over W7 
columns and eluted in 1 ml fractions with TBS containing 10 mM EDTA. 10 pi of 
each fraction containing protein as detected by BCA assay were analysed on a 12% 
SDS-PAGE gel and stained using Coomassie blue.
kDa 
A 175 
83 
62
47.5
25
kDa
62
47.5
32.5 
25
125
kDa
62
47.5
32.5
kDa
62
47.5
32.5
E
kDa
62
47.5
32.5
►
126
FkDa
83
62
47.5
32.5
G
kDa 
62
47.5
32.5
H
kDa
62
47.5
32.5
M M06
M M04
M S011
127
kDa
62
47.5
32.5
J
K
kDa M B03 B04
M--------------------------- ► <-----------------
62 >
i  y'-:$ ■ . X;..
4 7 .5  >
32.5
25
128
kDa
62
47.5
32.5 
25
kDa
175
83
62
47.5
32.5 
25
129
kDa 1 2 3 4 5 6 7
83 
62
47.5
32.5 
25
Figure 3.16 Coomassie stained SDS-PAGE gel of purified B03-CaM. S2 cells were 
treated as for Figure 3.5. On day 5-post induction 200 ml of supernatant was harvested 
and supplemented with ImM CaCl2. scFv B03-CaM was purified over a W7 column 
and eluted in 1 ml fractions with TBS containing 10 mM EDTA. 10 pi of each sample 
containing protein as detected by BCA assay were analysed on a 12% SDS-PAGE gel 
and stained using Coomassie blue. Lane 1 - broad range molecular weight marker, 
Lanes 2-7 -  fractions 1-6.
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Figure 3.17 Binding of Con A-HRP to purified scFv-CaM. BSA-N9A was coated onto 
ELISA plates and CaM tagged scFvs were subsequently captured. Detection of N- 
linked glycosylation was by binding of Con A-HRP to each scFv.
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Figure 3.18 Coomassie stained SDS-PAGE gels of S06-CaM and M02-CaM.
Stable S2 cell lines expressing S06 and M02-CaM were scaled up into 400 ml of 
complete DES media before induction with 500 pM C uS04. On day 5 post induction 
400 ml of supernatant was harvested and supplemented with ImM CaCl2. scFv-CaM 
was purified over a W7 column and eluted in 1 ml fractions with TBS containing 10 
mM EDTA. 10 pi of each sample containing protein as detected by BCA assay were 
analysed on a 12% SDS-PAGE gel and stained using Coomassie blue. A) S06-CaM 
Lane 7 - broad range molecular weight marker, Lanes 1-6 -  fractions 1-6, B) M02- 
CaM Lanes 1-3 -  fractions 2-4.
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3.4 Discussion
The work described in this chapter concerns the construction and subsequent analysis 
of two expression vectors for the expression of scFvs in Drosophila S2 cells. The 
ultimate aim of this work was to provide a simple, reliable strategy for the expression 
and purification of a large panel of scFvs. A well-characterised scFv specific for the 
leu-33 alleloform of platelet GPIIbllla, from the laboratory, scFv-B2 was initially used 
to assess the efficacy of both plasmids, particularly the performance of the purification 
tags (His and CaM) and the functional activity of the final purified scFv. A 
comparison was also made between the Drosophila expressed scFv-B2 and scFv-B2 
derived from a TGI E. coli expression system that had previously provided adequate 
scFv, in both quality and quantity (Griffin & Ouwehand, 1995).
The expression data for scFv-B2 shows that the Drosophila expression system is 
capable of producing between 15 mg/L (B2-V5/His) and 20 mg/L (B2-CaM) 
compared to 1 mg/L from the TGI E. coli expression system (B2-myc-His). The 
overall yield is apparently increased by the use of the CaM tag. There are two possible 
explanations for this. Firstly, purification of the CaM tagged protein does not require 
any dialysis pre or post purification. Secondly, the propensity for cleavage of the His 
tag means that not all of the protein produced may be available for purification using 
the nickel-agarose columns. Moreover, the scFv-CaM fusion appears less prone to 
cleavage. Evidence shown in this chapter for scFv-B2 also shows that the Drosophila 
derived protein has a better functional activity than its E. coli counterpart as 
established by the IC50 value in Figure 3.8. Approximately 2-fold more of the E. coli 
produced scFv was needed to achieve 50% inhibition of binding of the polyclonal anti­
idiotype antibodies. This may be explained by the quality of the protein, eukaryotic
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systems tend to produce better folded and therefore more active protein than 
prokaryotic systems (reviewed in Verma et al (Verma et al., 1998)). Interestingly both 
scFvs were unable to produce 100% inhibition of binding whilst IgGl B2 at 80 p,g/ml 
did result in complete inhibition. There could be several reasons for the incomplete 
inhibition of the binding of the polyclonal IgG by the recombinant proteins. A 
potential explanation is that the polyclonal serum contains a population of antibodies 
reactive to the constant domains of IgGl B2 that are not present in the scFvs.
However, this is unlikely as the rabbits were only immunised with a vaccine devoid of 
constant domains. Alternatively bivalency is required to produce complete inhibition 
and a population of the polyclonal antibodies does bind with a far greater avidity to B2 
IgGl than to scFv-B2. Finally the highest concentration of scFv was too low, but this 
seems unlikely, as a plateau had been reached at 74% and 80% for E. coli and 
Drosophila respectively with a concentration of scFv at 20 p,g/ml.
The functional activity of B2-His was also assessed by the platelet 
immunofluorescence test (PIFT). B2-His bound to GPIIbllla on HPA-lala positive 
but not —lblb  platelets. This method could not be used to test B2-CaM because the 
binding of the N9A peptide to CaM is calcium dependant and platelets become prone 
to aggregation in the presence of calcium. Therefore, real-time binding of purified 
GPIIbllla to B2-CaM was shown using mirror resonance technology. The CaM 
binding peptide N9A, conjugated to BSA, was immobilized to the surface of the 
cuvette; the B2-CaM was added in the presence of calcium and subsequently captured. 
The purified GPIIbllla from HPA-lala platelets bound to the recombinant scFv 
whereas GPIIbllla from - lb lb  platelets did not. Both recombinant scFvs B2-His and
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B2-CaM have allelic specificity with no binding to the proline-33 alleloform of 
GPIIbllla but robust binding to the leucine-33 alleloform.
Expression in Drosophila using the pMT/BiP/V5 His D plasmid did not provide the 
same degree of success for the first three patient derived scFvs. Although the scFv was 
expressed in each case as detected by the binding of anti-V5, the anti-His antibody 
failed to bind. The most likely explanation for this is that partial cleavage of the C- 
terminal end of the fusion protein had occurred, removing some or all of the histidines 
preventing binding of the anti-His. Without the histidine tag the fusion protein could 
not be purified using a simple nickel-chelating column. However, the same three scFvs 
were then successfully expressed using pMT/BiP/CaM, which incorporates the gene 
for calmodulin in place of the V5 and His tags in pMT/BiP/V5-His D and purified 
using a W7 column. In total 25 out of 26 scFvs were expressed and purified using the 
Drosophila CaM tag system. Only one scFv, M05, failed to yield any purified protein. 
Analysis of the amino acid sequence for codon usage, potential post-translational 
modifications and the isoelectric point (pi) have failed to offer any explanations for 
the lack of expression. The post purification yields of scFvs produced from the 
Drosophila system varies from 0.5 mg to 85 mg/L, the majority produce at least 2.5 
mg/L. In comparison expression of scFv in E. coli can result in yields of 5-7 mg/L in 
shake flask cultures this requires careful optimisation of the growth conditions and is 
limited to a small number of scFvs (Verma et al., 1998; Ziegler & Torrance, 2002). 
The development of an expression system for the production of recombinant scFv with 
C-terminal Calmodulin tags in Drosophila S2 cells permits simple, single-step affinity 
purification of tagged antibody from culture supernatants without the need for cell
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lysis or dialysis. The final fusion product remains stable in the EDTA elution buffer at 
4 °C for several months (data not shown) with no evidence of proteolytic cleavage.
The CaM tag can also be utilized to capture / immobilize the recombinant scFv onto a 
solid surface, for example in ELISA or mirror resonance technology (this chapter and 
Li et al 2000) (Li et al., 2000). The 23-mer alanine mutant (N9A) derived from myosin 
light-chain kinase (Montigiani et al., 1996) is bound directly to the surface and the 
fusion protein is directly captured by means of the CaM tag, the scFv of interest is 
therefore likely to be maintained in its native configuration with the epitopes available 
for binding of the anti-idiotypes than if it had been immobilized directly. This 
immobilisation has been successfully used in mirror resonance technology (Chpt 2.2.5 
and figure 3.11) and in ELISA, which will be discussed in chapter 4. The Kd between 
CaM and N9A is in the order of 1 O' 1 2  allowing direct capture of the fusion protein from 
supernatants thus facilitating a simple single step purification.
The apparent differences in the molecular weights of the expressed scFvs, as 
visualised by Coomassie blue staining cannot be explained solely by the calculated 
molecular weights of each scFv (Appendix B). V genes derived from the malignancies 
of patients with Follicular Lymphoma have been shown to contain more putative re­
linked glycosylation sites than is usually expected (Zhu et al., 2002). In this chapter it 
has been shown that the Drosophila expression system is capable of N-linked 
glycosylation as demonstrated by the ability of some of the scFvs to bind Con A 
(Figure 3.17). There are several observations that can be made from the binding of 
Con A to the scFvs. Firstly, as expected in eight clones, binding of the Con A to scFvs 
that contain predicted glycosylation sites was observed and conversely in three clones,
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no binding of Con A to scFvs with no predicted sites. Secondly, in 11 clones with 
predicted sites no binding of Con A was observed. Although the Asn-X-Ser/Thr (N-X- 
S/T) sequon is generally required for N-linked glycosylation, many such sequons are 
glycosylated inefficiently (Plummer & Hirs, 1964; Pohl et al., 1984; Thim et al., 1988; 
Curling et al., 1990; Shakin-Eshleman et al., 1992) or not at all (Gavel & von Heijne, 
1990). Finally, binding of Con A to three scFvs that contain no predicted sites was 
observed in M04, S06 and S017. S06 does contain one N-X-S/T sequon although it 
was not predicted to be glycosylated. In rare cases other sequence motifs have been 
shown to support glycosylation (Gavel & von Heijne, 1990), although these are not 
present in either M04 or S017. However, both scFvs do contain several asparagine 
residues, which the Drosophila cells may be able to glycosylate. In the majority of 
cases the variability in the molecular weights of the purified proteins can be explained 
by a combination of the primary amino acid sequence and by the presence or absence 
of N-linked glycosylation. For M08, B03 and S09 that have been shown not to contain 
N-linked glycosylation, the increased molecular weight could be due to the presence 
of O-linked glycosylation, which Drosophila is capable of achieving.
The viability of the S2 cells plays an important role in the quality of the purified 
recombinant scFv. Loss of viability at the time of harvest reduces the yield of purified 
scFv for two reasons. Firstly, cell death allows the release of proteases from the 
cytoplasm, which causes proteolysis, and secondly FKBP is also released and 
competes for binding to W7 during purification.
Overall, although expression in E. coli is effective for the production of scFv antibody 
fragments and high yields can be achieved it is not the ideal system for the
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simultaneous production of large amounts of many proteins. The Drosophila system 
with the CaM tag, though initially more time consuming due to the production of 
stable lines, has several clear advantages over the E. coli and baculovirus systems 
described by Neri and Li (Neri et al., 1995b; Li et al., 2000). Firstly, several cell lines 
can be maintained at the same time and protein expression can be induced when 
required. Secondly, manipulation of several samples can be done simultaneously as 
smaller volumes of culture supernatant are needed to provide milligram yields. 
Thirdly, it produces high yields of good quality scFv. Finally once the stable cultures 
have been established they can be maintained at room temperature, without the need 
for specialised incubators.
The pMT/BiP/V5 His D and pMT/BiP/CaM have been successfully used by 
collaborating scientists to express a number of scFvs (personal communication Nancy 
Wandersee, The Blood Centre of Southeastern Wisconsin, USA) and other proteins 
containing immunoglobulin folds, for example human glycoprotein VI (GPVI) 
(Smethurst et al., 2004) and the triggering receptor expressed on myeloid cells 
(TREM) like transcript-1 (TLT-1) (Barrow et al., 2004). An original manuscript 
detailing the use of calmodulin tagged D1D2 (extracellular domains of GPVI) for 
phage antibody isolation has been accepted for publication in Journal of 
Immunological Methods (Jennings et al., 2006).
The Drosophila expression system and the C-terminal Calmodulin tag provide an 
excellent protein expression system, with high yields and purity.
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Chapter 4A
Production of clinical grade DNA vaccines for administration to Follicular 
Lymphoma patients enrolled in the Cancer Research UK clinical trial (PH2/039)
4.1 Introduction
4.1.1 Follicular Lymphoma
Follicular Lymphoma (FL) is one of over 20 different types of Non-Hodgkin’s 
Lymphoma (NHL); NHL can be split into B cell and T cell lymphomas. FL is a B cell 
lymphoma and makes up about 25% of all NHL. FL can occur at anytime during 
adulthood, with the average age of onset in the sixth decade. Painless swelling in the 
neck, armpit or groin, due to enlarged lymph nodes, some loss of appetite and 
tiredness are the most common symptoms. A definitive diagnosis is performed by 
lymph node biopsy and microscopy, giving a histological classification. Histology 
further classifies the B cell NHL into low-grade, intermediate-grade and high-grade 
varieties (www.cancerbacup.org.uk)(Harris etal., 1994). Although these varieties of 
tumours are usually indolent and only slowly progressive, they seldom respond to 
conventional forms of treatment (chemotherapy and radiotherapy). Despite the fact 
that most follicular lymphomas are advanced at the time of diagnosis, the median 
survival of patients with follicular lymphomas is approximately 1 0  years, and 
allogeneic bone marrow/stem cell transplantation can induce long-term remissions in 
these patients (Forrest et al., 2002), but transplant-associated mortality is high.
Autologous bone marrow transplantation has low transplant-associated mortality, but 
most patients relapse after this modality of therapy. More recently trials with 
humanized antibodies against CD20 as adjuvant therapy seem to substantially improve 
the outlook for FL patients (Maloney et al., 1994; Maloney et al., 1997a; Maloney et 
al., 1997b; Davis et al., 1999). Recent studies have shown that the analysis of the 
transcriptome of FL cells does allow better categorization of disease genotype and the 
transcriptome signatures provide a better predictor for disease severity and survival 
than the morphological grading and clinical prognostic parameters currently used 
(Alizadeh et al., 2000; Glas et al., 2005).
4.1.2 The tumour specific target
For several reasons FL has become a model disease for immunotherapy. Firstly, 
impressive results were achieved in a small human trial infusing monoclonal anti­
idiotype in nine patients (Kwak et al., 1992). Complete tumour regression was 
reported in two patients. Secondly, the waxing and waning properties typical of 
lymphomas suggests a role for immune surveillance in FL. Finally, FL may result 
from profound immunosuppression, for example post-transplant lymphoproliferative 
disorders (PTLD). The incidence of PTLD has increased as a direct result of the long 
term use of cyclosporin A (CyA) and the new very potent immunosuppressants such 
as anti-CD3 monoclonal OKT3 and FK506 given for the prevention of transplant 
rejection (Penn et al., 1969; Otto et al., 1987; Boubenider et al., 1997; Bates et al., 
2003). Many research groups using different immunological approaches have pursued 
the notion that the immune system could be exploited to take control of minimal 
residual disease (MRD) in FL.
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The tumour cells express on their surface the B-cell differentiation markers, MHC 
class I and II molecules and monoclonal immunoglobulin (Ig) (Anderson et al, 1984). 
The monoclonal Ig is unique to a given lymphoma clone, distinguishing it from the 
patients healthy B cells and the lymphomas of other patients (Stevenson & Stevenson, 
1975; Levy et al., 1977). Immunoglobulins consist of two identical light polypeptide 
chains and two identical heavy polypeptide chains linked together by disulphide bonds 
(Roitt et al, 2001) (Figure 1.3). The light chain consists of one constant and one 
variable (V) domain, whereas in the case of IgG the heavy chain consists of one 
variable and three constant domains. The antigen-binding site is composed by the 
pairing of two individual V domains, one from the heavy chain (VH) and one from the 
light chain (VL). The variable domains are made up of framework regions (FR1-4) and 
three short hypervariable loops of amino acids, the complementarity-determining 
regions (CDR1-3). The binding specificity of the surface Ig is determined by sequence 
variability in these loops, length variability of both CDR3’s coupled with minor 
alterations in residues in the underlying p-sheet framework, which serve to adjust the 
orientation of individual loops.
During B cell development, random assembly of VH, D (Diversity) and J (Joining) 
gene segments on the heavy chain locus of a V and J gene on either of the light chain 
loci results in the de novo formation of a coding VH or VL gene respectively. A process 
of somatic hypermutation can then alter the sequence of the rearranged V genes, which 
is an important mechanism for affinity maturation (Neuberger & Milstein, 1995). 
Therefore, each B cell expresses a unique combination of VH and VL domains and 
hence a unique antigen binding site. The antigen-binding site itself is also an antigenic 
determinant and the collection of epitopes that it produces is known as the idiotype 
(Slater et al., 1955). It can therefore be the target of an anti-idiotypic response.
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The clonally derived population of transformed B cells in NHL expresses surface Ig 
whose idiotype represents a truly unique tumour-specific antigen (Stevenson & 
Stevenson, 1975). It is believed that immunotherapeutic strategies directed against the 
lymphoma idiotype will be able to mediate anti-idiotypic and / or cytotoxic (CTL) 
responses to elicit tumour destruction.
A phase I trial of idiotypic protein vaccination in 41 patients with NHL has been 
reported (Hsu et al., 1997). Briefly, heterohybridomas were prepared from tumour 
biopsies by fusion; clones expressing tumour derived Ig were expanded and idiotypic 
Ig were purified for administration to patients. The outcome of this study was 
suggestive that idiotypic vaccination is a potentially beneficial approach in the 
treatment of FL (Hsu et al., 1997). However the time and labour involved in making 
each patient specific vaccine, typically several months, limits the wider clinical 
application of this approach. Recent advances in antibody engineering and the advent 
of vaccination with naked plasmid DNA mean that patient-specific idiotypic DNA 
vaccines can now be readily produced. Pre-clinical studies in mice immunised with 
scFv DNA vaccine produced good cytotoxic and humoral responses against idiotype 
(Stevenson et al., 1995; Spellerberg et al., 1997; King et al., 1998). The immunisation 
against the idiotype by means of DNA vaccination is simpler and DNA vaccines for a 
phase I and phase I/II DNA vaccination trial in FL have been prepared in our 
laboratory (Hawkins et al., 1997; Stevenson et al., 2004).
4.1.3 pVAC2
The plasmid (pVAC2) used in this trial contains the VH/VL gene cassette derived from 
the patient’s malignant clone fused to the gene for fragment C of tetanus toxoid (FrC)
142
used as an immune enhancing element (Spellerberg et al., 1997). Tetanus Toxoid (TT) 
is a 1315 amino acid protein produced by the bacterium Clostridium tetani and is the 
most powerful neurotoxin known to man (Kisasato, 1889). It is composed of a heavy 
and light chain joined by disulphide bonds. FrC is the 451 amino acid, 50 kDa carboxy 
terminal fragment of the heavy chain. It is a highly immunogenic protein with several 
MHC class II restricted T cell epitopes (Demotz et al., 1989) and also has a 
promiscuous universal T helper cell epitope (TT 947-967), which can be presented by 
multiple Human Leucocyte Antigen (HLA) class II and murine MHC alleles (Panina- 
Bordignon et al., 1989). FrC has been used as an adjuvant in licensed clinical vaccines 
such as Hib (Plotkin & Orenstein, 1988) and in several experimental vaccines against 
Plasmodium falciparum and Plasmodium berghei (Valmori et al., 1992). A plasmid 
DNA vaccine encoding FrC has been shown to produce potent antibody responses and 
provide protection against TT challenge in mice (Anderson et al., 1996). It has also 
been shown that anti-idiotype responses in DNA vaccinated mice can be enhanced up 
to 50 times with FrC (Spellerberg et al., 1997) and the mean survival time after 
challenge with A31, a B-cell splenic lymphoma cell line is also increased (King et al., 
1998).
4.1.4 Assembly of VH / VL gene cassette
Rapid DNA sequencing can now identify the idiotypic immunoglobulin from RNA 
isolated from a tumour biopsy in a matter of days. The rearranged antibody V genes 
are amplified individually using the polymerase chain reaction (PCR), these amplified 
DNA fragments are then cloned and sequenced, and the tumour V genes, predominant 
in the starting material, are identifiable as recurring sequences. The tumour cell V
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genes can then be assembled as a single chain antibody fragment (scFv), in which a 
short glycine-serine peptide linker (GGGGS) 3  connects the VH and VL domains 
(Huston et al., 1991).
4.1.5 Clinical Trial
The outcome of the phase I clinical trial (PH1/027) did not show signs of obvious 
toxicity when administering escalating doses of naked plasmid DNA in patients with 
advanced stage FL (Hawkins et al., 1997). The objectives of the phase I/II trial, Study 
of Idiotypic Vaccination for Follicle Centre Lymphoma (LIFTT) (PH2/039), discussed 
here were to establish whether patients with FL can generate an immune response 
against, 1) a known immunogen (FrC) and 2) a tumour derived antigen (scFv), 
delivered by a DNA vaccine. The eligibility criteria for patient entry into the trial are 
given in Table 4.1.
The plasmid containing the scFv was directly administered into the deltoid muscle by 
simple needle injection, whereupon it is taken up and expressed by cells near the 
injection site (Wolff et al., 1990; Jiao et al., 1992; Wolff et al., 1992). The expressed 
protein is processed by antigen presenting cells (APCs) to elicit both humoral and 
cellular immune responses.
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Inclusion Exclusion
Histologically confirmed low-grade FL 
expressing surface Ig
Chemo or radiotherapy in the 10 weeks 
preceding proposed commencement of 
immunisation
Clinical complete remission A monoclonal band on serum 
electrophoresis
Life expectancy > 1 year Pre-existing anti-DNA, anti-muscle, 
rheumatoid factor activity or active 
autoimmune disease
Minimum age 18 years Positive for Human Immunodeficiency 
Virus (HIV) or Hepatitis B Virus (HBV)
Lymph node biopsy prior to 
chemotherapy suitable for RNA 
extraction
Other malignancies
Platelet count > 50 x 109  / L Pregnant or lactating
Signed informed consent Receiving other anti-cancer therapy
Withdrawal of consent
Table 4.1 Eligibility for patients in the LIFTT (PH2/039) clinical trial.
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Once accepted the patient was given a unique study identifier and RNA was extracted 
from a lymph node biopsy. Twenty-five FL patients were enrolled in the trial (Table
4.2), which was designed as a dose escalation study with 5 patients receiving 6  
immunisations of the designated dose over a 12-week period; the doses of DNA 
vaccine ranged from 0.5 mg -  2.5 mg. Each dose group must have completed their 
course of immunisations before patients could be enrolled at the next dose level. The 
duration of the trial from first to last vaccination was 50 months (from November 1999 
to January 2004).
4.1.6 Testing the DNA vaccines in rabbits
The validated patient vaccines were administered to Dutch rabbits; serum was assayed 
pre and post DNA vaccination for anti-tetanus and anti-idiotype responses. The 
recombinant scFv-CaM proteins (Chapter 3) were used in ELISA to detect the anti­
idiotype responses in these rabbits. The anti-tetanus and anti-idiotype data provided 
positive controls for the efficacy of the plasmid vaccine and a control for the scFvs 
and anti-idiotype assay. Once the assays were validated using rabbit serum the serum 
samples from a selected number of patients were also tested for the presence of anti­
tetanus and anti-idiotype IgG pre and post immunisation.
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4.2 Experimental Design
All reagents purchased for the making of the DNA vaccines were British 
Pharmaceutical (BP) grade or similar where possible. The lot numbers and date of 
receipt were recorded. The water used for making media or performing dilutions of the 
reagents was sterile water for irrigation and was purchased from Addenbrookes 
pharmacy. Any reagents used were made and sterilised on site and assigned unique 
batch numbers and 1 2 -month expiration dates.
The vaccines were produced under Good Manufacturing Procedures (GMP) and 
subjected to pre-release sterility and quality checks after they had been aliquoted into 
sterile vials for administration. Each vaccine was assigned a unique batch number.
4.2.1 Cloning of scFv in pVAC2
The patient VH/VL gene cassettes were assembled in pVAC2 at the trial centres in 
Southampton and Manchester. The pVAC2-scFv DNA along with a sequence file and 
alignments to the closest germline VH and VL genes were transferred to Cambridge. In 
our laboratory the cassettes were transformed into batch recorded DH5a competent 
cells (Gibco) (Chpt 2.2.1.9) and a single colony was grown O/N in LB media (Chpt
2.2) and used to inoculate 5 L of LB media in a 7 L fermentor (Applikon).
4.2.2 Giga prep of DNA vaccine
Plasmid DNA was isolated using Qiagen Gigaprep (Chpt 2.2.1.12), the contents of the 
buffers are listed in Appendix C.
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The fermented DH5a containing pVAC2-scFv DNA was pumped from the 
fermentation vessel into five sterile centrifuge bottles and centrifuged at 18000g for 2 0  
min at 4°C. Each pellet was resuspended in 125 ml of buffer PI, the bacteria was then 
lysed by the addition of 125 ml of buffer P2, mixed by inversion and incubated at RT 
for 5 min. The lysed bacteria was then neutralised with 125 ml of chilled buffer P3, 
mixed by inversion and each added to a QIAfilter Mega-Giga cartridge and incubated 
at RT for 10 min. The liquid was pulled through the filter using a vacuum. The filter 
was then washed with 50 ml of FWB2 and pulled through using a vacuum; the 
precipitate was stirred gently to aid filtration. The filtered lysates were transferred to a 
class II safety cabinet and a 75 pi sample was taken from each for an analytical gel to 
determine whether growth and lysis conditions were optimal (sample 1 a-e). The 
filtered lysates were then applied to pre-equilibrated Qiagen-tip 10000s and allowed to 
enter the resin by gravity flow. A 75 pi sample of each flow-through was taken for an 
analytical gel to determine the efficiency of DNA binding to the Qiagen resin (sample 
2 a-e). Each Qiagen-tip was then washed with a total of 600 ml of buffer QC. A 120 pi 
sample of the combined wash fractions was taken for an analytical gel (sample 3 a-e). 
The DNA was then eluted from the Qiagen-tips with 100 ml of buffer QF. A 22 pi 
sample of each eluate was taken for an analytical gel (sample 4 a-e). The DNA was 
precipitated by the addition of 70 ml of isopropanol and centrifuged at 18000 g for 30 
min at 4°C. The supernatant was removed and each pellet resuspended in 10 ml of 70 
% ethanol and centrifuged as above for 10 min. The pellets were air-dried for 10 min 
and resuspended in a total volume of 10 ml of sodium chloride injection BP 0.9% w/v 
(Phoenix Pharma Ltd). The DNA pellet was then subjected to two rounds of ethanol 
precipitation (Chpt 2.2.1.13) then resuspended in sodium chloride as above to the 
appropriate concentration. A 2 pi sample of the final product was taken for the
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analytical gel (sample 5). Samples 1-5 were analysed on a 1.2% agarose gel (Chpt 
2.2.1.3).
4.2.3 Sterile Fill of DNA vaccine
The DNA vaccines were aliquoted into nitrogen filled sterile vials (Amersham) in a 
Grade A laminar flow cabinet in a Grade B aseptic suite designed for sterile 
manipulation of blood, blood products and tissues at the National Blood Service 
Cambridge. All equipment entering the room was autoclaved in double bags where 
appropriate and sprayed with isopropanol. Personnel entering the room were required 
to wear single use all-in-one suits, including surgical facemasks and hats. The 
outermost covers of the equipment were removed before placing in the laminar flow 
cabinet. Once the vials had been filled they were removed from the cabinet and 
labelled before being sealed in individual bags. Only one patient vaccine was allowed 
in the room at any one time.
4.2.4 Vaccine validation
4.2.4.1 Sterility of DNA vaccines
The sterility test was performed in the Public Health Laboratory (PHLS East), 
Addenbrookes Hospital, Cambridge. Two sterile filled vials of DNA vaccine were 
added under sterile conditions into two bottles of BacT/Alert® FAN® aerobic culture 
bottles and incubated at 37°C for 5 days. Any growth was recorded and an 
Environmental Microbiology Report was filed.
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4.2A.2 Endotoxin Levels in the DNA vaccines
The amount of endotoxin in each vaccine was tested at two laboratories, the Bio 
Products Laboratory (BPL), Hertfordshire and National Institute for Biological 
Standards and Controls (NIBSC), Hertfordshire. The endotoxin levels were measured 
in Endotoxin Units (EU) or International Units (IU) /ml, which is equivalent to 0.1 ng 
endotoxin/ml. For the vaccine to be accepted the endotoxin level was required to be 
below 2500 EU/ml. The vaccine was accepted based on the highest level recorded.
4.2.4.3 Quality checks of the DNA vaccine
After the sterile fill each DNA vaccine was sequenced (Chpt 2.2.1.14) and the 
sequence compared to the original that was provided at the transfer of the pVAC2- 
scFv cassette to Cambridge. The vaccine plasmids were also digested with Sail, 
Hindlll / Notl and Sfil / Notl (Chpt 2.2.1.15) and the sizes analyzed on a 1.2% agarose 
gel (Chpt 2.2.1.3).
4.2.5 Immunisation and assay of sera
To test the efficacy of each of the patient vaccines, one Dutch rabbit was immunised 
i.m. with each of the patient vaccines (Chpt 2.2.3.1). Each rabbit was initially 
vaccinated with 200 [ig of pVAC2-scFv plasmid DNA in PBS injected at equal dose 
into two sites in the quadriceps muscles. Immunisations were performed at days 0, 14 
and 28. Bleeds were taken at days 0 and 35 to measure antibody responses. Serum was
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assayed by ELISA for the presence of IgG against tetanus toxoid (Chpt 2.2.4.1), 
cognate idiotype and non-cognate idiotype for cross reactivity (Chpt 2.2.4.2).
4.2.6 Site directed mutagenesis and expression of mutants
scFvs B04 and B05 each contain one putative N-linked glycosylation site at residues 
50 and 99 respectively. These Putative glycosylation sites are identified by the 
following amino acid sequons, B04 Asn-Ile-Thr and B05 Asn-Ile-Ser. Primers were 
designed to mutate the asparagines to alanine residues (Table 4.3) and used in 
Stratagene XL site directed mutagenesis kit (Chpt 2.2.1.17).
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Primer
Code
Sequence 5’ to 3*
M elting  
point 
(Tm  °C)
B04
N50AF
GCGACTGGAGTGGATTTCAGCCATTACTAGTAGTGGC 78.3
B04 
N50A R
GCCACTACTAGTAATGGCTGAAATCCACTCCAGTCGC 78.3
B05
N99AF
GTATTACTGTGCGAAGGCTATTAGTATGGAAATATGGGGCC 7 8 .2
B05
N99AR
GGC C C CATATTT C CATAC TAATAGC C T TC GCACAGTAATAC 7 8 .2
Table 4.3 Nucleotide sequences and melting temperatures of the site directed 
mutagenesis primers. The nucleotide substitutions to mutate Asparagine to Alanine are 
shown in red. F (Forward primer) is the sequence of the sense strand, R (Reverse 
primer) is the sequence of the antisense strand.
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4.2.7 Clinical Trial patient serum
Patients received 6  doses of their tailor-made DNA vaccine over a 12-week period. 
Immunisations were given on weeks 0,1, 2,4, 8  and 12. Blood samples were taken on 
weeks 0,1,2, 3,4, 8,12,16 and then every 4 weeks up to 52 weeks after the first 
immunisation. Patients unable to attend clinic at these specific time points were 
sampled at their closest outpatient appointment.
The work described in this chapter shows firstly the processes required to generate the 
clinical grade pVAC2-scFv DNA and the necessary sterility, endotoxin and plasmid 
structure checks needed before the vaccine can be administered. Secondly it reports on 
studies to establish whether our DNA vaccination plasmid pVAC2-scFv is capable of 
eliciting anti-tetanus and anti-idiotype responses in Dutch rabbits. Thirdly, to what 
extent is the polyclonal anti-idiotypic response cross-reactive? Fourthly, do the 
patients in the clinical trial produce anti-idiotype responses and are they showing an 
increase in anti-tetanus post vaccination? Finally, does the binding of anti-idiotype 
IgG depend on the presence of the glycan moieties in the second and third CDRs of 
the VH domains?
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4.3 Results
A summary of the 25 patient vaccines that were made and administered during the 
course of the trial is in Table 4.5. The vaccines that I prepared and checked are 
indicated by **. The results shown in this chapter are from one of these vaccines 
(B05) and it is representative of all the vaccines prepared. Copies of the DNA vaccine 
preparation sheets completed in Cambridge are shown in Appendix E.
4.3.1 Analysis of Giga-Prep
The aliquots taken during the DNA preparation (Chpt 4.2.2) were analysed on a 1.2% 
agarose gel (Figure 4.1). As expected the cleared lysate contains supercoiled and open 
circular plasmid DNA, lanes 1-5 (sample 1). Four of the five flow-through fractions, 
lanes 6-10 (sample 2) contain no DNA, indicating that the DNA binding to the resin 
was efficient. In lane 9 some of the DNA has passed through the column, compared to 
lane 4 this is a small fraction of the DNA initially added to the column. No bands were 
visible in lanes 11-15, no DNA was present in the combined wash fractions (sample 
3), and the pure plasmid DNA remained on the column. Lanes 16-20 shows the eluates 
containing pure plasmid DNA. Interestingly it appears that the DNA was not equally 
distributed over the five columns, lanes 1-5 and 16-20. Lane 21 shows the aliquot of 
the pooled plasmid DNA from columns a-e.
The DNA from lane 21 was diluted 1:100 and the OD at 260 and OD 280 nm was 
measured (Table 4.4 A). The concentration was calculated using the equation in 
Chapter 2.2.1.2 and the 260:280 ratio was also recorded (Table 4.4 B) A ratio between 
1.7 and 2.0 was accepted.
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Patient B05 received the 2.5 mg dose; no further dilution of the DNA was needed and 
16 vials were filled in total.
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A)
Wavelength (nm) Optical Density (OD)
260 0.491
280 0.269
B)
Dilution Factor 
(df)
Concentration (fig/ml) 
OD @ 260nm x 50 x df
260:280 ratio
1 : 1 0 0 2455 1.825
Table 4.4 DNA concentration and purity measurements. A) Optical density of B05 
DNA vaccine at 260 and 280nm. B) Concentration and purity calculation of B05 DNA 
vaccine.
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M 1 2 3 4 5 6 7 8 9  10 M
Figure 4.1 Agarose gel of samples recovered during Giga-prep plasmid DNA 
purification. Samples were removed and the DNA precipitated with 1 volume of 
isopropanol. The pellet was then washed with 200 pi of 70% ethanol, the pellet was 
resuspended in 10 pi of water, 2 pi of each fraction was analysed on a 1.2% agarose 
gel. Five columns were used in the preparation of this vaccine; samples were taken 
from each column and labelled a-e. Lanes 1-5 cleared lysate a-e, Lanes 6-10 column 
flow-through a-e, Lanes 11-15 pooled wash a-e, Lanes 16-20 eluted DNA a-e, Lane 21 
pooled, ethanol precipitated DNA vaccine, M -  1 Kb DNA marker.
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4.3.2 Vaccine validation
4.3.2.1 Sterility
Two vials of vaccine were incubated in two vials of BacT/Alert® FAN® aerobic culture 
bottles and grown at 37°C for 5 days. No growth was reported (Figure 4.2) during this 
period, the vaccine is classed as sterile.
4.3.2.2 Endotoxin level
The sterile vaccine was sent to BPL and NIB SC for endotoxin testing. The test results 
are shown in Figure 4.3 and 4.4 respectively. BPL measured the amount of endotoxin 
present as 14.4 EU/ml (Endotoxin Units) whereas NIBSC reported levels of between 
3-6 IU/ml (International Units). 1 EU or IU/ml is approximately equal to 0.1 ng/ml. 
Both measurements fall within the maximum criteria so the vaccine is acceptable.
4.3.2.3 Plasmid structure
The plasmid structure of the final product was confirmed by restriction enzyme digest 
analysed on a 1.5% agarose gel (Figure 4.5). Firstly, a Sail digest was performed. 
pVAC2 Sail digest should produce bands at 2745, 2188, 938, 63 and 34 base pairs 
(bp), whereas pVAC2-scFv Sail digest should produce bands at 2745, 2188, 1700 
(approx.) and 34 bp. Figure 4.5 A confirms the predicted pattern of bands. The 6 8  and
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34 bp fragments are not visible on the gel. Secondly, Hindlll / Notl and Sfil / Notl 
double digests were performed on pVAC2-scFv. The Hindlll / Notl digest should 
produce bands at approximately 900 and 4552 bp and the Sfil / Notl digest should 
produce bands at approximately 850 and 4606 bp. Figure 4.5 B confirms the predicted 
pattern of bands. pVAC2-scFv incubated with restriction enzyme buffer only provided 
an undigested control. Two bands are present, the upper band is supercoiled plasmid 
DNA and the lower band is nicked circular plasmid DNA (Figure 4.5 A and B).
DNA sequencing confirmed that the sequence of the final product is identical to the 
sequence of the original pVAC2-scFv construct received from Bournemouth.
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PHLS East - Public Health Laboratory, Addenbrookes Hospital, Cambridge
1 4 / 0 8 / 0 2  C . P . A .  a c c r e d i t e d  E n q u i r i e s :  ( 0 1 2  2 3 ) 2 5 7 0  3 6 29
E N V IR O N M E N T A L  M IC R O B IO L O G Y  R E P O R T
Cumulative record reference;A 9 3 8 4 3 7 0  ZZDNAVACCINBLAB
sender: H a n n e r ,X a n
Anti-idiotypic DNA vaccine Lab
(Location; MEDNAVL )
SENDERS REFERENCE: . Lab No: 02:ME0002596R BC#: 709380
Collected: 07/08/02 1115
SAMPLE: DNA Vaccine Received: 07/08/02 1115
DNA VACCINE IN FAN BOTTLE X2
Source/place of sampling: WILKS,PAMELA 
Reason for request: Informal test
• REPORT: '
[Sterility check] Final 14/08/02-1551
No growth.
Figure 4.2 Environmental microbiology report for DNA vaccine B05. Sterile filled 
DNA vaccine was added to BacT/Alert® FAN® aerobic culture bottle and incubated at 
37°C for a minimum of 5 days. No growth was recorded by 14/08/02, seven days after 
starting the incubation.
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Figure 4.3 LAL (Lymulus amoebocyte lysate) test for endotoxin performed by Bio 
Products Laboratory (BPL) Hertfordshire. The results are given as Endotoxin units 
(EU) /ml, 1 EU/ml s  0.1 ng/ml.
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Figure 4.4 LAL test for endotoxin performed by National Institute for Biological 
Standards and Controls (NIBSC), Hertfordshire. The results are given as International 
units (IU) /ml, 1 IU/ml e 0.1 ng/ml.
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Figure 4.5 Restriction fragment analysis of the final pVAC2-scFv DNA vaccine B05.
1 pg of DNA was incubated with 1 pi of restriction enzyme and 1 pi of reaction buffer 
at the appropriate temperature for 4 hours. 5 pi of each digest was analysed on a 1.5% 
agarose gel. A) Lane 1 -  pVAC2 Sail digest, Lane 2 -  pVAC2-scFv uncut, Lane 3 -  
pVAC2-scFv Sail digest. B) Lane 1 -  pVAC2-scFv uncut, Lane 2 -  pVAC2-scFv 
Hindlll / Notl digest, Lane 3 -  pVAC2-scFv Sfil / Notl digest. M -  1 Kb DNA 
marker.
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Chapter 4B
Antibody Responses in Rabbits and Follicular Lymphoma Patients receiving 
pVAC2-scFv DNA vaccines
4.4 Results
4.4.1 Antibody responses in rabbits
Dutch rabbits were immunised intramuscular with 200 pg of pVAC2-scFv at days 0, 
14 and 28, bleeds were taken at days 0 and 35. IgG responses against tetanus and 
idiotype was measured and used to assess transcription and translation of the patient 
vaccine plasmids in vivo. The potential immunogenicity of the vaccine was measured 
by the ability of the individual rabbits to produce anti-idiotype responses. However, it 
is important to note that there were no tests performed for the expression of antigen 
(patient recombinant scFv). Therefore failure to detect an immune response in the 
rabbit sera may be due to failure of expression, lack of immunogenicity or inadequate 
delivery of the scFv.
4.4.1.1 Anti-tetanus
Sera from rabbits immunised with pVAC2-scFv were assayed for the presence of anti­
tetanus IgG; pre-immune samples were also assayed as negative controls (Figure 4.6).
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ELISA was performed as described in Chpt 2.2.4.1. The anti-tetanus IgG produced 
varied between vaccines but the majority were able to elicit good to excellent 
responses after three immunisations (19/23) (Figure 4.6 A-D). The responses were 
arbitrarily graded based on values for the area under the curves (Table 4.6). The 
remaining four, M06, M08, S03 and SOD required a further two immunisations in 
order to produce measurable but low potency anti-tetanus responses (Table 4.6). For 
21 of the 23 rabbits tested the IgG levels had titrated out at a dilution of 1/1280. The 
remaining 2, S09 and S011 required further dilutions (1/20000) to complete the 
titration curve (Figure 4.6 D).
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Vaccine Identifier Anti-tetanus response Anti-idiotype response
No. of immunisations 3 5 3 5
B01 +++ +++
B02 +++ +++
B03 +++ +
B04 +++ +++
B05 +++ +++
M01 +++ +++
M02 +++ -
M03 ++ +++
M04 +++ +++
M05 +++ nt nt
M06 ++ +++
M08 ++ +++
SOI +++ +++
S02 +++ +++
S03 ++ -
S04 +++ +++
S05 +++ +++
S06 +++ ++
S07 +++ +
S09 +++ +++
soil +++ +++
S012 +++ -
S013 +++ ++
Table 4.6 Summary of IgG responses in Dutch rabbits receiving pVAC2-scFv. The 
anti-tetanus and anti-idiotype was measured after 3 immunisations, a negative 
response resulted in 2 further immunisations and re-testing. The responses were 
graded based on values for area under the curve (AUC). Key: AUC > 0.7, ++++ = 
Excellent; AUC 0.5-0.7, +++ = Good; AUC 0.2-0.5, ++ = Adequate, AUC 0.1-0.2, + = 
Poor; AUC < 0.1, no response.
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Figure 4.6 A) Anti-tetanus responses in Dutch rabbits immunised with
pVAC2-scFv patient DNA vaccines.
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B) Anti-tetanus responses in Dutch rabbits immunised with pVAC2-scFv patient DNA
vaccines.
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C) Anti-tetanus responses in Dutch rabbits immunised with pVAC2-scFv patient DNA
vaccines.
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D) Anti-tetanus responses in Dutch rabbits immunised with pVAC2-scFv patient DNA
vaccines.
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Figure 4.6 A-D Anti-tetanus responses in Dutch rabbits immunised with pVAC2-scFv 
patient DNA vaccines. Each line represents a titration of pre-immune (pre, broken 
line) or immune (post, solid line) serum from a single rabbit. Animals were immunised 
i.m. into both quadriceps, with two doses of 100 p,g of patient DNA vaccine on days 0, 
14 and 28. An ear vein bleed was taken on days 0 and 35 and tested in ELISA. The 
responses are shown as specific IgG present in immune compared to pre-immune 
serum samples.
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4.4.1.2 Anti-idiotype
ELISA was performed as described in Chpt 2.2.4.2. The responses of anti-id between 
the rabbits were varied. Nine vaccines elicited good to excellent responses after three 
immunisations. The remaining thirteen received a further two immunisations; resulting 
in a good to excellent response in a further six rabbits and four achieved poor to 
adequate responses (Table 4.6). Of the remaining five vaccines, B03, S07 and SO 12 
produced a poor response and M02 and S03 still failed to elicit an anti-id response 
(Figure 4.7 B, C and D). Interestingly the poor response to vaccination for three 
vaccines (M02, S03 and SO 12) was related with poor expression of the respective 
scFvs in Drosophila S2 cells (Table 3.1). Anti-idiotype responses to vaccine M05 
could not be measured as no recombinant scFv was produced but a rabbit anti-Tet 
response was observed with this vaccine (Figure 4.6 B). The responses were graded as 
before based on values for area under the curve. As with the anti-tetanus responses 21 
of the 22 sera tested titrated out beyond the dilution of 1/1280. Due to the high titres of 
anti-tetanus for S09 and S011 these samples were titrated further than the other 
samples. The anti-idiotype titration for S09 was similar to that of the other anti­
idiotypes titrating out at 1/2560. S011 however titrated out at 1/20480.
173
Ab
s 
@ 
45
0n
m 
Ab
s 
@ 
45
0n
m
Figure 4.7 A) Anti-idiotype responses in Dutch rabbits immunised with pVAC2-scFv
patient DNA vaccines.
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B) Anti-idiotype responses in Dutch rabbits immunised with pVAC2-scFv patient
DNA vaccines.
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C) Anti-idiotype responses in Dutch rabbits immunised with pVAC2-scFv patient
DNA vaccines.
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D) Anti-idiotype responses in Dutch rabbits immunised with pVAC2-scFv patient
DNA vaccines.
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Figure 4.7 A-D Anti-idiotype responses in Dutch rabbits immunised with pVAC2- 
scFv patient DNA vaccines. Each line represents a titration of pre-immune (pre, 
broken line) or immune (post, solid line) serum from a single rabbit. Animals were 
immunised i.m. into both quadriceps, with two doses of 100 pg of patient DNA 
vaccine on days 0, 14 and 28. An ear vein bleed was taken on days 0 and 35 and tested 
by the CaM-scFv capture ELISA. The responses are shown as specific IgG present in 
immune compared to pre-immune serum samples.
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4.4.2 Cross reactivity of anti-idiotypes in rabbit serum
Polyclonal anti-idiotype responses are prone to cross-reactivity (reviewed in (Davie et 
al., 1986)) possibly as the direct result of the sharing of VH or VL domains between 
cognate and non-cognate idiotypes. In this chapter the level of cross-reactivity has 
been investigated in some detail using the unique panel of serum samples from 23 
Dutch rabbits immunised with FrC enhanced DNA vaccines harboring unique VH/VL 
gene cassettes. The anti-idiotype activity against the cognate idiotype was determined 
in all samples (Table 4.7) and the 17 rabbit sera with good to excellent activity against 
the cognate idiotype were entered in further studies to investigate cross-reactivity. 
Excluded from the analysis were the rabbit serum samples that failed to give a good 
(minimum ++) response to cognate scFv (Table 4.6) and the four for which 
recombinant expression of scFv proved awkward. The experiment for cross-reactivity 
will also establish whether any of the rabbit sera has activity against the common 
amino-terminal Arg-Ser-Met-Ala and the carboxy-terminal Ala triplet motifs 
introduced into the recombinant protein by the Ncol and Notl restriction sites 
respectively or the CaM tag. The experiment was therefore limited to 17 recombinant 
FL patient derived scFv-CaM and the prototype scFv-B2 and its corresponding rabbit 
anti-id serum, which was used to produce a titration curve for each ELISA plate. In 
the first instance cross-reactivity was performed using each of the 18 rabbit serum 
samples in turn against the panel of 18 recombinant CaM tagged scFvs. Five of the 
serum samples tested were cross-reactive; a summary of these findings is presented in 
Table 4.7.
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13 of the 18 serum samples do not cross react, they are specific for the cognate 
idiotype that was used for immunisation. Five of the serum samples (B01, M04, S05, 
S09 and S011) did cross-react with 6 , 3, 9, 3 and 7 scFvs respectively. For all these the 
extent of cross-reactivity was further quantitated by testing the reaction with the non- 
cognate scFvs in titration (Figures 4.8 A-D). The cross-reacting serum was titrated to 
establish the strength of the cross reactivity (Chpt 2.2.4.2). Based on this additional 
analysis the antisera can be divided in two types of narrow and broad cross-reactivity. 
M04 and S09 are examples of the former and the remaining three of the latter (Table 
4.7).
M04 only reacts with three of the 17 scFvs and two of these (S05 & S09) have a high 
degree of homology to the same germline VH gene V3-48 and the same germline VL 
gene DPK9 (Vkl). The antiserum also reacts with B05, a scFv with a similar VH 
domain encoded by the VH3 family gene 3-23 and a VK1 family gene A30. As 
expected the antiserum obtained by immunisation with vaccine S05 does react with 
scFv M04 but the one obtained by S09 immunisation does not. The latter is another 
example of an antiserum with narrow cross-reactivity and anti-S09 sees only three 
additional clones (S04, S05 and S013). Two of the three (S05 and S013) carry VH 
genes with homology to V3-48 paired with the V k I and V k3 domains homologous to 
DPK9 and DPK22 respectively. The VH domain shows 85% homology to the one 
used for immunisation. The third reactive scFv is S04 (encoded by germline genes 3- 
21/Vg38) with a Vh and VK domain belonging to the same gene family groups as the 
other two reactive idiotypes.
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The antisera against B01, S05 and SOll have rather broad cross reactivity. On initial 
observation the pattern of cross-reactivity is poorly explained but a more careful 
inspection shows some striking similarities between several of the cross-reactivities. 
For anti-BOl the most reactive scFvs, M01, SOI and SOll all have a VH domain 
encoded by a Vh4 family gene either paired with DPK22 (SOI) or DPK24 (M01,
SOll). The three other reactive scFvs M08, S02 and B02 are of structurally different 
categories but all three have a Vx domain, either from the Vx2 or Vx3 gene family. For 
one of the six reactive scFvs (SOll) the corresponding SOll antiserum was also shown 
to be strongly cross-reactive with scFv B01 confirming the presence of a shared 
idiotype between the 4-59 and 4-34 germline VH domains.
The anti-S05 serum cross-reacts with 9 of the 17 scFvs, three of which B04, S09 and 
SOI3 are all encoded by the V3-48 VH germline homologous to the VH domain of the 
immunogen. As expected the anti-S09 reacts strongly with scFv S05. The other anti- 
SOS reactivities are more complex. Phylogenetic analysis of the 27 VH3 genes reveals 
three groups of 10, 14 and 3 genes respectively. Interestingly the 3-15, 3-21 and 3-23 
(germlines of M08, S02 and S04 and B05 respectively) are clustered in the second 
group of 14. Anti-S05 binds the 3-23 strongly when paired with the A30 VK1 domain 
(B05), but not at all when paired with the Vx2 domain DPL11 (M03) or the VK4 
domain DPK24 (M06).
In total four (B04, S05, S09 and SOI3) antibodies have a 3-48 VH domain and all are 
paired with a VK domain. Interestingly all three ‘S’ ones share idiotypes defined by 
anti-S05 and -S09 and two of them (S05 and S013) by anti-SOll, but the same three 
sera are inert (S09 and SOll) or weak (S05) against scFv B04. Amino acid sequences
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of the VH and Vk domains of S05, S09 and B04 antibodies are shown aligned to their 
closest germline genes in Figures 4.9 and 4.10. As expected there is a high degree of 
homology between the VH domains (Figure 4.9). The most notable difference is the 
length of the CDR3 of S09,15 amino acids compared with the 10 amino acids of S05 
and B04. The VL genes of S05 and S09 also align to the same VkI germline gene, 
DPK9 whereas the VL gene of B04 aligns with a Vk3 germline gene DPK22 (Figure 
4.10).
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Figure 4.8 A) Cross-reactive anti-idiotype responses in Dutch rabbits immunised with
pVAC2-scFv patient DNA vaccines.
2 . 0  n
1 .5 -
1 .0 -
0 .5 -
0 . 0
0 . 1 0 . 0 1 0 . 0 0 1 0 . 0 0 0 1
—— cognate M04
—  B05
—  S05
—  S09
—— negative B2
log (1/serum dilution)
2 . 0  n
1 .5 -
1 .0 -
0 .5 -
0 .0 -
—-cogn ate  S09
—  S04
—  S05
—  S013
—  negative B2
0.1 0 . 0 1  0 . 0 0 1  
log (1/ serum dilution)
— i 
0 . 0 0 0 1
183
Ab
s 
@ 
45
0n
m
 
Ab
s 
@ 
45
0n
m
 
Ab
s 
@ 
45
0n
m
B) Cross-reactive anti-idiotype responses in Dutch rabbits immunised with pVAC2-
scFv patient DNA vaccines.
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C) Cross-reactive anti-idiotype responses in Dutch rabbits immunised with pVAC2-
scFv patient DNA vaccines.
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D) Cross-reactive anti-idiotype responses in Dutch rabbits immunised with pVAC2-
scFv patient DNA vaccines.
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Figure 4.8 A-D Cross-reactive anti-idiotype responses in Dutch rabbits immunised 
with pVAC2-scFv patient DNA vaccines. Each line represents a titration of post 
immune serum from a single rabbit. The cognate is shown in red and the negative 
control in black. Animals were immunised i.m. into both quadriceps, with two doses 
of 100 j^g of patient DNA vaccine on days 0, 14 and 28. An ear vein bleed was taken 
on days 0 and 35 and tested by the CaM-scFv capture ELISA. The responses are 
shown as specific IgG present in immune serum samples.
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4.4.3 Anti-tetanus responses in normal human serum
Serum from a random sample of ten donors from the National Blood Service 
Cambridge donor clinic was assayed for the presence of anti-tetanus IgG (Figure 4.11) 
(Chpt 2.2.4.1). The samples tested show varied IgG responses against the TEFT coated 
onto the ELISA plate (Figure 4.11).
4.4.4 Anti-idiotype responses in normal human serum
The same panel of 11 donor serum samples was investigated for the presence of anti­
idiotype (Chpt 2.2.4.2). The ELISA data shows that anti-idiotypes are present in 
random serum samples, with some having broad reactivity and others being more 
specific, for example samples 4 and 6  (Table 4.8, Figure 4.12). Of the eleven scFvs 
only M01 was not recognized by any of the donor samples, conversely M03, B04 and 
B2 were recognized to some degree by all the samples. The remaining seven scFvs 
were selectively recognized by a small number of donor samples (Table 4.8).
There is no evidence for the presence of antibodies against common epitopes 
introduced during recombinant scFv expression. However, as discussed in Chapter 3, 
several of the recombinant scFvs are glycosylated (Table 3.1). B04, M02, M04, M06 
and SOI 1 were discovered to bind concanavalin A, which indicates the presence of N- 
linked glycosylation. Human serum has naturally occurring antibodies against non-self 
carbohydrate moieties and can therefore explain the wide reactivity observed with 
some of the scFvs, for example B04. Site-directed mutagenesis has been used on B04 
and B05 to remove the N-linked glycosylation sites (Chpt 4.2.3).
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d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 
donor sample
Figure 4.11 Anti-tetanus in normal human serum. Each bar represents a 1:20 serum 
dilution from an individual donor. Serum was taken with the donors consent from a 
routine visit to the donor clinic at the National Blood Service Cambridge. Samples 
were tested for the presence of anti-tetanus by ELISA. The results are shown as bound 
IgG present in each sample.
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scFv
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B04 ' ---------
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B05
M01
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Table 4.8 Summary of the ELISA data assessing the anti-idiotype binding in control 
human serum samples. The OD value @ 450nm was taken and the responses 
quantified as follows; OD > 1.5 H H , OD > 1.0 < 1.5 OD > 0.5 < 1.0 ¥JM, OD > 
0.25 < 0.5 &M,  OD < 0.25 CZL
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Figure 4.12 A) Anti-idiotype activity in control human serum samples.
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B) Anti-idiotype activity in control human serum samples.
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C) Anti-idiotype activity in control human serum samples.
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D) Anti-idiotype activity in control human serum samples.
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E) Anti-idiotype activity in control human serum samples.
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F) Anti-idiotype activity in control human serum samples.
Ec
o
1 0
<§)
(/)A
<
2 .0 n
1.5-
1 .0 -
0.5-
0 .0 -
-x-:-
» x
v»
1 2 3 4 5 6 7 8 9  10 11
donor sample
Figure. 4.12 A-F Anti-idiotype activity in normal human serum. Each bar represents a 
1:20 serum dilution from an individual donor. Serum was taken with the donors 
consent at a routine visit to the donor clinic at NBS Cambridge. Samples were tested 
for the presence of anti-idiotype by the CaM-scFv capture ELISA. The responses are 
shown as specific bound IgG.
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4.4.5 Anti-idiotype responses in patients’ pre and post vaccination with pVAC2-
scFv
The serum samples from selected patients were tested for the presence of IgG against 
their cognate scFvs by ELISA (Figure 4.13). Each patient sample was used at a 
dilution of 1:20, and results with B03, M01, M02, M04, M06 and M08 are shown in 
Figure 4.13 A, B and C. From this we conclude that there is no measurable IgG 
response against cognate scFv either pre- or post-immunisation. Patients B04, B05, 
M03 and S011 (Figure 4.13 D, E) have measurable IgG responses against cognate 
scFv, however there is no increase in this response post-immunisation. The pre- and 
final post-immunisation samples from each patient were tested against the 
extracellular domains of GPVI (DlD2-CaM) as a negative control. The OD at 450 nm 
for each sample was less than 0 . 2  (data not shown).
4.4.6 Anti-tetanus responses in patients pre and post vaccination with pVAC2- 
scFv
The patient serum samples that were positive for anti-idiotype were tested for the 
presence of anti-tetanus (Figure 4.14). There is no significant difference in the IgG 
responses against TEFT in the pre- and post-immune samples. Also there is no 
significant difference to the anti-tetanus in these patients compared with the donor 
control panel (Figure 4.11).
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Figure 4.13 A) Anti-idiotype activity against cognate scFv in sequential patient 
samples.
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B) Anti-idiotype activity against cognate scFv in sequential patient samples.
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C) Anti-idiotype activity against cognate scFv in sequential patient samples.
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D) Anti-idiotype activity against cognate scFv in sequential patient samples.
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E) Anti-idiotype activity against cognate scFv in sequential patient samples.
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Figure 4.13 A-E Anti-idiotype activity against cognate scFv in sequential patient 
samples. Several serum samples from selected patients were tested for the presence of 
specific IgG against cognate idiotype by the CaM-scFv capture ELISA. The responses 
are shown as specific bound IgG. Each bar represents a 1:20 serum dilution from each 
individual, the timepoint of sampling in relation to the first vaccination is presented.
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Figure 4.14 A) Anti-tetanus activity in sequential patient samples.
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B) Anti-tetanus activity in sequential patient samples.
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Figure 4.14 A-B Anti-tetanus activity in sequential patient samples. Several serum 
samples from selected patients were tested for the presence of specific IgG against 
tetanus by ELISA. The responses are shown as specific bound IgG. Each bar 
represents a 1 : 2 0  serum dilution, the timepoint of sampling in relation to the first 
vaccination is presented.
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4.4.7 Mutation of N linked glycosylation sites
The patients showed no increase in IgG titre against cognate scFv-CaM during the 
course of the clinical trial. The presence of IgG reactivity against the cognate idiotype 
in patients M03, B04, B05 and S011 may be a true reflection of a pre-existing immune 
response against the malignant clone. Alternatively the positive reaction is due to 
antibodies against the glycan moieties on the recombinantly expressed scFv. Insect 
cells add less complex glycosylation than mammalian systems therefore the human 
sera may contain naturally occurring IgG antibodies against these glycan moieties. In 
order to test whether the human sera contains carbohydrate reactive antibodies it was 
necessary to mutate the asparagine residues N50 in B04 and N99 in B05. These were 
chosen for following reasons. Firstly, both had a single N-linked glycosylation site. 
Secondly, there is control donor serum that is strongly positive for both B04 and B05 
scFv. Thirdly, since B05 did not bind Con A (Figure 3.17) and is therefore not 
expected to be glycosylated the alanine mutant will provide a suitable loss of function 
control. Finally, the B04 and B05 patient serum bind to their respective cognate scFvs.
4.4.7.1 Site directed mutagenesis (SDM)
B04 and B05 scFvs were mutated to incorporate an alanine residue in place of an 
asparagine residue at positions 50 and 99 respectively. The templates for the SDM 
were pMT/BiP/CaM-B04 and pMT/BiP/CaM-B05 (Appendix A). SDM was 
performed (Chpt. 2.2.1.17) using the primers in Table 4.3. The mutated sequence was 
confirmed by DNA sequencing (Chpt. 2.2.1.14). The mutated VH/VL gene cassettes of
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B04 and B05 were sub-cloned into pMT/BiP/CaM; confirmation of correct gene 
insertion was by sequence analysis (Figure 4.15).
4.4.7.2 Expression and purification of asparagine mutants
pMT/BiP/CaM+B04-N50A and pMT/BiP/CaM+B05-N99A were expressed and 
purified from supernatant as before; the eluted fractions were analyzed on a 12% SDS- 
PAGE gel and stained with Coomassie blue (Figure 4.16). Interestingly the apparent 
molecular weight of the mutated B04-N50A is lower than the original B04 this is a 
good indicator that the protein has lost some or all of its glycosylation. The lack of 
glycosylation will make the protein traverse the gel faster. Purified B05-N99A appears 
to have the same molecular weight as B05, indicating that the mutation has not 
affected the glycosylation status of the protein. The concentration of protein in the 
purified fractions was determined by BCA assay (Chpt 2.2.2.10) with yields of 0.2 
mg/ml and 0.7 mg/ml for B04-N50A and B05-N99A respectively.
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Figure 4.16 Coomassie stained SDS-PAGE gel of purified scFv-CaM. A stable S2 cell 
line expressing each scFv-CaM was scaled up in 200 ml of serum free medium before 
induction with 500 pM CuS04. On day 5 post induction 200 ml of supernatant was 
harvested and supplemented with 1 mM CaCl2. scFv -CaM was purified over a W7 
column and eluted in 1 ml fractions with TBS containing 10 mM EDTA. 10 pi of each 
fraction analysed on a 12% SDS-PAGE gel and visualised with Coomassie blue.
Lanes 1 and 6 -  precision plus protein standard, Lane 2 - B04-CaM, Lane 3 - B04- 
N50A-CaM, Lane 4 - B05-CaM, Lane 5 -  B05-N99A-CaM.
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4.4.7.3 Binding of human sera to B04-N50A and B05-N99A
The purified alanine mutants of B04; -N50A and B05; -N99A were tested alongside 
the original purified samples of B04 and B05 to reassess the binding of the panel of 
eleven normal human serum to the scFvs. Results in table 4.8 show that all eleven 
serum samples bind to B04. However, the B04-N50A-CaM mutant reduces the 
binding of all serum samples to background (Figure 4.17). Only one serum sample 
showed reactivity against B05 (Table 4.8). This sample also showed reactivity against 
the asparagine mutant B05-N99A-CaM, the binding was slightly reduced but not to a 
significant degree (Figure 4.17).
The mutants were then used to reassess the binding of the cognate patient serum 
samples to the scFvs (Figure 4.18). Once again where the B04 patient samples 
exhibited activity against B04-CaM this was reduced to background levels against 
B04-N50A-CaM. There was no discemable difference between the pre- and post­
vaccination samples. In contrast there is no difference in the binding of the B05 patient 
samples to B05-CaM compared to B05-N99A-CaM. Again there is no significant 
difference between the pre- and post-vaccination samples.
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Figure 4.17 Comparison of anti-idiotype activity in normal human serum after removal 
of N-linked glycosylation on the recombinant scFv-CaM. Each bar represents a 1:20 
serum dilution from an individual donor. The red bars correspond to the original scFv- 
CaM and the blue bars are the alanine mutants of the scFv-CaM. The results are shown 
as specific bound IgG.
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Figure 4.18 Comparison of anti-idiotype activity against cognate scFv and 
unglycosylated cognate scFv in sequential patient samples. Each bar represents a 1:20 
serum dilution. The red bars correspond to the original scFv-CaM and the blue bars 
are the alanine mutants of the scFv-CaM. The results are shown as specific bound IgG.
2 1 2
4.5 Discussion
The work described in this chapter is in two parts. Firstly, the details of the production 
and pre-release testing of the clinical grade DNA vaccines in the LIFTT clinical trial, 
CRC Code: 98/04, Protocol No: PH2/039. In the second part the efficacy of the 
vaccines to elicit a response against tetanus and against the cognate idiotype is 
determined. For the latter the recombinant calmodulin fused scFvs expressed in S2 
cells were used (Chapter 3).
The rearranged V genes derived from the malignant clone from each patient were 
assembled into a VH/VL gene cassette of a typical average length of 246 base pairs 
(range 237 -  263). The V gene cassettes were cloned into the plasmid pVAC2 by the 
collaborating clinical centres in Bournemouth, Manchester and Southampton. Each 
pVAC2-V gene construct was transferred to Cambridge for large-scale sterile 
preparation of the plasmid vaccines under conditions of Good Manufacturing Practice 
(GMP). At each stage of the process the V gene cassette was sequenced and aligned to 
the original sequence derived from the malignant clone. Any nucleotide differences in 
the sequences were re-analysed and a consensus was agreed between collaborators.
The sequence of the 25 V gene cassettes is depicted in Appendix A and the clones 
carry all the classical hallmarks of rearranged V genes in lymphoma cells (Bahler & 
Levy, 1992; Zhu et al., 1994; Zhu et al., 2002). Most remarkably in 23 of the 25 
clones putative N glycosylation sites had been introduced by somatic hypermutation or 
by the recombinatorial events (Zhu et al., 2002).
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A typical batch of patient-specific vaccine consisted of at least 15 ampoules of which 
five were used for pre-release testing. Vaccines were tested for sequence of the V 
gene cassette, intactness of the plasmid backbone by restriction enzyme digestion, 
DNA quantity (OD at 260 nm), DNA purity (OD 260/280 nm), sterility, and endotoxin 
level. The accepted range of 260/280 nm ratio was between 1.7 and 2.0 and values < 
1.7 were failed because of protein contamination. Providing the quantitative and 
qualitative characteristics met the required standards the DNA vaccine was sterile 
filled into at least 12 single dose ampoules. Two ampoules each were used for 
endotoxin and sterility testing and one for sequencing and restriction enzyme digest.
A batch of vaccine was only released for clinical use if it had passed all the pre-release 
test criteria. The data shown in Table 4.5 only concerns the successful vaccines. Six 
batches of vaccine needed to be produced more than once for the following reasons. 
The first batch of SOI and the second batch of B03 did not yield adequate amounts of 
plasmid. The first batches of B03 and SOD failed sterility tests. Because of technical 
fermentation problems three unsuccessful production runs of S06 were completed. 
Finally, patients B01 and S05 relapsed before the vaccine could be administered.
These patients re-achieved remission and were allowed re-entry into the trial, 
however, the initial batches of vaccine had exceeded their expiration dates resulting in 
the preparation of fresh vaccine.
In parallel to the clinical use of the vaccines, twenty-three were also administered to 
Dutch rabbits to determine the response against tetanus and against the cognate 
idiotype.
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All 23 vaccines were able to elicit an IgG response against tetanus toxoid. The 
responses varied between vaccines with four producing only a weak response after 
five immunisations. Poor responses against tetanus toxoid are exceptional when 
immunising with a standard protein vaccine. Seventeen of the 23 rabbits produced 
measurable IgG responses against the cognate idiotype. Of the six remaining ones, the 
poor response to S012 and the lack of a response to M02 and S03 can be explained by 
poor expression of the scFv after plasmid delivery, a notion supported by the poor 
expression of the corresponding scFv-CaM in S2 cells. An alternative explanation of 
poor anti-id responses is the relative low level of sequence diversity of the V domains 
with self. This could explain a poor immune response in humans but it is unlikely in 
rabbits as there is at least 40% sequence diversity between rabbit and human V 
domains. Interestingly S03 was one of the vaccines that also produced a weak 
response against tetanus indicating that there was relatively low expression of 
fragment C. Based on the experimental results we conclude that the majority of the 
vaccines are being transcribed and translated in vivo and that the recombinant fusion 
protein of scFv and FrC is available for antigen presentation. However, the magnitude 
of the response is rather blunted in a substantial subset of vaccines indicating that the 
amount of antigen produced is below the threshold to induce a robust B and T cell 
proliferation. Our observations are in line with those from others who have observed 
excellent immune responses in small laboratory mammals (mainly mice) whilst the 
magnitude of response was less impressive when testing larger animals.
The panel of recombinant scFvs and the immune rabbit serum generated by DNA 
vaccination with pVAC2-scFv provides a unique opportunity to ascertain whether the 
anti-idiotypic serum is universally cross-reactive or more specific in its binding. The
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experiment was limited to include the 18 serum samples and recombinant scFv that in 
combination gave good to excellent IgG responses (Table 4.6). Of these 18 antisera 
and recombinant scFvs thirteen were specific in their binding to the cognate idiotype 
and showed no significant binding to the non-cognate ones. The remaining five were 
shown to have cross-reactive profiles and were against so called public idiotypes 
(Roitt & Delves, 2001). Interestingly S05 and S09 are encoded by the same germline 
VH and VL genes and as expected the cross reactivity is high. The anti-S05 is equally 
reactive for both S05 and S09, conversely the anti-S09 although has a high reactivity 
for S05 it is not as high as with cognate. Obviously there are a number of shared 
epitopes between these two proteins, however the CDR3 of S09 is five amino acids 
longer than S05, which would offer an explanation for the titration curves of the cross­
reactivity profiles (Figures 4.8 A and B). The implication is that a greater response to 
S09 is directed toward the CDR3, and therefore less of the total anti-id IgG is against 
the common determinants shared between S05 and S09, which result in a decrease in 
the overall response to S05.
Patterns to the cross reactivity can be seen, generally scFvs derived from the same 
family of V genes or even the same germline gene are shown to be cross-reactive.
Control normal human serum samples were tested for the presence of anti-tetanus and 
anti-idiotype. As expected all samples were strongly positive for anti-tetanus IgG as a 
direct result of the current immunisation program adopted for the control of tetanus 
infections (Figure 4.11). The patient samples were also strongly positive for anti­
tetanus but no increase in activity was observed post vaccination (Figures 4.15). There 
are two possible explanations for the lack of increase in the anti-tetanus response post­
vaccination. Either the fragment C of tetanus toxoid included in pVAC2 is incapable
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of boosting the patients pre-existing response to tetanus because the fragment is not 
properly expressed or processed or the rise in antibody titre is too small to be detected 
by ELISA.
When testing normal human control serum samples for the presence of anti-idiotype 
reactivity we were surprised to observe some robust positive reactions. All 11 serum 
samples were cross-reactive for at least three of the recombinant scFvs. Two of the 11 
scFvs, B04 and M03, were recognised by all 11 serum samples. Conversely B05 and 
M02 were only recognised by one serum sample and there was no reactivity against 
M01. One possible explanation for the binding of IgG to idiotypic protein is the 
presence of a population of IgG antibodies against glycan moieties specifically 
conferred by S2 cells. However, close inspection of the primary amino acid sequence 
of the V domains for putative N-glycosylation sites and the Con A binding experiment 
(Table 3.1) showed that this was not the explanation for scFv clones B03, B05, M08 
and B2. Clone B04 and B05 both contained the classic glycosylation sequons and Con 
A binding to the recombinant scFv B04, but not B05, was observed. Therefore the 
latter was used to test whether the binding of the IgG in sample 5 was dependent on 
the glycan moiety. The asparagine at positions 50 and 99 in clones B04 and B05 
respectively were both mutated to alanine and both scFvs were expressed. The eleven 
normal human serum samples were tested against both mutants and no binding of IgG 
to scFv-B04-N50A was observed. However, serum sample 5 that was reactive against 
B05 remained reactive against the alanine mutant scFv-B05-N99A. There are two 
possible explanations for the observation with clone B04. Either, the serum samples 
did not contain specific anti-idiotype against B04, instead they had naturally occurring 
IgG anti-carbohydrate activity directed against the glycans on the recombinant scFv,
or the asparagine itself was critical to IgG binding. The latter explanation is most 
likely as residue 50 resides in CDR2 and plays an important role in antibody binding 
and an asparagine to alanine mutation is severe. The binding of serum sample 5 to 
both B05 and B05-N99A strongly suggest that these potent IgG anti-idiotype 
antibodies are present in the human serum samples.
A more suitable method to determine the contribution of the sugar residues in the 
binding assays would be to pre-treat the recombinant scFv with glycosylase enzymes.
The recombinant idiotypes were also used to investigate the sequential serum samples 
from ten patients who received their full six-vaccine course. We were not able to test 
the samples from the remaining 15 patients, as the clinical trial centre was reluctant to 
transfer samples. The anti-idiotype activities observed in the ten patients are presented 
in Figures 4.13 A-E. There are two main types of reaction patterns, no reactivity 
above background (binding of IgG to D1D2) or significant binding but no increase of 
reactivity during the course of vaccination. Six (M01, M02, M04, M06, M08 and B03) 
were of the first type and four (M03, B04, B05 and S011) showed reactivity against 
cognate idiotype. For patients B04 and B05 the assays were repeated with the alanine 
mutants of B04 and B05 respectively. The reactivity with B04-N50A was negligible 
strongly suggestive of the presence of anti-carbohydrate IgG activity in this patient. 
The B05 serum samples were equally reactive with B05 and B05-N99A. No definite 
conclusions can be drawn from this data set on the outcome of the clinical trial. Where 
a positive anti-idiotype response was detected, it was not boosted after six 
vaccinations with pVAC2-scFv and none of the patients showed an increase in the titre 
of the anti-tetanus. Studies by our collaborators on T-cell mediated anti-id responses 
were suggestive for some Id specific activity although the responses were weak in all
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cases (Stevenson et al., 2004). The conclusion of this DNA vaccination trial is that 
plasmid vaccination only is not sufficient to induce clinically effective responses 
against the idiotype in patients with FL. This observation is in line with other DNA 
vaccine trails in oncology or infectious diseases. Further improvements in DNA 
vaccine formulation will be required and particularly the results of priming with 
plasmid followed by boosting with Modified Vaccinia Ankara (MVA) seem to be a 
promising way forward. It is unlikely that this modification can be applied to FL 
patients, as the production of a patient specific MVA stock is laborious and expensive. 
Several groups have achieved promising results in phase II trials of patient-specific 
recombinant idiotype vaccines. Notably Genitope’s phase I/II recombinant idiotype- 
keyhole limpet haemocyanin (KLH) co-administered with granulocyte-macrophage 
colony stimulating factor (GM-CSF) and Favrille’s phase II recombinant idiotype- 
KLH led to the initiation of phase III trials using the vaccine in patients after 
treatment. Currently three such idiotype-KLH GM-CSF phase III trials are operational 
in America, National Cancer Institute (NCI), Genitope and Favrille. NCI and Genitope 
are treating patients using multi-agent chemotherapy, briefly NCI’s regimen is 
prednisone, doxorubicin, cyclophosphamide and etoposide to best clinical response 
and the patients in the Genitope study receive eight cycles of cyclophosphamide, 
vincristine and prednisone. Patients that accomplish remission and are free from 
disease progression for a further six-month recovery period are entered for 
vaccination. Favrille’s patients are receiving a standard course of weekly Rituximab 
for four weeks prior to vaccination (reviewed in (Hurvitz & Timmerman, 2005)). In 
conclusion, vaccination against lymphoma idiotype appears to be a promising strategy, 
unfortunately the results from our phase I/II trial using DNA vaccination were 
disappointing.
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Chapter 5
Molecular characterisation of the variable domains of an allbj33 specific IgM k  
platelet cold agglutinin in a follicular lymphoma patient with profound 
thrombocytopenia
5.1 Introduction
Classical pathogenic cold agglutinins (CA) are autoantibodies, usually of the IgM k  
type that bind carbohydrate epitopes, most frequently I/i, on red blood cells (RBC) at 
low temperatures causing haemagglutination and haemolysis (reviewed in (Pruzanski 
& Katz, 1984; Roelcke, 1989)), a condition known as cold haemagglutinin disease 
(CHAD). This condition is frequently related with B-cell lymphoproliferative 
disorders and in most cases the CA is a monoclonal paraprotein. CA can also be 
associated with a variety of infections (McNicholl, 2000) particularly Mycoplasma 
pneumoniae.
Autoantibodies in chronic immune thrombocytopenia show reactivity at 37°C and are 
generally of the IgG class although IgA and IgM or combinations have also been 
reported (Kiefel et al., 1996). Cold reactive platelet agglutinins are a rare phenomenon 
and only a few cases have been described, all of them IgM isotype using both k  and X 
light chains where characterised. These antibodies, which recognise both EDTA 
dependant (van Vliet et al., 1986; De Caterina et al., 1993; Pujol et al., 1998) and 
independent epitopes (Watkins & Shulman, 1970; Girmann et al., 1984; van Vliet et 
al., 1986; Cunningham & Brandt, 1992; Huss et al., 1995; Muniz-Diaz et al., 1995;
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Schimmer et al., 1998) were found associated with pseudothrombocytopenia.
(Watkins & Shulman, 1970; van Vliet et al., 1986; Cunningham & Brandt, 1992; De 
Caterina et al., 1993; Schimmer et al., 1998). None were associated with profound 
thrombocytopenia. Where the antigen was identified, binding to the glycoproteins allb 
(GPIIb) (van Vliet et al., 1986), allb|33 (GPIIbllla) (Schimmer et al., 1998) or GP78 
(De Caterina et al., 1993) was demonstrated, however the involvement of 
carbohydrate moieties in the epitope was not determined.
All pathogenic anti-I/i CA studied to date use the heavy chain variable gene V ^-34 
with minimal mutation from the germline (Potter et al., 1993). The germline-encoded 
framework 1 and particularly the Ala-Val-Tyr sequence motif at position 23-25 have 
been shown to be critical to antibody specificity (Anderson et al., 1996). Light chain 
use is also restricted with a marked preference for k  over X and pathogenic anti-I 
almost always use Vk3 light chains (Capra et al., 1972; Gergely et al., 1973;
Silberstein et al., 1991). Anti-I/i CA associated with infection are less restricted in 
their use of V genes (Smith et al., 1995).
Immune thrombocytopenia is often seen in patients with B-cell lymphoproliferative 
disorders (Hedge et al., 1985; Kuznetsov et al., 1992; Lim & Ifthikharuddin, 1994). 
Rather than specific autoantibody being produced by the monoclonal malignant 
population itself, it is more likely that the inherent immunomodulated state in these 
diseases allows the emergence of autoreactive clones (Gupta et al., 2000). In some 
cases the autoantibody is derived from the malignant clone and the thrombocytopenia 
can only be effectively corrected by controlling the malignant clone. In this chapter I 
present the molecular structure of the V domains of an IgM k  platelet CA in a patient 
with a low grade B-cell lymphoma and profound thrombocytopenia not responsive to 
1st, 2nd and more advanced lines of treatment. Thrombocytopenia did however resolve
after a single treatment with a standard dose of Rituximab. The paraprotein derived 
from the malignant clone recognises the allbp3 integrin, independent of platelet 
activation state and shows idiotypic overlap with our HPA-lala specific alloantibody 
B2.
5.2 Clinical Summary
The patient at the basis of this study concerns a 70-year-old female with a 10-year 
history of rheumatoid arthritis with low-grade B-cell non-Hodgkin’s lymphoma and 
associated thrombocytopenia. A year later she was admitted to hospital with rectal 
bleeding accompanied by widespread petechiae, bruising, tongue and buccal mucosa 
bleeding and epistaxes. On admission she had haemoglobin of 7.4 g/dl (normal range 
12-16.9 g/dl), a platelet count of 12 x 109/1 (normal range 150-450 x 109 /1), a leucocyte 
count of 19.4 x 109/1 (neutrophils 9.8, lymphocytes 7.7 x 109 /1) and her coagulation 
screen was normal. A bone marrow aspirate showed evidence of infiltration with low 
grade B-NHL and increased megakaryocytes. Immunophenotyping studies of the bone 
marrow revealed a CD20+, FMC7+, CD23' and bcl-2 negative B-cell population. 
Immunoglobulin gene rearrangement studies showed a monoclonal IgH rearrangement 
with a serum IgM paraprotein of 3.3 g/1 and a trace of k  Bence Jones protein in the 
urine. Her chest X-ray and abdominal computed tomography (CT) scan were normal. 
She had a negative anti-nuclear antibody and rheumatoid factor was elevated at 107 
iu/ml.
Her bleeding was treated with platelet transfusion, intravenous immunoglobulin and 
prednisolone lmg/kg/day. There was no response and she then went on to receive 
azathioprine with no response, vincristine 1.5 mg weekly for three weeks again with
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no response and further intravenous immunoglobulin. During this time her platelet 
count fluctuated between 4 and 14 x 109 /1.
Subsequent treatment for her refractory immune thrombocytopenia (ITP) included 
tranexamic acid, plasma exchange and further intravenous immunoglobulin, all with 
no response. When platelet antibody investigations revealed the presence of a potent 
IgM k cold agglutinin a link between the intractable thrombocytopenia and the 
malignant clone was suggested and she received Rituximab (anti-CD20 monoclonal 
antibody, Mabthera) at a dose of 375 mg/m2  as an intravenous infusion weekly for four 
weeks. On Day + 6  of the first dose of Rituximab her melaena had stopped, and on 
Day +20 her platelet count had risen to 17 x 109/1 rising further to 50 x 109/1 and a 
bone marrow examination on Day +41 was normal with complete remission of her B- 
NHL on morphological, immunophenotypic, and gene rearrangement analyses.
Further routine investigations performed by the platelet laboratory at the National 
Blood Service Cambridge revealed that allbp3 was the likely antigen recognised by 
the monoclonal IgM (personal communication with Graham Smith).
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5.3 Experimental Design
5.3.1 Determination of platelet antigen
The serum from the patient was used in the platelet immunofluorescence test (PIFT) 
(Chpt. 2.2.6). HPA typed panel platelets and platelets from a Glanzmann’s 
Thrombasthenia (GT) patient were used and the assay was performed at a variety of 
temperatures.
5.3.2 Isolation of V genes
To establish whether the dominant clone of the Follicular Lymphoma was responsible 
for the patients’ thrombocytopenia the rearranged V genes were rescued from a bone 
marrow biopsy and an scFv was constructed.
5.3.2.1 Amplification of V genes
Total RNA was isolated from a bone marrow biopsy taken from the patient (Chpt 
2.2.1.1) and first strand cDNA was synthesised (Chpt 2.2.1.5). Rearranged VH and Vk 
genes were amplified by PCR using signal peptide primers specific for each gene 
family in combination with CY, C  ^or CK specific primers (Table 5.1) (Dohmen et al., 
2005). PCR products were cloned into pCR2.1 (Invitrogen) (Chpt 2.2.1.7) and 
sequenced (Chpt 2.2.1.14). The V-base directory (Cook & Tomlinson, 1995) was used 
to identify the germline genes prior to amplification with FR1/J region primers to
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append restriction sites (Table 5.1) without modifying the amino acid sequence. PCR 
products were cloned into pCR2.1 as above and sequenced. Clones with unmodified 
FR1 sequences (some primers are degenerate) were excised using the appended 
restriction sites and transferred to the phage display vector pHenIX (Finnem et al., 
1997) to generate an scFv cassette.
5.3.2.2 Removal of IgG surface positive B-cells from bone marrow biopsy
IgG membrane positive B-cells were removed from a bone marrow biopsy sample by 
antibody mediated magnetic separation. Purification was carried out according to the 
manufacturer’s protocol; briefly, 1 ml BioMag (Perseptive Biosystems, Framingham, 
USA) goat anti-mouse IgG beads were saturated ( 8  mg) with mouse monoclonal anti­
human IgG (Dako Cytomation) and then added to lxlO6  cells. After incubation at RT 
for 1 hour, IgG+ cells were removed and the remaining cells washed with PBS.
5.3.3 Anti-idiotype antibodies by DNA vaccination
V hV l gene cassettes were excised from pHenIX as Sfi I/Not I fragments and cloned 
into the vaccination plasmid pVAC2. Plasmids were maintained in E. coli strain 
DH5a. DNA for vaccination was prepared using a Qiagen Plasmid Giga Kit (Qiagen) 
(Chpt 2.2.1.12). Dutch rabbits were immunised three times intramuscularly with 200 
pg of plasmid at two weekly intervals and a test bleed was taken. Animals that failed 
to respond were given two additional immunisations (Chpt 2.2.3.1).
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5.3.4 Purification of whole IgM from patient serum
IgM was purified from patient serum using goat anti-human IgM agarose. Briefly, 0.5 
ml of goat anti-human IgM agarose (Sigma) was added to a Biorad poly-prep 
chromatography column. The agarose was washed with 20 ml of PBS before 10 ml of 
patient serum was passed over the column. The column was washed with 20 ml of 
PBS and the bound IgM was eluted in 1 ml fractions with 0.1 M glycine-HCl pH 2.5. 
Fractions containing protein were dialysed in PBS and the IgM concentration 
determined by BCA assay (Chpt 2.2.2.10), all steps were performed at 4°C.
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Primer Name Sequence 5’-3
Cy GTCCACCTTGGTGTTGCTGGGCTT
C[i TGGAAGAGGCACGTTCTTTTCTTT
Ck AGACTCTCCCCTGTTGAAGCTCTT
VHla/7 signal ATGGACTGGACCTGGAGGRTC
VHlb signal AT G GAC T G GAC C T G GAGMAT C
Vh2 signal ATGGACACACTTTGCTMCACRC
Vh3 signal ATGGAGTTTGGGCTGAGCTGG
Vh4 signal ATGAAACACCTGTGGTTCTTCC
Vh5 signal ATGGGGTCAACCGCCATCCT
Vh 6  signal ATGTCTGTCTCCTTCCTCATCT
VK1 signal ATGAGGGTCCCYGCTCAGC
Vk2 signal ATGAGGCTCCCTGCTCAGC
VK3a signal ATGGAAACCCCAGCGCAGC
VK3b signal AT G GAG G C C C CAG CACAG C
Vk4 signal ATGGTGTTGCAGACCCAGG
Vk5 signal ATGGGGTCCCAGGTTCACC
VK6 a signal ATGTTGCCAT CACAAC T CAT T G
VK6 a signal ATGGTGTCCCCGTTGCAATTC
VHla Sfi I AACTGCGGCCCAGCCGGCCATGGCCCAGGTKCAGCTGGTGCAG
CO VHlb Sfi I AACTGGGCCCAGCCGGCCATGGCCCATGTGCAGCTGGTTCAG
VK3a ApaL I CACAGTGCACTCGAAATTGTGTTGACRCAG
Jh4-5 Sal I CTCGTGTCGACACGGTGACCAGGGTTCC
Jk5 Not I ACTTGCGGCCGCACGTTTAATCTCCAGTCGTGTC
Table 5.1 Nucleotide sequences of the signal peptide specific primers for amplification 
of the rearranged V genes and FR1 and J region primers to append Sfil/Sall and 
ApaLI/Notl restriction sites.
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5.4 Results
5.4.1 PAIg
Direct and indirect PIFT were performed to determine the presence of PAIg. The 
direct PIFT when performed at 20°C was strongly positive for IgM. The patient’s 
plasma was tested by indirect PIFT at 20°C and gave a strong positive reaction with 
anti-IgM and anti-K reagents only (Figure 5.1); the strength of reaction was 
independent of the HP A genotype of the panel cells (data not shown). Testing over a 
range from 4-37°C showed the binding of the IgM antibody to be strongly temperature 
dependent with a clearly positive reaction up to 25°C, weak reactions at 30 °C and 
negative at 37°C (Figure 5.2). The binding of the IgM in the presence and absence of 
EDTA (data not shown) indicated that the antibody does not recognise an EDTA 
dependent epitope. The temperature dependence of the platelet IgM is suggestive of a 
low affinity antibody. Determining the specificity of a low affinity antibody is 
cumbersome. Therefore I investigated whether the patients IgM reacted with platelets 
from a patient with Glanzmann’s Thrombasthenia (GT). GT is a serious, but rare, 
autosomal recessive disorder, characterised by longer bleeding times and absence of 
platelet aggregation. GT platelets lack the allbp3 complex.
PIFT was performed as before, RFGP56 (a murine monoclonal anti-allbp3 which 
blocks platelet aggregation and fibrinogen binding to allbp3) was used as a control. 
Both patient IgM (at 4°C) and RFGP56 (at RT) bound to normal platelets but neither 
bound the GT platelets (Figure 5.3).
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Figure 5.1 Immunofluorescence test on patient serum. Donor platelets were reacted 
with the patient sample (or an inert control) and binding of immunoglobulin was 
detected with isotype and light chain specific FITC labelled conjugates at 20°C. 
Bound FITC was measured by flow cytometry and results expressed as median 
fluorescence intensity (MFI) of 10,000 events. Reproduced by kind permission K. 
Campbell, Platelet Immunology Laboratory, National Blood Service, Cambridge.
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Figure 5.2 Temperature dependence of patient IgM. Donor platelets were reacted with 
the patient serum (red bars) or an inert control serum (blue bars) at increasing 
temperatures. Binding of immunoglobulin was detected with anti-human IgM FITC 
labelled conjugate. Bound FITC was measured by flow cytometry and results 
expressed as median fluorescence intensity (MFI) of 10,000 events.
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Figure 5.3 identification of the platelet antigen as allb|33. Mouse monoclonal RFGP56 
(anti-allb(33) (left) and patient serum (right) was reacted with donor platelets (red 
bars) or Glanzmann’s Thrombasthenia (GT) platelets (blue bars). Binding of 
immunoglobulin was detected with the corresponding FITC labelled conjugate (as 
shown). Bound FITC was measured by flow cytometry and results expressed as 
median fluorescence intensity (MFI) of 10,000 events.
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5.4.2 Isolation of V genes encoding IgM secreted by malignant clone
First strand cDNA synthesis of the extracted RNA from the bone marrow biopsy was
\
used in RT-PCR to isolate the dominant lymphoma variable genes. Primers against the 
constant region of IgM (C,,) and IgG (CY) were paired with family specific variable 
heavy chain primers VH 1-6 (Table 5.1). Primers against the constant region of the 
kappa light chain (CK) were paired with family specific variable light chain primers VK 
1-6 (Table 5.1).
Products of the expected size (~700 bp) were amplified from the cDNA using all 
combinations of VH primers and CY (Figure 5.4 A), only with the VH1 primers when 
priming with (Figure 5.4 B) and all VK primers and CK combinations (Figure 5.4 C). 
To increase the chance of obtaining the appropriate VK gene RT-PCR was also 
performed with the RNA obtained from the IgG+ depleted bone marrow biopsy. RT- 
PCR amplified products of ~700bp using combinations of VHla and VHlb primers 
with C  ^(Figure 5.5 A) and VK1 and VK3 primers with CK (Figure 5.5 B). No products 
were amplified using any combination of VH primers and CY (data not shown).
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Figure 5.4 Rescue of rearranged VH and VK genes from a bone marrow aspirate by RT- 
PCR based amplification. V gene family specific signal peptide primers (indicated) 
were combined with the human immunoglobulin constant region primers. 5 pi of PCR 
product was analysed on a 1% agarose gel. A) IgG constant region primer (CY), B)
IgM constant region primer (C^) and C) kappa light chain constant region primer (CK). 
M -  1 kb DNA ladder (Gibco BRL).
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Figure 5.5 Rescue of rearranged VH and VK genes from the IgG+ B-cell depleted RNA 
sample. 5 pJ of PCR product was analysed on a 1% agarose gel. A) IgM constant 
region primer (C^) with V H la and V H lb specific primers. Lanes 1 and 3 -  V H la, 
lanes 2 and 4 -  VHlb, lanes 3 and 4 are negative controls and contain no DNA. B) 
kappa light chain constant region primer (CA with V„ 1-6 specific primers (indicated). 
M -  1 kb DNA ladder (Gibco BRL).
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The PCR products amplified with VH1/ and Vkl/ CKand VK3/ CKfrom the IgG+ B 
cell depleted samples were inserted into the pCR2.1 vector and 20 random clones 
sequenced. Two dominant VH gene rearrangements were identified (C01VHa and 
C01VHb (Figure 5.6 A)), with very similar sequences and identical Complementarity 
Determining Regions (CDR) 3 loops encoded by the DH5-24 and Jh4-02 gene 
segments. Both are derived from the VHl-02 germline gene having 96.6/97.3% and 
96.6/93.9 % homology with germline at nucleotide/amino acid level respectively. 
Nucleotide differences from the germline VHl-02 and Jh4-02 gene elements encode 
four amino acid replacements located in FR3 with the exception of the A>T 
transversion in CDR3 leading to replacement of tyrosine (Tyr) with phenylalanine 
(Phe). A further two common silent mutations were found in the VH and JH segments. 
The C01VHa domains had 4/2 unique replacement/silent mutations from VHl-02 
whereas the C01VHb had 5/2 unique replacement/silent ones.
Sequencing of the VK1/CK PCR products revealed diverse unrelated clones, whereas a 
single dominant clone was identified from the VK3/CKPCR products (Figure 5.6 B) 
that uses a Vk gene with 99.3/97.9% homology (nucleotide/amino acid) to the Vk3-20 
germline gene in combination with the Jk5 gene.
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5.4.3 Construction of scFvs COla and COlb
Two scFvs were constructed using the two dominant VH sequences and the one VK.
The Vk3 gene was removed from the pCR2.1 plasmid by restriction enzyme digest 
(Chpt 2.2.1.15) with ApaLI and Notl (~ 300 bp band) (Figure 5.7 A) and cloned into 
pHenIX cut with ApaLI and Notl (~4 kb band) (Figure 5.7 A). VK3 was ligated into 
pHenIX and transformed into electrocompetent TOP 10F. Plasmid minipreps of 
pHenIX- Vk3 were prepared and recombinants identified by digestion with ApaLI and 
Notl (Figure 5.7 B). The ~300 bp band indicates that the VK3 has been successfully 
cloned into 5 of the 7 plasmids tested (Figure 5.7 B).
The C0VHla and C0VHlb genes were removed from the pCR2.1 plasmid by restriction 
enzyme digest with Sfil and Sail, the 400 bp band was gel purified (Figure 5.7 C) and 
each was cloned into pHenIX- VK3 as above. Plasmid minipreps were prepared and 
confirmation of V gene insertion was by sequence analysis (Chpt 2.2.1.14) (Appendix
A). The resulting scFvs were named COla and COlb.
5.4.4 Expression and purification of scFvs COla and COlb
scFvs COla and COlb were removed from the pHenIX plasmid by restriction enzyme 
digest with Ncol and Notl and subcloned into the pMT/BiP/CaM expression plasmid. 
Recombinants were identified by sequencing. Stable S2 cell lines of pMT/BiP/CaM- 
COla and pM/BiP/CaM-VCOlb were produced as before (Chpt 3.3.4). The level of 
expressed scFv in the supernatant 5 days post induction was determined by Western 
blotting (Figure 5.8 A) and scFv-COla-CaM and COlb-CaM were grown up in 200 ml
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of serum free media and expression induced for 5 days. The supernatants were 
harvested and purified over W7 columns; 10 pi of the eluted fractions were analyzed 
on a 12% SDS-PAGE gel and stained with Coomassie blue (Figure 5.8 B). The 
concentration of protein in the purified fractions was determined by BCA assay (Chpt 
2.2.2.10) with yields of 0.4 mg/ml and 0.7 mg/ml for COla and COlb respectively.
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Figure 5.7 Restriction enzyme digests of plasmids for the construction of scFv. A) Gel 
extracted ApaLI/Notl digests of lane 1 pHenIX (~4 kb band), lane 2 Vk3 (~300 bp 
band) from pCR2.1. B) Confirmation of Vk3 insertion into pHenIX by ApaLI/Notl 
digest lanes 2-6 and no insert lanes 1 and 7 (absence of 300 bp band). C) Sfil/Sall 
digests of pCR2.1-VC01a, lane 1 and pCR2.1-VC01b, lane 2. The ~400bp band 
marked by the arrow is the VH gene and was excised from the gel and purified. M -  1 
Kb DNA ladder.
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Figure 5.8 A Detection of COla-CaM and COlb-CaM by immunoblot. Stable S2 cell 
lines expressing COla-CaM and COlb-CaM were scaled up in 200 ml serum free 
media before induction with 500 pM CuS04. A 1 ml sample was taken at day 5-post 
induction and 10 pi of cleared supernatant analysed on a 12% SDS-PAGE gel. CaM 
tagged proteins were detected with peroxidase labelled N9A and visualised by 
enhanced chemiluminescence. Lane 1 COla-CaM and lane 2 COlb-CaM.
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Figure 5.8 B Coomassie stained SDS-PAGE gel of purified scFvs COla and COlb- 
CaM. S2 cells were treated as for Figure 5.6A. On day 5-post induction 200 ml of 
supernatant was harvested and supplemented with 1 mM CaCl2. scFvs were purified 
over a W7 column and eluted in 1 ml fractions with TBS containing 10 mM EDTA. 10 
pi of each fraction was analysed on a 12% SDS-PAGE gel and visualised with 
Coomassie blue (Chpt 2.2.2.8.1). Lanes 1 and 2 COla-CaM fractions 2 and 3, lanes 3 
and 4 COlb fractions 2 and 3. M Broad range molecular weight marker.
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5.4.5 Production of anti-idiotypic sera
Both V gene cassettes were subcloned into the DNA vaccination vector pVAC2.
Dutch rabbits were immunised as before and bleeds were taken at days 0 and 35. IgG 
responses against tetanus and idiotype was measured by ELISA (Figure 5.9 and 5.10). 
Anti-COla bound to TEFT (Figure 5.9 A) and its cognate CaM tagged scFv derived 
from the patient, but not an irrelevant CaM tagged protein (D1D2) (Figure 5.10 A). 
The rabbit immunised with pVAC2-C01b failed to make an anti-tetanus (Figure 5.9 A) 
or anti-idiotypic response after 3 immunisations (Figure 5.10 A). The rabbit was 
boosted twice with 200 pg of pVAC2-C01b at days 42 and 49 and a third bleed was 
taken at day 56. The anti-tetanus and anti-idiotype responses were measured again 
(Figure 5.9 B and 5.10 B); both anti-tetanus and anti-idiotypic responses were 
produced although not as high a titre as the anti-COla.
5.4.6 Cross reactivity of anti-idiotypic sera
The antisera were also screened against the panel of twenty-one scFvs derived from 
patients with follicular lymphoma (Chapter 4) and scFv-B2 (Chapter 3). 5/21 
lymphoma scFvs and B2 were positive for the C01 idiotype (>20% of cognate signal 
at 1/20 dilution of sera) with a range of cross-reactivity (Figure 5.11). scFv-B2 is 
derived from the same germline VH gene as COlVHa/b and had almost identical 
reactivity to that of the cognate scFv. scFv-B04 which is encoded by a member of the 
Vh3 gene family but has a kappa light chain derived from the same germline gene also 
demonstrated strong cross-reactivity as did S011 for which both heavy and light chains 
are encoded by members of different V gene families. C01 also shares some idiotypic
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determinants with three other lymphoma scFvs (S04, S06 and M08) tested that are 
encoded by diverse V genes. The homology of C01VHa and C01VHb to these genes is 
listed in Table 5.2. Anti-idiotypic serum raised against B2 was strongly cross-reactive 
with CO la and CO lb (data not shown).
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Figure 5.9 Anti-tetanus responses in Dutch rabbits immunised with pVAC2-C01a and 
-COlb DNA vaccines. Each line represents a titration of pre-immune (pre, broken 
line) or immune (post, solid line) serum from a single rabbit. A) Animals were 
immunised i.m. into both quadriceps, with two doses of 100 pg of DNA vaccine at 
days 0, 14 and 28. An ear vein bleed was taken at days 0 and 35 and tested in ELISA.
B) CO lb rabbit was immunised twice more at days 42 and 49. An ear vein bleed was 
taken at day 56 and tested as before. The responses are shown as specific IgG present 
in immune compared to pre-immune serum samples.
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Figure 5.10 Anti-idiotype responses in Dutch rabbits immunised with pVAC2-C01a 
and -COlb DNA vaccines. Each line represents a titration of pre-immune (pre, broken 
line) or immune (post, solid line) serum from a single rabbit. A) Animals were 
immunised i.m. into both quadriceps, with two doses of 100 pg of DNA vaccine at 
days 0, 14 and 28. An ear vein bleed was taken at days 0 and 35 and tested in ELISA 
against cognate scFv-CaM and irrelevant DlD2-CaM. B) CO lb rabbit was immunised 
twice more at days 42 and 49. An ear vein bleed was taken at day 56 and tested as 
before. The responses are shown as specific IgG present in immune compared to pre- 
immune serum samples.
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Figure 5.11 Idiotypic cross reactivity of CO la  and CO lb. Rabbit anti-idiotypic 
antiserum raised against CO la was tested by ELISA for IgG binding to a panel of 22 
CaM tagged scFvs encoded by a range of variable region genes. Binding curves are 
shown for the seven cross-reactive scFvs. The cognate is shown in red and the 
negative control irrelevant CaM tagged D1D2 is shown in black.
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Antigen
Germline % homology
v H v L v H v L
COla 1 - 0 2 k  3-20 1 0 0 1 0 0
COlb 1 - 0 2 k  3-20 91 1 0 0
B2 1 - 0 2 X2-14 85 46
M03 3-23 X2-14 47 40
M08 3-15 X2-0S 45 44
B04 3-48 k  3-20 41 8 8
S04 3-21 K 3-11 46 82
S06 3-30 k  1-09 48 65
S011 4-34 k  4-01 44 70
D1D2 N/A N/A — —
Table 5.2 Germline genes encoding each of the scFvs shown in Figure 5.9. Percentage 
(%) homology at the amino acid level is that between C01VHa or C01VLa and the 
VH/VL genes of each scFv.
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5.4.7 Relationship between the isolated scFvs and the IgM paraprotein
To investigate the relationship between COla/COlb and the patients IgM paraprotein, I 
investigated whether purified IgM from the patient’s serum could inhibit the binding 
of anti-idiotypic sera to cognate scFv.
5.4.7.1 Purification of patient IgM
The purified IgM was analyzed on a 12% SDS-PAGE gel (Figure 5.12). 10 pil of 
normal human IgM (1 mg/ml Sigma) was used to assess the quality of the patient IgM. 
The concentration of protein in the purified fraction was 0.7 mg/ml as determined by 
BCA assay (Chpt 2.2.2.10).
5.4.7.2 Inhibition of anti-idiotypic serum
The binding of polyclonal rabbit antibodies against the CO la idiotype to recombinant 
COla-CaM was inhibited with purified patient IgM and normal human IgM. In short, 
COla-CaM was immobilised on the solid phase and the signal of the rabbit anti-serum 
was determined in the presence of increasing amounts of purified IgM. The antiserum 
was used at a final dilution of 1/480, based on the results in Figure 5.11. The purified 
IgM was used at a range of concentrations (1000 ng/ml to ~2 ng/ml).
The patient’s IgM but not control IgM produced 50% inhibition of binding at 
approximately 5 ng/ml. The control IgM was able to inhibit anti-idiotype binding to a
248
similar degree at 1 0 0 -fold higher concentration suggesting that the relevant idiotype is 
present in normal human serum, but at very low concentrations (Figure 5.13).
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M 1 2
kDa
83 ►
62 ►
47.5 ►
32.5 ►
Figure 5.12 Purified IgM from patient serum. IgM was purified from 10 ml of patient 
serum using an anti-human IgM agarose column. Bound IgM was washed with 20 ml 
PBS before elution in 1 ml fractions with 0.1 M glycine-HCl pH 2.5. 10 pi of the 
eluted fraction was analyzed on a 12% SDS-PAGE gel. Lane 1 purified patient IgM, 
lane 2 normal human IgM (Sigma). M broad range molecular weight marker.
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Figure 5.13 Inhibition of the binding of polyclonal anti-COla (rabbit sera to 
calmodulin tagged scFv-COla with IgM purified from the serum of the patient (red) or 
by normal human IgM (blue) (Sigma). Minimum and maximum concentrations of 
inhibitor are 2 ng and 1000 ng/ml respectively. The IC50 values were extrapolated 
from the graph using GraphPad Prism®.
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5.5 Discussion
The work described in this chapter presents a detailed analysis and characterisation of 
an IgM k  paraprotein associated with non-Hodgkin’s Lymphoma and concomitant 
severe thrombocytopenia. The patient had a 10-year history of rheumatoid arthritis and 
had previously been diagnosed with low-grade B cell non-Hodgkin’s lymphoma 
associated with a severe and treatment refractory thrombocytopenia. Her serum was 
shown to contain an IgM paraprotein with a k  Bence-Jones protein trace in the urine. 
The initial screen for PAIg and platelet serum antibodies by platelet 
immunofluorescence at 37°C were both negative, however the severity and therapy 
refractoriness of the thrombocytopenia and the presence of a paraprotein prompted 
further investigations at temperatures below 37°C. These studies revealed a potent, 
IgM k , platelet antibody (Figure 5.1), with results suggesting that the platelet antibody 
and the paraprotein were derived from the same (malignant) B cell clone. The results 
presented define the molecular characteristics of the variable domains of the IgM 
paraprotein. The idiotypic cross-reactivity between the paraprotein and the platelet 
IgM was investigated by raising idiotype specific antibodies in rabbits using tetanus- 
toxoid enhanced DNA-based idiotype vaccination (King et al.t 1998).
Initially, assays were conducted to determine the temperature dependence of the 
PAIgM with a decrease in binding observed with increasing temperature (Figure 5.2). 
This pattern of reactivity is very similar to that of cold agglutinins in CHAD patients. 
Second the serum was reacted with the platelets from a patient with Glanzmann’s 
Thrombasthenia and no binding of IgM was observed, strongly suggestive of allb|33 
being the prime target (Figure 5.3). The rearranged V genes were rescued by RT-PCR. 
When using Cy or CK primers bands for all Vh and VK gene families were observed
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(Figure 5.4 A and C). However, as expected, using a primer Vh gene amplicons 
were obtained only in combination with primers of a single Vh family (VhI) (Figure 5. 
4 D). After depleting the bone marrow aspirate of y+ B-cells, prominent amplicons 
were again obtained with the and VhI primers (Figure 5.5 A) and with CK and VK1 
and Vk3 family primers only (Figure 5.5 B). Sequencing of the cloned amplicons 
revealed two dominant heavy chain clones both with a sequence highly homologous to 
the VhI-02 (allele 4) germline gene (97.3 and 93.9% at amino acid level) and with 
identical Vh-CDR3 sequences (Figure 5.6 A). We assume that all the differences 
between the germline gene and the bone marrow derived clones were caused by 
somatic hypermutation or gene rearrangement as sequencing the patients germline 
gene did not identify novel allelic variants of the VhI-02 gene (data not shown). The 
sequence identity in Vh-CDR3 and the four common nucleotide mutations between 
the two Vh clones is diagnostic of a strong clonal relationship, with both being derived 
from the same malignant B-cell clone. Sequencing of 10 Vk3 clones derived from the 
RNA of y" B-cells showed a single dominant sequence, which was identical at 
nucleotide level to the VK3-20-l germline gene except for two non-synonymous 
mutations in CDRs 2 and 3 (residues 52 and 93 respectively, Figure 5.6 B). Several 
studies have shown that the level of somatic hypermutation of rearranged V genes 
varies between cases of follicular lymphoma. Minimal to no hypermutation is 
generally associated with a benign outcome and is indicative of the malignant clone 
being derived from early germinal centre B-cells, whilst a poor outcome is more 
frequently associated with clones which have undergone extensive hypermutation 
(Bahler et ah, 1991; Zelenetz et ah, 1991; Alizadeh et ah, 2000). The low level of 
somatic hypermutation of the rearranged V genes rescued from the malignant clone is 
compatible with the relatively benign course of the patient’s lymphoma.
A number of avenues of investigation were pursued to confirm the hypothesis that the 
IgM k  paraprotein present in the patient’s plasma was the platelet reactive IgM 
antibody and to determine whether either of the Vh domains showed preferential 
platelet binding. First, the rearranged V genes were used to prepare a tetanus toxoid 
enhanced idiotype vaccine to raise polyclonal idiotypic antibodies against the two 
dominant clones. Both antisera were specific for the cognate idiotype and were non­
reactive with 16/21 irrelevant idiotypes derived from other low grade follicular 
lymphoma patients or a control antigen. The anti-idiotypic sera were used as probes to 
investigate the relationship between the paraprotein and the platelet-reactive IgM. 
Several lines of evidence firmly support that the two populations of antibody are the 
same. Firstly the platelet reactive antibody was IgM k  (Figure 5.1) and the dominant 
clones isolated from the bone marrow biopsy were also IgM k  (Figure 5.5). Secondly 
the binding of the anti-idiotype serum to its cognate scFv was inhibited by the IgM 
purified from the patient’s serum at low concentration, whilst 1 0 0 -fold higher levels of 
purified IgM from a healthy individual were required to achieve the same inhibition 
(Figure 5.13).
When studying the reactivity of the anti-idiotype serum against C01 Vna with a panel 
of 21 recombinant scFvs, 5 of the 21 showed reactivity (Figure 5.11). These five 
positive scFvs are interesting in that they indicate three clusters of reactivity. The anti- 
COlVna serum showed an almost equally strong reactivity with the Vh1-02 encoded 
scFv-B2 as with the two cognate scFvs, in addition the B2 anti sera reacted equally 
strongly with both patient derived scFvs. This strong cross-reactivity is best explained 
by the fact that all three Vh domains are derived from the VhI - 0 2  germline gene and 
the high level of homology between their sequences (C01 Vna versus COlVnb, 91% 
homology; C01VHb versus B2, 85% homology). It is highly unlikely that the cross­
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reactivity is explained by the Vl domains with B2 having a X domain and the 
lymphoma derived IgM a k . The observation that the strong cross-reactivity is in both 
direction is interesting against the backdrop of the completely different Vl domains 
and the 15% sequence difference between B2 and C01. The latter is mainly due to the 
somatic hypermutation of the C01 and the B2 Vh genes and the difference between 
their respective VH-CDR3.
Germline encoded blood cell antibodies are generally of low affinity and are removed 
from their target antigen by washing with saline at 37°C (Bye et al., 1992). This was 
reflected in our inability to demonstrate binding of the monomeric scFv C01 to 
platelets (data not shown). Identifying the epitope of a low affinity autoantibody is 
challenging as standard techniques are unsuitable.
Further experiments were performed by Dr Ian Harmer to obtain further evidence that 
the platelet reactive IgM is indeed encoded by the malignant B cell clone. Firstly 
F(ab’ ) 2  fragments from anti-idiotypic sera raised against COla were used in PIFT in 
place of the anti-human isotype conjugate. Anti-COla revealed binding of antibodies 
in the patient’s plasma to platelets. Secondly, platelet reactive IgM was purified from 
the patients plasma. The IgM heavy chain protein band was analysed by Maldi-Tof. 
The analysis detected two peptides common to both VHC01a and VHC01b and four 
unique to VHC01b.
In conclusion this study is the first to characterise the V genes encoding a clinically 
harmful platelet cold agglutinin. The use of minimally mutated V genes in this low 
affinity platelet IgM mirrors the pattern seen for classical anti-I/i cold agglutinins in 
CHAD (reviewed in (Pruzanski & Katz, 1984; Roelcke, 1989)). As noted in the 
clinical summary, the patient’s autoimmune thrombocytopenia failed to respond to all 
conventional and more advanced treatments. Consistent with reports on chronic
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haemagglutinin disease, treatment with Rituximab produced a marked clinical 
response and her platelet counts returned to normal. After six weeks a bone marrow 
examination was normal with complete remission of her B-cell non-Hodgkin 
lymphoma on morphological, immunophenotypic, and heavy chain gene 
rearrangement analyses and the paraprotein band resolved. The response to Rituximab 
provides additional strong evidence that the paraprotein was causative and the Maldi- 
Tof analysis indicates that only the VHb/VK3-20 encoded IgM was platelet reactive. 
The clinical history suggests that the Vnb clone emerged at a later stage in the disease 
coinciding with the acute onset of a profound and treatment refractory 
thrombocytopenia. Generally the platelet autoantibodies in immune thrombocytopenia 
in patients with a B-cell lymphoproliferative disorder (Hedge et a l , 1985; Kuznetsov 
et al, 1992; Lim & Ifthikharuddin, 1994) are thought to be produced by autoreactive 
B-cell clones that have emerged as a consequence of the patients’ immunomodulated 
state (Gupta et al, 2000). All the evidence that we have accrued supports our 
contention that in this case the IgM paraprotein produced by the lymphoma clone was 
responsible for the severe thrombocytopenia and such platelet cold agglutinin cases 
warrant another treatment modality.
The data described in this chapter has been accepted by Transfusion as an original 
manuscript.
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Chapter 6 -  Conclusions
6.1 Production of recombinant scFv
The use of the Drosophila expression system to produce large quantities of 
recombinant scFv was investigated in this study. Firstly, I modified the open reading 
frame of the multiple cloning site of Invitrogen’s pMT/BiP/V5 His C so that it was 
complementary to the DNA vaccine plasmid pVAC2. This modified plasmid is called 
pMT/BiP/V5 His D (Figure 3.2). Secondly, I inserted the gene for Calmodulin (CaM) 
in place of the V5/His sequences to produce pMT/BiP/CaM (Figure 3.3). I then 
compared the expression of four scFv’s in both modified plasmids, with pMT/BiP/V5 
His D 3/4 lost the hexahistidine tag and were unavailable for purification (Figure 
3.12). PMT/BiP/CaM was more successful with all four producing milligram 
quantities of scFv-CaM (Table 3.1). I also used a bacterial expression plasmid 
pUCl 19-His and compared the yields and binding abilities of one scFv, B2 an anti­
glycoprotein (GP) Ilbllla. The yields were far superior using Drosophila and with the 
added benefit of post-translational modifications the decision was taken to continue 
with the pMT/BiP/CaM construct.
This construct was used to express all twenty-five patient derived scFvs, the results 
show that one failed and the remaining twenty-four produced yields of between 0.5 mg 
and 85 mg/L (Table 3.1). I conclude that I have developed a reliable expression system 
capable of producing large quantities of pure recombinant scFv.
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6.2 Clinical trial
The clinical trial was ongoing throughout the duration of this project; together with 
two colleagues we prepared twenty-five clinical grade vaccines to GMP standard 
(Table 4.5). The vaccines were quality controlled for concentration, purity (260/280 
nm ratio), sterility, endotoxin level and sequence integrity (DNA sequencing and 
restriction enzyme digest). These vaccines were then administered to Dutch rabbits to 
provide control serum to assess the potential immunogenicity of the vaccines and to 
establish the ELISA protocols for measuring anti-tetanus and anti-idiotype responses 
(Table 4.6).
Once the vaccines had passed the quality controls they were released to the trial 
centres in Bournemouth, Manchester and Southampton for administration to the 
patients. For this thesis ten patient serum samples were tested for anti-tetanus (Figure 
4.14) and anti-idiotype responses (Figure 4.13) pre and post vaccination. From this 
cohort the results suggest that this DNA vaccination regime as a means to produce 
anti-idiotypic responses in patients with Follicular Lymphoma (FL) is not successful. 
However, it is known from the research of groups in America that anti-idiotypic 
antibodies and subsequent patient remissions are attained in patients who have been 
given recombinant idiotype vaccinations. Further studies could potentially employ the 
recombinant scFv-CaM fusions that I produced in Drosophila S2 cells as a potential 
vaccine.
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6.3 Case Study
The purpose of this study was to provide a unique set of reagents utilizing the 
recombinant protein expression and DNA vaccination to confirm that the paraprotein 
derived from the malignant clone of a patient with low-grade FL binds to platelets 
causing life-threatening thrombocytopenia. I have presented a detailed account of this 
autoantibody proving that it was derived from the patients’ malignant clone. The 
antigen was also discovered to be the ccllbp3 integrin. Immunoprecipitation and 
immunoblot are unsuitable for identifying the epitope of low affinity autoantibodies, 
we chose a potentially time consuming study utilising platelets from patients lacking 
expression of individual surface proteins. We obtained platelets from a patient with 
Glanzmann’s Thrombasthenia (GT) and the malignant IgM failed to bind. GT platelets 
lack expression of the allbp3 integrin; therefore the antigen can be confirmed as the 
allbp3 integrin.
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Appendices
A -  scFv nucleotide and amino acid sequences
scFv cloned nucleotide and amino acid sequences between Ncol and Not I restriction 
sites in pMT/BiP/CaM and pVAC2.
B 2
CCATGGCCCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGGCCGC 
Q V Q L V Q S G A E V K R P G A A  
AGTGAAGGTCTCCTGCAAGGCTTCTGGCTACAGATTCACCGGCCACTATATGCACTGG 
V K V S C K A S G Y R F T G H Y M H W  
GTGCGGCAGGCCCCTGGCCAAGGACTTGAGTGGATGGGATGGATCAACCCTAACAGTG 
V R Q A P G Q G L E W M G W I N P N S  
GCGGCACGAGCTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTC 
G G T S Y A Q K F Q G R V T M T R D T S  
CATCAGCACAGCCTATATGGAGATGACCAGGCTGAGATATGACGACACGGCCGTCTAT 
I S T A Y M E M T R L R Y D D T A V Y  
TATTGCGCGGCGGGAGGTCTAGGGGGCTATTATTACTACGCTATGAACATCTGGGGCC 
Y C A A G G L G G Y Y Y Y A M N  I W G  
AAGGGACCACGGTCACCGTGTCGAGTGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGG 
Q G T T V T V S S G G G ' G S G G G G S G  
CGGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGA 
G G G S Q S A L T Q P A S V S G S P G  
CAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATG  
Q S I T I S C T G T S S D V G G Y N Y  
TCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGTCAG  
V S W Y Q Q H P G K A P K L M I Y E V S  
TAATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCC 
N R P S G V S N R F S G S K S G N T A  
TCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCAT 
S L T I S G L Q A .  E D E A D Y Y C S S  
ATACAAGCAGCAGCACTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT 
Y T S S S T W V F G G G T K L T V L G
B 0 1
CCATGGCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGAC 
Q V Q L Q E S G P G L V K P S E T  
CCTGTCCCTCTCCTGCAGTGTCTCTGGTGCCTCCGTCACTGCTTACTCCTGGAGCTGG  
L S L S C S V S G A S V T A Y S W S W  
ATCCGGCAGTCCCCAGACAAGGGACTGGACTGGATTGGTAACATCTCTTACACCGGAA 
I R Q S P D K G L D W I G N I S Y T G  
ATACCAAGTACAATCCTTCCGTCAAGAGTCGAGTCATTATTTCACTAGACACGTCCAA  
N T K Y N P S V K S R V I  I S L D T S K  
GAATCATTTCTCCCTGAAAGTGACGTCTGTGACCGTCGCAGATACGGCCATTTATTAC  
N H F S L K V T S V T V A D T A I Y Y
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TGTGCGAGGCTCCGGAGCGGCAGCTCGGCCTTTGACTACTGGGGCCAGGGAACCCTGG 
C A R L R S G S S A F D Y W G Q G T L  
TCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATC 
V T V S S G G G G S G G G G S G G G G S  
GCAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGCGGGTCACC 
Q S V L T Q P P S V S G A P G Q R V T  
GTCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACAGTGGTACC 
V S C T G S S S N I G A G Y D V Q W Y  
AACAGGTTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACTTCAATCGGCCCTC  
Q Q V P G T A P K L L I Y G N F N R P S  
AGGGGTCCCTGATCGATTCTCTGGCTCCAAGTCTGCCACCTCAGCCTCCCTGGCCATC  
G V P D R F S G S K S A T S A S L A I  
ACTGGGCTCCAGGCTGAGGATGAGGCTGAATATTATTGTCAGTCCTATGACGGCAGCC 
T G L Q A E D E A E Y Y C Q S Y D G S  
TGAGTGGTGTAATATTCGGCGGGGGGACCAACCTGACCGTCCTAGGT 
L S G V I  F G G G T N L T V L G
B 0 2
CCATGGCCGAGATGCAGTTGGTGGAGTCTGGGGGAGGCTTGGTCCAGACGGGGGAGTC 
E M Q L V  E S G G G L V Q T G E S  
CCTGAGACTCTCCTGTTCAGCCTCTGGATTCACTATCAGTAGTCACATTATGCATTGG  
L R L S C S A S G F T I S S H I M H W  
GTCCGCCAGGCTCCGGGGCAAGGACTGAAATATGTTTCAGGTATTAGTGCTTATGGTG 
V R Q A P G Q G L K Y V S G I S A Y G  
ATAAAACATATTACGCAGACTCCATGAGGGACAGATTCGCCATCTCTAGAGACAATTC  
D K T Y Y A D S M R D R F A I S R D N S  
CAAGAACACAGTATAT C T T CAAAT GAG CAGT C T GAGAAT T GAG GACAC G GC T G TATAT  
K N T V Y L Q M S S L R I E D T A V Y  
TACTGTGCGACCAATCACTCGGAAGGCTCTTTTGACTCATGGGGCCAGGGAACCCTGG 
Y C A T N H S E G S F D S W G Q G T L  
TCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATC 
V T V S S G G G G S G G G G S G G G G S  
GGACATCGTGATGACCCAGTCTCCAGACTCCCTGGTTGTGTCTCTGGGCGAGAGGGCC 
D I V M T Q S P D S L V V S L G E R A  
ACCATCAGATGCAAGTCTAGCCACAGTATTTCATACTATTCCAACAATAAGCACTACT  
T I R C K S S H S I S Y Y S N N K H Y  
TAGGTTGGTACCAGCAGAAACCAGGACAGCCTCCTAAGTTACTCATTAATTGGGCATC 
L G W Y Q Q K P G Q P P K L L I N W A S  
TACCCGGGAATCCGGGGTCCCTGACCGATTTAGTGGCAGCGGGTCTGGGACAGATTTC 
T R E S G V P D R F S G S G S G T D F  
ACTCTCACCATCAGCAGCCTGCAGACTGAAGATGTGGCAGTCTATTACTGTCAGCAAT 
T L T I S S L Q T E D V A V Y Y C Q Q  
ATTATTTTACTCCGTGGACGTTCGGCCAAGGGACCAAGCTGGAAATCAAACGT 
Y Y F T P W T F G Q G T K L E I K R
283
B03
CCATGGCCGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTC 
E V Q L V E S G G G L V Q P G G S  
C CT GAGACT C T C CT GTACAAC C T C C G GAT T TAC C T T CAGTAAT TATAACAT GAGT T G G 
L R L S C T T S G F T F S N Y N M S W  
GTCCGCCAGGCTCCGGGGAAGGGGCTGGAATGCATTTCAGACATTAATAGTAGTGGTA 
V R Q A P G K G L E C I S D I N S S G  
AAAACATCTTCTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAATGT 
K N I F Y A D S V K G R F T I S R D N V  
CAAGAACGTAGTGTACCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTAT 
K N V V Y L Q M N S L R D E D T A V Y  
TACTGTGCGAGAGACACTCCGGAGGCACCTGTCTCCGACTACTACGATGTGGACGTCT 
Y C A R D T P E A P V S D Y Y D V D V  
GGGGCCAAGGGACCACGGTCACCGTCTGCTCAGGTGGAGGCGGTTCAGGCGGAGGTGG 
W G Q G T T V T V C S G G G G S G G G G  
CTCTGGCGGTGGCGGATCGGACATCCAGATGACCCAGTCTCCATCTTCCCTGTCTGCA 
S G G G G S D I Q M T Q S P S S L S A  
TCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATT 
S V G D R V T I T C R A S Q G I R N D  
TAGTCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATA  
L V W Y Q Q K P G K A P K R L I Y A A  Y 
CAGTTTGCAAGCTGGGGTCCCATCAAGATTCAGCGGCAGTGGATCTGGCACAGAATTC 
S L Q A G V P S R F S G S G  S G T E F  
ACTCTCACAGTCAGCAGCCTGCAGTCTGAAGATTTTGCAACTTATTACTGTCTCCAAC  
T L T V S S L Q S E D F A T Y Y C L Q  
ATCATAATTACCCTCGAACGTTCGGCCAGGGGACCAAGGTGGAAATCAAA 
H H N Y P R T F G Q G T K V E I K
B 0 4
CCATGGAGGTGCAGGTGGTGGAGTCTGGGGGACGGTGGGTACAGCCGGGGGGGTCCTT 
V Q V V E S G G R W V Q P G G S L  
GAGACTCTCCTGTGTAGCCTCTGGATTCAGCTTCAATGCCTATACCATGAACTGGGTC  
R L S C V A S G F S  F N A Y T M N W V  
CGCCAGGCTCCAGGGAAGCGACTGGAGTGGATTTCAAACATTACTAGTAGTGGCTTTA 
R Q A P  G K R L E W  I  S N ' I  T S S G F 
CTAAAGATTACGCAGACTCTGTGAAGGGCCGATTCACGGTCTCCAGAGACAATGCCAA 
T K D Y A D S V K G R F T V S R D N A K  
GAACTCACTGTATCTGCAAATGAACGGCCTGAAAAACGAGGACACGGCTCTTTATTAC 
N S L Y L Q M N G L K N E D T A L Y Y  
TGTGTGAGACAAAACTTCGGAGGATATGTTTTTGATTTCTGGGGCCAAGGGACCACGG  
C V R Q N F G G Y V F D F W G Q G T T  
TCACCGTCTCTTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATC 
V T V S S G G G G S G G G G S G G G G S  
GGAAATTGTGTTGACGCAGTCTCCAGGAACCCTATCTTTGCCTCCAGGGGAAAGAGCC 
E I V L T Q S P G T L S L P P G E R A  
ACTCTCTCCTGCAGGGCCAGTCAGAGTGTTACTAATAATTATTTAGCCTGGTACCAGC  
T L S C R A S Q S V T N N Y L A W Y Q
284
AGATACCTGGCCAGGCTCCCAGGCTCCTCATTTCTGGTGCATCCAGCAGGGCCACTGG  
Q I  P G Q A P R L L I  S G A S  S R A T G  
CATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGCC 
I P D R F S G S G S G T D F T L T I A  
AGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTTACTCACGGA  
R L E P E D F A V Y Y C Q Q Y G Y  S R  
CGTTCGGCCAAGGGACCAAGGTGGAAATCAAA 
T F G Q G T K V E I K
B 0 5
CCATGGCCGAGGAGCGACTGGTGGAGTCTGGGGGAGGCTTCGTACAGCCGGGGGGGTC 
E E R  L V E S G G G F V Q P G G S  
TCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAATAACTATGACATGACTTGG  
L R L S C A A S G F T F N N Y D M T W  
GTCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTCTCCACTATTAGTGGCAGCGGTG 
V R Q A P G K G L E W V S T I  S G S G  
TCAAGACATACTACGCAGACTCTGTGAAGGGTCGCTTCAGCACCTCCAGAGACAACTC  
V K T Y Y A D S V K G R F S T S R D N  S 
CAAGGACACAGTAAATGTCCAAATGAACAGCCTGAGAGTCGAGGACACGGCCATGTAT 
K D T V N V Q M N  S L R V E D T A M Y  
TACTGTGCGAAGAATATTAGTATGGAAATATGGGGCCAGGGAACCCTGGTCACCGTCT 
Y C A K N I  S M E I W G Q G T L V T V  
CCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATCCA 
S S G G G G S G G G G S G G G G S  D I Q  
GATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACT 
M T Q S P S S L S A S V G D R V T I T  
TGTCGGGCAGGTCAGGCCATTAGAAATGATTTAGACTGGTATCAGCAGAAACCAGGGA 
C R A G Q A I R N D L D W Y Q Q K P G  
AAGCCCCTAAGCGCCTGATTTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAG  
K A P K R L I Y A A S S L Q S G V P S R  
GTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCT 
F S G S G S G T E F T L T I S S L Q P  
GAAGATTTTGCAACTTATTACTGTCTACAGCTTAATACTTACCCGCTCACTTTCGGCG  
E D F A T Y Y C L Q L N T Y P L T  F G  
GAGGGACCAACGTGAAGATCAAT 
G G T N V K I N
M 01
CCATGGCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAGGCCTTCTGAGAC 
Q V Q L Q E S G P G L V R P S E T  
CCTGTCCCTCATTTGCACTGTCTCTGGTGGCTCCATCAGCGACAGTAATTATTTTTGG  
L S L I C T V S G G S I S D S N Y F W  
GCCTGGATCCGCCAGCCCCCCGGGGAGGGGCTGGACTGGATTGGAAATATTTCATCTA 
A W I R Q P P G E G L D W I G N I S S  
ATGCGAAGACTTACAATCCGTCCCCCAAGAGTCGGGTCACCTTATTCATAGACACGTC  
N A K T Y N P S P K S R V T L F I  D T S
285
CAAAAATCAGTTCTCCCTGAAATTGAGCTCTGTGACCGTCGCAGACACGGCTATTTAT 
K N Q F S L K L S S V T V A D T A I Y  
TACTGCGCGAGAGGGAACTGGACCAACAATTCCTTCGACTTCTGGGGCCAGGGAACCC 
Y C A R G N W T N N S F D F W G Q G T  
TGGTCACCGTCTCCTCAGGTGGAGGCGGTTCATGCGGAGGTGGCTCTGGCGGTGGCGG 
L V T V S S G G G G S C G G G S G G G G  
ATCGGACATCCAGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGG 
S D I Q M T Q S P D S L A V S L G E R  
GCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTAAATAGGTCCAACAATAAGAACT 
A T I N C K S S Q S V L N R S N N K N  
ACTTAGCTTGGTATCAACAAAAGTCAGGACAGCCTCCTAAACTGCTCATTTACTGGAG  
Y L A W Y Q Q K S G Q P P K L L I Y W T  
ATCTACCAGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGAT 
S T R E S G V P D R F S G S G S G T D  
TTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTATATTACTGTCAGC  
F T L T I S S L Q A E D V A V Y Y C Q  
AATCTTTTAGTACTCCGTGCACGTTCGGCCAAGGGACCAAAGTGGATATCAAACGT 
Q S F S  T P C T  F G Q G T  K V D  I  K R
M 02
CCATGGCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGAC 
Q V Q L Q E S G P G L V K P S E T  
CCTGTCCCTCACCTGCACTGTCTCAGGTGGTTCCATCAATAGTAGTGATTATTACTGG  
L S L T C T V S G G S I N S S D Y Y W  
GCCTGGATCCGCCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGAACTATCTTTTATA 
A W I R Q P P G K G L E W I G T I F Y  
TTGGGAGAACCTACTACAATCCGTCCCTCAAGAGTCGCGTCACCATATCCGGAGACAC  
I G R T Y Y N P S L K S R V T I S G D T  
GTCCAAGAACCAATTCTCCCTGCAACTGAGGTCTATGACCGCCGCAGACACGGCTGTG 
S K N Q F S L Q L R S M T A A D T A V  
TTTTACTGTGTGAGACAAACTGTCGGGGATAAGTATCGTTGTGACTTTGACTATTGGG  
F Y C V R Q T V G D K Y R C D F D Y W  
GCCAGGGAACCCTGGTCACCGTCTCCTCAAGTGGAGGCGGTTCAAGCGGAGGTGGCTC 
G Q G T L V T V S S S G G G S S G G G S  
TGGCGGTGGCGGTTCGGACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCT 
G G G G S D I Q M T Q S P S F L S A S  
GTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGGGCATTAGTAGTAATTTAG 
V G D R V T I T C R A S Q G I S S N L  
CCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAC  
A W Y Q Q K P G K A P K L L I Y A A S T  
TTTGCAAAGTGAGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACT 
L Q S E V P S R F S G S G S G T E F T  
CTCACAATCAACAGCCTGCAGCCTGAGGATTTTGCAACTTATTACTGTCAACAGCTTA  
L T I N S L  Q P E D F A T Y Y C Q Q L  
GTAGTTACCCGGTCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGT 
S S Y P V T F G Q G T R L E I K R
286
MO 3
CCCAGGTGCAGCTGGTGCAGTCTGGGGGAGACTTGGTGCAGCCGGGGGGGTCCCTGAG 
Q V Q L V Q S G G D L V Q P G G S L R  
ACTCTCCTGTGTAACCTCTGGAGGCACATTTAGTAATCATGTCGTGACCTGGGTCCGC 
L S C V T S G G T F S N H V V T W V R  
CAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAAGTATTAGTGGTAGTGATAGGCGAA 
Q A P G K G L E W V S S I S G S D R R  
CAGATTATGCAGAGTCTGTGAAGGGCCGCTTCAGTTTCTCCAGAGACACTTGCAACAA 
T D Y A E S V K G R F S F S R D T C N K  
AACATTTTTTCTGCAAATGAACAATCTGACAGTCGCGGACACGGCCGTATATTATTGT 
T F F L Q M N N L T V A D T A V Y Y C  
GCGACTGATCGGACTGAGGGGCACGATTTTTGGAATGGTTCTTATATCAGTGGCGGGC 
A T D R T E G H D F W N G S Y I S G G  
CTCACGGACGAAAGTGTCACAGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGT 
P H G R K C H S L D V W G Q G T T V T V  
CTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGCAATCT 
S S G G G G S G G G G  S G G G G S Q S  
GCCCTGACTCAGCCTGCCTCCGTGTCGGGGTCTCTTGGACAGTCGATCACCATTAATT 
A L T Q P A S V S G S L G Q S I T I N  
GCACTGGAACCGGCAGTGACTTTGATGTTTGTGCATCTGTCTCCTGGTACCAACAACA 
C T G T G S D F D V C A S V S W Y Q Q H  
CCCAGGCAAAGTCCCCACACTCATAATATATGATGTCACTAATCGGCCCTCAGGCATT 
P G K V P T L I  I Y D V T N R P S G I  
TGTAGTCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGC 
C S R F S G S K S G N T A S L T I S G  
TCCAGGCTGAGGACGAGGCGGATTATTACTGCGGCTCATATATTAGAACCAACACTCT 
L Q A E D E A D Y Y C G S Y I R T N T L  
GCTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT 
L F G G G T K L T V L G
MO 4
CCGAGGTGCAGCTGGTGGAGTCTGGGGCAGAACTTGTGAGGTCAGGGACCTCAGTCAA 
E V Q L V E S G A E L V R S G T  S V K  
GTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACTCCTATATGCACTGGTTGAGG  
L S C T A S G F N I K D S Y M H W L R  
CAGGGGCCTGAACAGGGCCTGGAGTGGATTGGATGGATTGATCCTGAGAATGGTGATA 
Q G P E Q G L E W I G W I D P E N G D  
CTGAATATGCCCCGAAGTTCCAGGGCAAGGCCACTTTTACTACAGACACATCCTCCAA 
T E Y A P K F Q G K A T F T T D T S S N  
CACAGCCTACCTGCAGCTCAGCAGCCTGACATCCGAAGACACTGCCGTCTATTATTGT 
T A Y L Q L S S L T S E D T A V Y Y C  
AATGAGGGGACTCCGACTGGGCCGTACTACTTTGACTACTGGGGCCAAGGCACCCTGG 
N E G T P T G P Y Y F D Y W G Q G T L  
TCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATC 
V T V S S G G G G S G G G G S G G G G S  
GGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTC 
D I Q M T Q S P S S L S A S V G D R V
287
ACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTATTTAAATTGGTATCAGCAGA 
T I T C Q A S Q D I S N Y L N W Y Q Q  
AACCAGGGAAAGCCCCTAAGCTCCTGATCTACGATGCATCCAATTTGGAAACAGGGGT 
K P G K A P K L L I Y D A S N L E T G V  
CCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGC 
P S R F S G S G S G T D F T F T I S S  
CTGCAGCCT GAAGATAT T G CAACATAT TAC T G T CAACAG T C T GATAAT CTCCCATTCA  
L Q P E D I A T Y Y C Q Q S D N L P F  
CTTTCGGCCCTGGGACCAAAGTGGATATCAAACGT 
T F G P G  T K V D I K R
MO 5
CCGAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAA 
E V Q L V E S G A E V K K P G A S V K  
GGTCTCCTGCAGGGCCTCTGGAAACACCTTCACCGCCTACTATGTGAACTGGGTGCGA 
V S C R A S  G N T  F T A Y Y  V N W V R  
CAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGCTGATCCACCCTACCAGTGGCGACA 
Q A P G Q G L E W M G L  I H P T S G D  
CATACTATGAACAGAAATTTCAGGGCAGGGTCACCATGACCAGGGACATGTCCATCAA 
T Y Y E Q K F Q G R V T M T R D M S  I N  
CACAGCCTACATGGACCTCTTCTGGCTGACCCCTGACGACACGGCCGTCTATTACTGT 
T A Y M D L F W L T P D D T A V Y Y C  
GCGAGTGGTCCCGACACGAAAAAAGCCGGCTACTGGGGCCAGGGCACCCTGGTCACCG 
A S G P D T K K A G Y W G Q G T L V T  
TCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGCAGTC 
V S S G G G G S G G G G S G G G G S Q S  
TGTGTTGACGCAGCCGCCCTCAGTGTCGGGGGCCCCTGGGCAGAGGGTCACTCTCTCC 
V L T Q P P S V S G A P G Q R V T L S  
TGCACTGGGAATAGCACCAACCTCGGGGCAAATTATGATGTGCACTGGTACAAGCAAC 
C T G N S T N L G A N Y D V H W Y K Q  
TTCCCGAAACGGCCCCCAAACTCCTCATTTACGGTAACCGCAAGCGGCCCTCAGGGGT 
L P E T A P K L L I Y G N R K R P S G V  
TCCTGATCGATTCTCTGGTTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGG  
P D R F S G S K S G T S A S L A I T G  
CTCCAGGCTGAGGATGAGGCTGCATATTATTGCCAGTCCTATGACTACAGCCTGCGAA 
L Q A E D E A A Y Y C Q S Y D Y  S L R  
CTGTGGTTTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT 
T V V F G G G T K L T V L G
MO 6
CCGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAG
E V Q L V E S G G G L V Q P G G S L R
ACTCTCTTGTGTAGCCTCTGGATTCACGTTCAGTACCTCGGCCATGAACTGGGTCCGC
L S C V A S G F T F S T S A M N W V R
CAGGCTCCAGGGAAGGGCCTGGAGTGGGTCTCACTTATGACTAGTGGTACTATTACAC
Q A P G K G L E W V S L M T S G T I T
288
AT TAC GCAGAC T C C G T GAAGGAC C GAT T TAC CAT C T C CAGAGACAAT T C CAAGAC TAC 
H Y A D S V K D R F T I S R D N S K T T  
GTTGTTTTTGCAAATGAACAGCCTGAGAGTCGAGGACACGGCCACATACTACTGTGCG 
L F L Q M N S L R V E D T A T Y Y C A  
AATGGTTCGGACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG 
N G S D W F D P W G Q G T L V T V S S  
GTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATCCAGATGAC 
G G G G S G G G G S G G G G S D I Q M T  
CCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAG  
Q S P D S L A V S L G E R A T I N C K  
TCCAGCCAGAGTATTTTTTCCTGGTCCTACAATAAGAACAACTTAACTTGGTATCAGC  
S S Q S I F S W S Y N K N N L T W Y Q  
AGAAACCAGGACAGCCTCCTAAATTGCTCATTTACTGGGCATCTACCCGGGAATCCGG  
Q K P G Q P P K L L I Y W A S T R E S G  
GGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC 
V P D R F S G S G S G T D F T L T I S  
AGCCT GCAGACT GAAGAT GT GGCAGT T TAT TATT GT CAACAATAT TATAGT C GT CCGC 
S L Q T E D V A V Y Y C Q Q Y Y  S R P  
TCACTTTCGGCGGAGGGACCAAAGTGGATATCAAACGT 
L T F G G G T K V D I K R
MO 8
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAGGCCTGGGGGGTCCCTTAGAC 
E V Q L V E S G G G L V R P G G S L R  
TCTCTTGTGTAGGCTCTGGATTCACTTTTAGTAATGCCTGGATGACCTGGGTCCGCCA  
L S C V G S G F T F S N A W M T W V R Q  
GGGTCCAGGAAAGGGGCTAGAATGGGTTGGTCGTATTAAAAACATAAGTGAAGGTGGG 
G P G K G L E W V G R I K N I  S E G G  
AC AAC AG AC T AC GC T AC AT C C GT T AAAG GC AG AT T T T AC AT C T C AAGAG AT GAT T C AA  
T T D Y A T S V K G R F Y I S R D D S  
AAAATATGGTGTATCTGCAAATGGACAGCCTGAAAACCGAGGACACAGCCATTTATTA  
K N M V Y L Q M D S L K T E D T A I Y Y  
TTGTTCCACAAATGTGACCGGACCTCGAGCGCCAATTATGCACTTTGAGTCTTGGGGC 
C S T N V T G P R A P I M H F E S W G  
CAAGGCACCCTGGTCACCGTCTCCTCGGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTG 
Q G T L V T V S S G G G G S G G G G S  
GCGGTGGCGGATCGCAGTCTGTGCTGACTCAGCCACCCTCCGCGTCCGGGTCTCCTGG 
G G G G S Q S V L T Q P P S A S G S  P G  
ACAGTCAGTCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTAT  
Q S V T I S C T G T S S D V G G Y N Y  
GTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATTTTTGAGGTCA  
V S W Y Q Q H P G K A P K L M I  F E V  
ATAAGAGGCCTTCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGC  
N K R P S G V P D R F S G S K S G N T A  
CTCCCTGACCGTCTCTGGGCTCCAGGCTGAGGATGAAGCTGATTATTATTGCAGCTCA  
S L T V S G L Q A E D E A D Y Y  C S  S
289
TATGCAGGCACCAACACAGTATTTGGCGGAGGGACCAAGCTGACCGTCCTAGGT
Y A G T N T V F G G G T K L T V L G
S O I
CCCAGGTGCAGTTACAGCAGTGGGGCGCGGGACTCTTGAAGCCGTCGGAGACCCTGTC 
Q V Q L Q Q W G A G L L K P S E T L S  
TCTCATCTGCGCTGTCTATGGGGGATCCCTCAATGATTACTACTGGAGTTGGATCCGC 
L I C A V Y G G S L N D Y Y W S W I R  
CAGCCCCCGGGGGGGGGCCTGGAGTGGCTTGGAGAAGTCGATTCTCGTGGAGGCACCA 
Q P P G G G L E W L G E V D S R G G T  
ACTACAGCCTGGCCCTCAGGGGTCGCGTCACGGTGTCCTTAGACATGTCCAAGAACTC 
N Y S L A L R G R V T V S L D M S K N S  
CTTCTCCCTAAAATTGACCTCTGTGACCGTCGCGGACACGGCTACCTATTTCTGCGCG  
F S L K L T S V T V A D T A T Y F C A  
AGAGGACTTGGTCTAGACATGGACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCG  
R G L G L D M D F D L W G R G T L V T  
TCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGAAAAG 
V S S G G G G S G G G G S G G G G S K S  
TGTGCTGACGCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGGGAAAACGCCACCCTC 
V L T Q S P D T L S L S P G E N A T L  
TCCTGTAGGGCCAGTCAGACGGTTGACGGCAACTTCTTAGCCTGGTATCAGCAAAAAC 
S C R A S Q T V D G N F L A W Y Q Q K  
CTGGCCAGGCTCCCAGGCTCCTCCTTTACGATGCTTCCACCAGGGCCACTGGCATCCC  
P G Q A P R L L L Y D  A S T R A T G I P  
AGACAGGTTCAGTGGCAGTGGGTCTGGGAGAGACTTCACCCTCACCATCAGCAGTCTG  
D R F S G S G S G R D F T L T I S S L  
GAGCCTGAGGATCTCGGAATATACTATTGTCAGAACTATGATAAGTCTTTGATGTACA  
E P E D L G I Y Y C Q N Y D K S L M Y  
CCTTTGGCCAGGGGACCAAGCTGGAGATCAAA 
T F G Q G T K L E I K
S 0 2
CCGAGGTACAATTAGTGGAGTCTGGGGGAGGCCTGGTCAAGCCGGGGGGGTCCCTGAG 
E V Q L V E S G G G L V K P G G S L R  
ACTCTTCTGTGCGGCCTCTGGATTCACCTTCAGAAGTTATACCATGAACTGGGTCCGC  
L F C A A S G F T F R S Y T M N W V R  
CAGGCTCCGGGGAAGGGTCTGGAGTGGGTCTCATCTATTAGTGGTTTTAGTTCTTACA  
Q A P G K G L E W V S S I S G F S S Y  
TATACTATGCAGACTCACTGAGGGGCCGATTCACCATCTCCAGAGACAACGCCAGAAA  
I Y Y A D S L R G R F T I  S R D N A R N  
TTCACTGTCTCTGCAAATCAACGACCTGCGACCCGACGACACGGCTATATATTATTGT  
S L S L Q I N D L R P D D T A I Y Y C  
GCGACAAATAGCACCTCGTCGAAGACATCGTACACCTTTGACTACTGGGGCCGGGGAA 
A T N S T S S K T S Y T F D Y W G R G  
CCCTGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCTGGCGGTGG 
T L V T V S S G G G G S G G G G S G G G  
CGGATCGCAGTCTGTGCTGGCTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGG 
G S Q S V L A Q P P S A S G T P G Q R
290
GTCATCATCCCTTGTTCTGGAAGCAGCTCCAACATCGGAACTAATACTGTAGACTGGT 
V I I P C S G S S S N I G T N T V D W  
ATCAACAATTCCCAGGAACGGCCCCCAAACTCCTCATCTACAGTAATAATCAGCGGCC 
Y Q Q F P G T A P K L L I Y S N N Q R P  
CTCGGGGGTCCCTGACCGATTCTCTGGCTCCAACTCTGGCACCTCAGCCTCCCTGGCC 
S G V P D R F S G S N S G T S A S L A  
ATCAGTGGGCTCCAGTATGAGGATGAGGCTGACTATTATTGTGCAACACGAGATGTCA 
I  S G L Q Y E D E A D Y Y C A T R D V  
ACCTGGATGCTCCGGTGTTCGGCGGAGGGACTAAACTGACCGTCCTA 
N L D A P V F G G G T K L T V L
S 0 3
CCCTGTTATATCTGGAGGAGTCTGGGGGAGGCTTGGTCAACCCTGGAGGGTCCCTGAG 
L L Y L E E S G G G L V N P G G S L R  
ACTCTCCTGTGCAGCCTCTGGCCTCACCTTCAGGGACTACAATATGAGTTGGATCCGC 
L S C A A S G L T F R D Y N M S W I R  
CAGGCTCCAGGGAAGGGGCTGGAATGGGTTTCAAATATTACTACTAGTGGTAACACCA 
Q A P G K G L E W V S N I T T S G N T  
TAGACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAA 
I  D Y A D S V K G R F T  I  S R D N A K N  
CTCACTGCATCTGCAGATGAACAACTTGAGAGGCGACGACACGGCCGTATATTATTGT 
S L H L Q M N N L R G D D T A V Y Y C  
GCGACAACAGTGCCTTCTGCTTCTTCTCCTGCCTATTACTACATGGACGTCTGGGGCA  
A T T V P S A S S P A Y Y Y M D V W G  
AAGGGACTACGGTCACCGGCTCCTCATGTGGAGGCGGTTCAAGCGGAGGTGGTTCTGG 
K G T T V T G S S G G G G S G G G G S G  
CGGTGGCGGATCGAAAATTATATTGACACAGTCTCCAGCCAACCTGTCTTTGTCTCCA  
G G G S K I I L T Q S P A . N L S L S P .  
GGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTCTTAGTAGTTCCTTAGCCT 
G E R A T L S C R A S Q S L S S S L A  
GGTACCAACAAAAACCTGGCCAGGCTCCCAGGCTCCTCATCCATGATGCATCCAACAG  
W Y Q Q K P G Q A P R L L I H D A S N R  
GGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGAGACAGACTTCACTCTC 
A T G I P A R F S G S G S E T D F T L  
ACCATCAGCAGTCTAGAGCCTGAAGATATTGCAGTTTATTACTGTCAGCAGCGGGTCA  
T I S S L E P E D I A V Y Y C Q Q R V  
CTTTCGGCGGAGGGACCAAGGTAGAGATCAAA 
T F G G G T K V E I K
S 0 4
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGAC 
E V Q L V E S G G G L V Q P G G S L R  
TCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTATAGCATGAACTGGGTCCGCCA  
L S C A A S G F T F S S Y  S M N W V R Q  
GGCTCCAGGGAAGGGGCTGGAGTGGATTTCAAACATTAGTAGTAGTATTAGTAACATA  
A P G K G L E W I S N I S S S I S N I
291
TACTACGCAGACTCTGTGAAGGGCCGATTCACCATTTCCAGAGACAATGCCAAGAACT 
Y Y A D S V K G R F T I  S R D N A K N  
CACTGTATCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTATTACTGTGC 
S L Y L Q M N S L R D E D T A V Y Y C A  
GAGAGATTCCTTGGGCAGTAGCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC 
R D S L G S S L D Y W G Q G T L V T V  
TCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCTGGCGGTGGCGGATCGGAAATTG 
S S G G G G S G G G G S G G G G S E I  
TGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAAGGGAAAATGTCACCCTCTC  
V L T Q S  P A T  L S L S P R E N V T L S  
CTGCAGGGCCAGTCAGAGTGTTACCAACTACTTAGCCTGGTACCAACAGAAGCCTGGC 
C R A S Q S V T N Y L A W Y Q Q K P G  
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCA 
Q A P R L L I Y D A S N R A T G I  P A  
GGTTCAGTGGCAGTGGGTATGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCC 
R F S G S G Y G T D F T L T I S S L E P  
TGAAGATTTTGCAGTTTATTACTGTCAACAACGTAGCAACTGGCTGTCTTTCGGCGGA  
E D F A V Y Y C Q Q R S N W L S  F G G  
GGGACCAAAGTGGAGATCAAA 
G T K V E I  K
S 0 5
GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGAC 
E V Q L V E S G G G L V Q P G G S L R  
TCTCCTGTGCAGCCTCTGGATTCACCTTCAGTTCCTATAGCATGACCTGGGTCCGCCA 
L S C A A S G F T F S S Y S M T W V R Q  
GGCTCCAGGGAAGGGGCTGGAGTGGGTTTCAAACATTAGCAGTAGTAGTAATACCGCA 
A P G K G L E W V S N I S S S S N T A  
TTCTACGCAGACTCCGTGAAGGGCCGATTCACCATTTCCAGAGACAATGTCAAGAATT 
F Y A D S V K G R F T I S R D  N V K N  
CACTGTATCTGCAAATGCACAGCCTGAGAGACGAGGACACGGCTGTATACTTTTGTGC 
S L Y L Q M H S L R D E D T A V Y F C A  
GAGAGATCGAAATGGCTACAATTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACC 
R D R N G Y N F F D Y W G  Q G T L V T  
GTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCTGGCGGTGGCGGATCGGACA 
V S S G G G G S G G G G S G G G G S  D 
TCGAAATGACCCAGTCTCCATCGTCCCTGTCTGCATCTATTGGGGACAGACTCACCAT 
I E M T Q S P S S L S A S I G D R L T I  
CACCTGCCGGGCAAGTCAGGCTATTCGTGAGTCTGTACAGTGGTATCAACAGAAACCA 
T C R A S Q A I R E S V Q W Y Q Q K P  
GGGAAAGCCCCTAAACTCCTTATGTTTTCAACATCTATTTTGGAAAGTGGTGTCCCGT 
G K A P K L L M F S T S I L E S G V P  
CAAGGTTCAGCGGCAGTGGATTTGGGACACATTTTACTCTCACCATCAGCAGTCTACA  
S R F S G S G F G T H F T L T I S S L Q  
ACCTGAAGATTTTGCAACTTATTCGTGTCAGCAGAATTACAGTGGCCCTTTCACTTTC  
P E D F A T Y S C Q Q N Y S G P F T F  
GGCCCCGGGACCAAGGTTGAAATGAGA 
G P G T K V E M R
292
S06
CAAGTTCAACTAGTGGAGTCTGGGGGCGGCGTGGTCCAGCCTGGGACGTCCCTGAGAC 
Q V Q L V E S G G G V V Q P G T S L R  
TCTCCTGTGCAGCCTCTGGATTCCCCTTCATCTACTATGGCATACACTGGGTCCGCCA 
L S C A A S G F P F I Y Y G I H W V R Q  
GGCTCCAGGCAAGGGGCTGGAGTGGGTTGCAGGTCTCTCGTGTGATGGAACTAATGAA 
A P G K G L E W V A G L S C D G T N E  
TATTATGCTGACTCCCTGAAGGGTCGCTTCGTCATCTCCAGAGACAACTCCAAGAACA 
Y Y A D S L K G R F V I S R D N S K N  
CGGTGTCTCTGCATATGAACCTCTTGAAAACTGAGGACACGGCTGTATATTATTGTGC 
T V S L H M N L L K T E D T A V Y Y C A  
GAAAGATTTTCACCAACATTATGGGTCAGGGAGTTATTATCAGGGCACCTTTGACTTT 
K D F H Q H Y G S G S Y Y Q G T F D F  
TGGGGCCAGGGAAGCCTGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTG 
W G Q G S L V T V S S G G G G S G G G  
GTTCTGGCGGTGGCGGATCGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGC 
G S G G G G S D I Q M T Q S P S S L S A  
AT CT GTAGGAGACAGAGT CACCAT CACT T GCC GGGCAAGT CAGAGCAT TAGCAACAAT 
S V G D R V T I T C R A S Q S I  S N N  
TTAAACTGGTATCAGCAAAAACCAGGGAAACCCCCTAGGCTCCTAATCTATGTTGCAT 
L N W Y Q Q K P G K P P R L L I Y V A  
CCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTT 
S S L Q S G V P S R F S G S G S G T D F  
CACTCTCAC CAT C AG GAG T C T G C AAC C T G AAG AT T T T G C AAC TTATTACTGT C AAC AA 
T L T I R S L Q P E D  F A T Y Y C Q Q  
AATTACAGTCTTTTGCCGCACACTTTTGGCCAGGGGACCAAGCTGGAGATCAGA 
N Y S L L P H T F G Q G T K L E I R
S07
GAGGTGCAGTTGGTGGAGTCGGGGGGAGGCTTGGTTCAGCCGGGGGGGTCCCTGAGAC 
E V Q L V E S G G G L V Q P G G S L R  
TCTCCTGTGAAGCCTCTGGCTTCAGCTTCAGTACTTACAGCATGAACTGGGTCCGCCA 
L S C E A S G F S F S T Y S M N W V R Q  
GGTTTCAGGGAAGGGACTAGAGTGGCTTTCAAACATTAGTAGTACAAGTGGAAGCACA 
V S G K G L E W L S N I S S T S G S T  
AATTACGCAGACTCTGTGACGGCCCGGTTCACCATTTCCAGAGACAATGCCCAGAATA 
N Y A D S V T A R F T I S R D N A Q N  
CACTGTGGCTACAGATGAACAGCCTGAGAGCCGAGGACACGGCTATATATTACTGTGC 
T L W L Q M N  S L R A E  D T A  I  Y Y C A  
GAGGACATCTTGTAGTGGTCGTTCCTGTCACTTTGACTACTGGGGCCAGGGAACCCTG 
R T S C S G R S C H F D Y W G Q G T L  
GTCACCGTCTTCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAT 
V T V F S G G G G S G G G G S G G G G  
CGGACATCCTGCTGACCCAGTCTCCATCCTCCCTGTCTGCGTCTGTTGGAGACAGAGT 
S D I L L T Q S P S S L S A S V G D R V  
CACCATCACTTGCCGGACAAGTCAGAGTATTTACACCTCTTTAAATTGGTTTCAGCAG
293
T I T C R T S Q S I Y T S L N W F Q Q
AAACCGGGGAAAGCCCCTAAACTCCTGATCTATTCTGCATCCACTTTGCAAAGTCAAG
K P G K A P K L L I Y S A S T L Q S Q
TCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCGG
V P S R F S G S G S G T D F T L T I S G
TCTGCAACCTGAAGATTTTGCAACTTACTATTGTCAACAAAGTTACAGTGCCCTGTAC
L Q P E D F A T Y Y C Q Q S Y S A L Y
ACTTTTGGCCAGGGGACCAAACTGGAGATCAA
T F G Q G T K L E I K
S09
GAGCTGCAACTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGAC 
E L Q L V E S G G G L V Q P G G S L R  
TCTCCTGTGTAGCCTCTGGATTCAATTTTACGAATTATAATATGAGTTGGGTCCGCCA 
L S C V A S G F N F T N Y N M S W V R Q  
GGCTCCAGGAAAGGGCCTGGAGTGGATTTCGTACATAAGCAACACTAGTACGAGCATA 
A P G K G L E W I S Y I S N T S T S I  
TAC TAC G CAGAT T C T G T GAAG GGCCGATTCATCATCTC CAGAGACAAT G C CAAG GAAT 
Y Y A D S V K G R F I  I S R D N A K E  
CTCTGTATCTGCAAATGAGCAGCCTGAGAGACGAGGACACGGCTGTCTATTACTGTGC 
S L Y L Q M S S L R D E D T A V Y Y C A  
GAGACGGAATGTGACAACGGTGAATCTCGGACTTGATGTTTTTGATATCTGGGGCCAA 
R R N V T T V N L G L D V F D I W G Q  
GGGACAATGGTCACCGTCTCTTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCG 
G T M V T V S S G G G G S G G G G S G  
GTGGCGGATCGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCTTCTGTTGG 
G G G S D I Q M T Q S P S S L S A S V G  
CGACAGAGTCACCGTCACTTGCCGGGCAAGTCAGAATATAAGTAATTACTTAAATTGG 
D R V T V T C R A S Q N I  S N Y L N W  
TATCAACTGAAGCCAGGGAAAGTCCCTAAACTCCTGATCTTTGCTGCATCCAGTTTGC 
Y Q L K P G K V P K L L I  F A A S  S L  
AAAGTGGGGTCCCATCAAGGTTCAGTGGCMGTCAATCTGGGGCAGATTTYACTCTCAC 
Q S G V P S R F S G S Q S G A D F T L T  
CAT C AAC AAT C T G C AAC C T G AAG AT T T T GC AAG T TAT T AC T GT C AAC AGAGT T AC AGT 
I N N L Q P E D F A S Y Y C Q Q S Y S  
TCCCCTTCGTGGACGTTCGGCCAAGGGACTAACGTGGAGATCAAC 
S P S W T F G Q G T N V E I K
S O U
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGACTTCGGAGACCCTCTCCC
Q V Q L Q Q W G A G L L K T S E T L S
TCACCTGCGCTGTCTATGGTGGGTCCTTCAATAATTACAACTGGACATGGATCCGCCA
L T C A V Y G G S F N N Y N W T W I R Q
GCCCCCAGGGAAGGGCCTGGAGTGGATTGGACAAATTAATCATAGTGGAACCACCAAT
P P G K G L E W I G Q I N H S G T T N
TATAATCCGTCCCTCAAGAGTCGAGTCACCATGTCAATAGACCCGTCCGAGAACCAGT
Y N P S L K S R V T M S I D P S E N Q
294
TCTCCCTGAAGGTGAGATCTGTGACCGCCGCGGACACGGCTATTTATTACTGTGTGAG 
F S L K V R S V T A A D T A I Y Y C V R  
AGGCTCCCCCGAATCTTCTGGCAATTACTGGGGACACTTCCAGTATTGGGGCCAGGGC 
G S P E S S G N Y W G H F Q Y W G Q G  
ACCCTGGCCACCGTCTCTTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTG 
T L A T V S . S G G G G S G G G G S G G  
GCGGATCGGACATCGTGATGACCCAGTCTCCAGACTCCCTGTCTGTGTCTCTGGGCGA 
G G S D I V M T Q S P D S L S V S L G E  
GAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCCACAATAAG 
R A T I N C K S S Q S V L Y S S H N K  
AACTACTTAGCTTGGTACCAACAGAAACCAGGACAACCTCCTAGGTTGCTCATTTATT 
N Y L A W Y Q Q K P G Q P P R L L I Y  
GGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGAC 
W A S T R E S G V P D R F S G S G S G T  
AGAT TTCACTCTCACCAT CAACAC CCTGCAGGCT G AAGAT GTGGCAGTTTATTACTGT 
D F T L T  I N T L Q A E D V A V Y Y C  
CAGCAATAT TATAC TAC T C C GTACAC T T T T GG C CAGG G GAC CAAG C T G GAGAT CAAA 
Q Q Y Y T T P Y T F G Q G T K L E I K
S012
CAGATCACCTTGAGGGAGTCTGGTCCTACGCTGGTGAAACCCACACAGACCCTCACAC 
Q I T L R E S G P T L V K P T Q T L T  
TGACCTGTACCTTCTCTAATTTCTCACTCACTACTCCTGGAATGGGTGTGGGCTGGGT 
L T C T F S N F S L T  T P G M G V G W V  
CCGTCAGCCCCCAGGAAAGGCCCTAGAGTGGCTTGCAGTCGTTTATTGGAATGATTAT 
R Q P P G K A L E W L A V V Y W N D Y  
AAGCGCTACAGCCCATCTCTGAAGACTAGACTCTCCATCACCGCGGACATTTCCAAAA 
K R Y S P S L K T R L S I T A D I S K  
ATCAGGTGGTCCTTACAATGACCAACATGGACCCTGTGGACACAGCCACATATTACTG 
N Q V V L T M T N M D P V D T A T Y Y C  
TACATACAACTCATCGGATCGCATCAAATTCGACCCCTGGGGCCAGGGAATTCGGGTC 
T Y N S S D R I K F D P W G Q G I R V  
ACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGG 
T V S S G G G G S G G G G S G G G G S  
ATTTTGTGTTGACACAGTCTCCAGGCACCCTGTCTGCATCTGTTGGAGACAGAGTCAA 
D F V L T Q S  P G T L S A S V G D R V N  
TATCACTTGCCGGGCCAGTCAGAGTGTTAGTAGGTGGTTGGCCTGGTATCAGCAGAAG 
I T C R A S Q S V S R W L A W Y Q Q K  
CCAGGGAAAGTCCCTGAACTTCTGATCTATGAGGCATCTAATTTAGAGAATGGGGTCC 
P G K V P E L L I Y E A S N L E N G V  
CATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCAATCTCACCATCAACAGCCT 
P S R F S G S G S G T E F N L T  I N  S L  
GCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGTATAATAGTTATTGGACATTC 
Q P D D F A T Y Y C Q Q Y N S Y W T F  
GGCCAAGGGACCCGGGTGGAAATCAAA 
G Q G T R V E I K
295
S013
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGTCTGGAGGGTCCCTGAGAC 
E V Q L V E S G G G L V Q S G G S L R  
TCTCCTGTGCAGCCTCTGGATTCACCTTCAGTTATTATGGAATGAACTGGGTCCGCCA 
L S C A A S G F T F S Y Y G M N W V R Q  
GGCTCCAGGAAAGGGGCTGGAGTGGGTCTCCTACATTAGTGGTAGTGGAGGAGCCATT 
A P G K G L E W V S Y I S G S G G A I  
TAC TAC G CAGAC T C T C T GAAG G G C C GAT TCATCATCTC CAGAGACAAC G C CAAGAAC T 
Y Y A D S L K G R F I I S R D N A K N  
CACTATATCTGCAAATGAACAACCTGAGAGCCGAAGACACGGCTATTTATTACTGTGC 
S L Y L Q M N N L R A E D T A I Y Y C A  
GAGTAATATATCAACTCGGACCTCGTACTTCTTTGACTCCTGGGGCCAGGGAACCCTG 
S N I S T R T S Y F F D S W G Q G T L  
GTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAT 
V T V S S G G G G S G G G G S G G G G  
CGGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTGTGTCTCCAGGCCAAAGAGT 
S E I  V L T Q S P G T L S V S P G Q R V  
CACCCTCTCTTGCAGGGCCAGTCAGAGCGTTATCAGCCCATACTTAGCCTGGTTCCAG 
T L S C R A S Q S V I S P Y L A W F Q  
CAAAAACCTGGCCAGGCTCCCAGTCTCGTCATCTATGGTACATCCAGCAGGGCCACTG 
Q K P G Q A P S L V I Y G T S S R A T  
GCATCTCAGACAGGATCAGTGGCAGTGGGTCTGGGACAGACTTCAGTCTCACCATCAG 
G I S D R I S G S G S G T D F S L T I S  
CAGACTGCAGCCTGAAGATTTTGGAATATATTACTGTCAGCATTATGGAAGTTCACCT 
R L Q P E D F G I Y Y C Q H Y G S S P  
CCGATGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAC 
P M W T F G Q G T K V E I N
S017
GAGAAACAAGTTTTGGAGTCTGGGGGAAAGTTGGTCCAGCCGGGGGGGTCCCTGAGAC 
E K Q V L E S G G  K L V Q P G G S L R  
TCTCCTGTGTTGCCTATGGATTCACTTTTGAGAAAAATGCCATCAACTGGGTCCGCCA 
L S C V A Y G F T F E K N A I N W V R Q  
GGCTCCAGGGAAGGGGCTGCAGTGGGTCTCAGGTCTTAGTGGTGGTGATTCATCCACA 
A P G K G L Q W V S G L S G G D S S T  
TATTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCGACAACA 
Y Y A D S V K G R F T I S R D N S D N  
TGTTTTATTTGCAAATGAGCAGCCTGAGAGTCGAGGACACGGCCTTATATTACTGTGC 
M F Y L Q M S S L R V E D T A L Y Y C A  
GACGACTTGCCCTAGTTCCAAGTACTCTTTGTCATATGCTTTTGATATCTGGGGCCGA 
T T C P S S K Y S L S Y A F D I W G R
GGGACAATGGTCACCGTGTCTTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCG 
G T M V T V S S G G G G S G G G G S G  
GTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACA 
G G G S Q S . A L T Q P A S V S G S  P G Q  
GTCGATCACCATCTCCTGTACTGGGTCCCGCAGTGACATTGGTGGTTACAACTATGTC
296
S I T I S C T G S R S D I G G Y N Y V  
TCCTGGTAC CAACAACAC C CAG G C AAAG T C C C CAAAG TCATCATTTTT GAAG T CAC T T 
S W Y Q Q H P G K V P K V I  I  F E V T  
GTCGGCCCTCAGGGATTTCTTCTCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTC 
C R P S G I S S R F S G S K S G N T A S  
CCTTACTATCTCTGGCCTCCAGGCTGACGACGAGGCTCATTATTACTGCAGCTCATAT 
L T I S G L Q A D D E A H Y Y C S S Y  
TCAAACAGTCGCACTCGTGTCTTATTCGGCGGAGGGACCAGGTTGACCGTCCTA 
S N S R T R V L F G G G T R L T V L
S018
GGGGTGCAGTTGGTGGAATCTGGGGGAGGGTTGGTAAAGCCTGGGGGGTCCCTCAGAC 
G V Q L V E S G G G L V K P G G S L R  
TCTCCTGTTCAGTCTCAGGATTCACCTTCACTAACGCCTGGATGAATTGGGTCCGCCA 
L S C S V  S G F T  F T N A W M  N W V R Q  
GGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAACAGAGCTGATGGTGAG 
A P G K G L E W V G R I K N R A D G E  
ACAACAGACTACGCTGCACCCGTGAAAGGCCGATTCAGCATCTCAAGAGATGAGTCGA 
T T D Y A A P V K G R F S I S R D E S  
AAAATAT GT T GT T T T T GCAAAT GAT CAGC C T GAAACC T GAGGACACAGCCAT T TAT TA 
K N M L F L Q M I  S L K P E D T A I Y Y  
TTGTACGTCAAATTGTAGTCATAGTCACTGTCCTAAAATTTCCTCATATAACGACTAC 
C T S N C S H S H C P K I S S Y N D Y  
GATATGGACGTCTGGGGCCCAGGGATCCTGGTCACCGTCTCCTCAGGTGGAGGCGGTT 
D M D V W G P G I L V T V S S G G G G  
CAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACGTCCTGATGACCCAGTCTCCATC 
S G G G G S G G G G S D V L M T Q S  P S  
CTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGC 
S L S A S V G D R V T I T C R A S Q G  
TTTAGAAATGATTTCGGCTGGTATCAACAGATACCAGGGAAAGCCCCTAAGTGCCTGA 
F R N D F G W Y Q Q I  P G K A P K C L  
TCTATGCTGCATCCACTTTGCAGAGTGGGGTCCCATCAAGATTCAGCGGCAGTGGATC 
I Y A A S T L Q S G V P S R F S G S G S  
TGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTAT 
G T E  F T L T  I  S S L Q P E  D F A T Y  
TACTGTCTACAACGTAACAATTCCGCCCTCACTTTCGGCGGAGGGACCAAGGTGGAGA 
Y C L Q R N N S A L T F G G G T K V E  
TCAAA 
I  K
297
COla
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG 
Q V Q L V Q S G A E V K K P G A S V K  
TCTCCTGCAAGGCTTCTGGATACACCTTCACCGACTACTATATGAACTGGGTGCGACA 
V S C K A S G Y T F T D Y Y M N W V R Q  
GGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACA 
A P G Q G L E W M G W I N P N S G G T  
AAGTATGCACAGAAGTTTCAGGGCTGGGTCACCATGACCAGGGACACGTCCATCAGCA 
K Y  A Q K F Q G W V T M T R D T S  I  S 
CAGTCTACATGGAGCTGAGCAGGCTGGGATCTGACGACACGGCCGTGTATTACTGTGC 
T V Y M E L S R L G S D D T A V Y Y C A  
GACAGACCAGATGGCTACAAGTCGAGCGGGGGTTTCAGAGGGCTTTGACTTCTGGGGC 
T D Q M A T S R A G V S E G F D F W G  
CAGGGAACCCTGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTG 
Q G T L V T V S S G G G G S G G G G S  
GCGGTGGCGGATCGGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCC 
G G G G S E I V L T Q S P G T L S L S P  
AGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTA 
G E R A T L S C R A S Q S V S S S Y L  
GCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCA 
A W Y Q Q K P G Q A P R L L I Y G T S  
GCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC 
S R A T G I P D R F S G S G S G T D F T  
TCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTAT 
L T I S R L E P E D F A V Y Y C Q Q Y  
GCTAGCTCACCTCCCACCTTCGGCCAAGGGACACGACTGGAGATTAAA 
A S S P P T F G Q G T R L E I K
COlb
CATGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG 
H V Q L V Q S G A E V K K P G A S V K  
TCTCCTGCAAGGCTTCTGGATACACCTTCACCGACTACTATATTAACTGGGTGCGACA 
V S C K A S G Y T F T G Y Y I H W V R Q  
GGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTGACAGTGGTGGCACA 
A P G Q G L E W M G W I N P D S G G T  
AAGTATGCACAGAAGTTTCAGGGCTGGGTCACCATGACCAGGGACACGTCCATCACCA 
N Y A Q K F Q G W V T M T R D T S  I  T 
CAGTCTACATGGAGATGAGCAGGCTGGGATCTGACGACACGGCCGTGTATTACTGTGC 
T A Y M E M S R L G S D D T A V Y Y C A  
GACAGACCAGATGGCTACAAGTCGAGCGGGGGTTTCAGAGGGCTTTGACTTCTGGGGC 
T D Q M A T S R A G V S E G F D F W G  
CAGGGAACCCTGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTG 
Q G T L V T V S S G G G G S G G G G S  
GCGGTGGCGGATCGGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCC 
G G G G S E I V L T Q S P G T L S L S P  
AGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTA 
G E R A T L S C R A S Q S V S S S Y L
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GCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCA 
A W Y Q Q K P G Q A P R L L I Y G T S  
GCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC 
S R A T G I  P D R F S G S G S G T D F T  
TCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTAT 
L T I S R L E P E D F A V Y Y C Q Q Y  
GCTAGCTCACCTCCCACCTTCGGCCAAGGGACACGACTGGAGATTAAA 
A S S P P T F G Q G T R L E I K
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B -  scFv protein data
scFv Number of Estimated VH CDR3 VL CDR3
amino acids M.Wt (kDa) length length
B01 245 25.1 10 11
B02 245 26.9 9 9
B03 246 26.5 15 9
B04 241 25.8 10 8
B05 237 25.0 6 9
M01 243 26.6 10 10
M02 247 25.8 13 11
M03 242 25.3 15 5
M04 239 25.4 9 8
M05 241 25.7 10 9
M06 250 26.7 18 10
M08 243 25.8 12 9
SOI 247 25.8 15 10
S02 251 27.2 15 9
S03 241 26.2 10 8
S04 246 25.9 12 11
S05 250 26.3 15 11
S06 253 26.7 22 9
S07 248 26.5 10 9
S09 246 26.4 13 9
S011 263 27.3 28 9
S012 243 25.9 11 10
SOD 245 25.8 9 11
S017 244 26.1 7 9
S018 250 25.9 14 9
B2 247 26.0 13 10
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C - Composition of Qiagen buffers used in plasmid DNA purification
Buffer Composition Storage
PI (resuspension buffer) 50 mM Tris.Cl, pH 8.0 
10 mM EDTA 
100 [xg/ml RNase A
2-8°C, after addition of 
RNase A
P2 (lysis buffer) 200 mM NaOH 
1% SDS (w/v)
15-25°C
P3 (neutralization buffer) 3.0 M potassium acetate, 
pH 5.5
15-25°C or 2-8 °C
FWB2 (QIAfilter wash 
buffer)
1 M potassium acetate, 
pH 5.5
15-25°C
QBT (equilibration buffer)
750 mM NaCl 
50 mM MOPS, pH 7.0 
15% isopropanol (v/v) 
0.15% Triton® X-100 (v/v)
15-25°C
QC (wash buffer) 1.0M NaCl
50 mM MOPS, pH 7.0 
15% isopropanol (v/v)
15-25°C
QF (elution buffer) 1.25 M NaCl 
50 mM Tris.Cl, pH 8.5 
15% isopropanol (v/v)
15-25°C
QG (solubilization buffer) 
pH indicator
Proprietary information 
Contains guanidine 
thiocyanate
15-25°C
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D - Plasmids
D1 -  pMT/BiP/V5 His D
pMT/BiP/V5-His
Ncol/Notl
3636 bp
ColEl
Ampicillin
Metallothionein prom oter
BiP signal 
NC0I sequence
Notl
epitope tag 
His tag
SV 40 polyA
4 0 0 800 900 1000
A V
1100 1270
A V
Ncol Notl
3C - r a a - m
Metallothionein promoter BiP signal sequence V5 tag His tag
 »____
SV40 polyA
□  Plasmid replication/selection genes l~T~l Expression related genes 
□  Expressed genes
Note: This plasmid is derived from a modified version of pMT/BiP/V5 His D. Two 
nucleotides were deleted immediately 5’ of the Ncol site to make the plasmid 
compatible with pHenIX, pVAC family, pUCl 19-His and pUCl 19-CaM 
such that scFv cassettes can be cloned in frame with the BiP signal sequence 
as Ncol/Notl fragments.
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D2 -  pMT/BiP/CaM
i
If
\  \  Metelhthionein orornoter
A
pMT/BiP/Calmodulin 
3950 bp
\ \V :  \\  \
O . C ?  N j i ;
B ,iP sign*) sequence
Ncol
Notl
r,-' > v y w  p o l y  i
400 1000 1200 1400 1 5 90
Ncol Not I
MetsJIothionein prornoter
Bi P signs! 
ssgusnct: CsJruodulin SY4U polyA
□  Plasmid replication selection penes I l I Hx press ion related penes
□  Hx pressed penes
Note: This plasmid is derived from a modified version of pMT/BiP/V5 His D. Two 
nucleotides were deleted immediately 5’ of the Ncol site to make the plasmid 
compatible with pHenIX, pVAC family, pUCl 19-His and pUCl 19-CaM such 
that scFv cassettes can be cloned in frame with the BiP signal sequence as 
Ncol/Notl fragments.
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D3 -  pVAC2
i
Hindi 11
Vf-i sign*) peptide
pVAC2 
5969 bp
f t  origin (7 5frc- or.-fy)
800 1000 1200 1400 14.00 1800 2000 2200 2400 260)0
AV 1-----------------------1---------------------- 1---------------------- 1---------------------- 1---------------------- 1---------------------- 1---------------------- 1-----------------------1------------------------- V ,--------------------- '-----
Hind III St'i I N otl Xbal
CMV promoter T eton us I oxoi d fragm ent
T 7 prom ol er Vh si goal Vh 1 f port)
peptide
□  IMasmid replication .selection penes Q U  Expression related penes 
□  Hx pressed penes □  Gene replaced b\ cloned \ ‘h  \ j  Printer site
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D4 -  pCR 2.1 (Invitrogen)
H ind III
EcoRI
EcoRI
Notl
Apol
pCR®2.1 
3906 bp
1
I
22 0
i
2 4 0
■
2 6 0  2 8 0  
1 1 V .
3 0 0  3 2 0  3 4 0 3 6 0 5 8 0
Hir.dill EcoRI EcoRI Notl 
1 1
Apai
- f  ; fmjjjjjf :: : : ; : : : : : : :  '*: ; : # P K -
F' lac PCR product lac 2 *
m  PCR2.1 dcri\cd □  Position of K 'R  product alter cloning Primer site
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E - Forms for the preparation of patient DNA vaccines
DNA vaccine preparation data sheet 1
Transfer of scFv cassette from trial centres to Cambridge
Surname: Forename(s):
Date of Birth: Study No.:
From trial centre:
Date sent: DD/MM/YY
Sent as: pHenlX-scFv GU pVAC2-scFv □
TO BE COMPLETED BY CAMBRIDGE CENTRE
Date received: DD/MM/YY 
Construct documentation CH 
Patient status sheet: □
Electronic sequence file □
APS/HITS number assigned: Affix Label
Print name ....................................... Sign name
Position .........................................
Comments:
Batch of competent bacteria ................. Date transformed: DD/MM/YY
Sequence of clones from stock plate prepared matches reference: Q
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DNA vaccine preparation data sheet 2
DNA purification-qualitv control 
Surname: Forename(s):
Date of Birth: Study No.:
Date of gel: DD / MM / Y Y
Patient details, size markers and test lanes to be printed on gel photo.
T O P  R O W B O T T O M  R O W
1 K b  m a r k e r  la d d e r 1 K b  m a r k e r  la d d e r
L a n e  1: S a m p le  l a L a n e  1 1 :  S a m p le  3 a
L a n e  2 : S a m p le  l b L a n e  1 2 :  S a m p le  3 b
L a n e  3 : S a m p le  l c L a n e  1 3 :  S a m p le  3 c
L a n e  4 : S a m p le  I d L a n e  1 4 :  S a m p le  3 d
L a n e  5 : S a m p le  l e L a n e  1 5 :  S a m p le  3 e
L a n e  6 : S a m p le  2 a L a n e  1 6 :  S a m p le  4 a
L a n e  7 : S a m p le  2 b L a n e  1 7 : S a m p le  4 b
L a n e  8 : S a m p le  2 c L a n e  1 8 :  S a m p le  4 c
L a n e  9 : S a m p le  2 d L a n e  1 9 : S a m p le  4 d
L a n e  1 0 :  S a m p le  2 e L a n e  2 0 :  S a m p le  4 e
1 K b  m a r k e r  la d d e r L a n e  2 1 :  S a m p le  5
1 K b  m a r k e r  la d d e r
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DNA vaccine preparation data sheet 3
DNA purification-quantitation/dilution of final product
Surname: Forename(s):
Date of Birth: Study No.:
Dilution of sample: 1/................  O.D. 260nm =.
O.D. 280nm =.........  Ratio O.D. 260nm : O.D. 280nm =........
DNA concentration: = O.D.260nm x 50 x Dilution factor = ng/ml
Total quantity of plasmid = ...................mg in ................ ml
Concentration required for fill:  ng/ml
Dilution factor from stock to concentration required for fill: 1/....................
 ml of stock diluted w ith ml of sterile saline to final volume o f  ml
Conformation of concentration of vaccine to be filled:
Dilution of sample: 1/.........  O.D. 260nm =.........
O.D. 280nm =.........  Ratio O.D. 260nm : O.D. 280nm =........
DNA concentration: = O.D.260nm x 50 x Dilution factor = ng/ml
Vial label details and printing
Label details match patient details?
Y / N
AFFIX EXAMPLE OF LABEL
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DNA vaccine preparation data sheet 4
Vaccine validation - plasmid structure A.
Surname: Forename(s):
Date of Birth: Study No.:
Date of digest: DD / MM / YY
Patient details, size markers and test lanes to be printed on gel photo.
Expected bands
1Kb marker ladder
Lane 1: pVAC2 Sail digest 2745, 2188, 938, 63 and 34bp.
Lane 2: pVAC2-scFv uncut
Lane 3: pVAC2-scFv Sail digest 2745, 2188,1700 approx. and 34bp.
1Kb marker ladder
Expected band pattern: Y / N
1.5% agarose gel
Comments:
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DNA vaccine preparation data sheet 5
Vaccine validation - plasmid structure B
Surname: Forename(s):
Date of Birth: Study No.:
Date of digest: DD / MM / YY
and
Patient details, size markers and test lanes to be printed on gel photo.
Expected bands
1Kb marker ladder
Lane 1: pVAC2-scFv uncut N/A
Lane 2: pVAC2-scFv Hindlll/Notl digest Approx. 900bp and 4552bp
Lane 3: pVAC2-scFv Sfil/Notl digest Approx. 850bp and 4606bp
1Kb marker ladder
Comments:
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DNA vaccine preparation data sheet 6
V accine validation -  Endotoxin/protein levels and microbiology
Surname: Forename(s):
Date of Birth: Study No.:
Endotoxin level: ........................IU/ml
OD 260/280 ratio: ........................ <2.0 = good 1.1-2.0 = acceptable
Microbiology: STERILE / NON-STERILE
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DNA vaccine preparation data sheet 7
Final approval:
Surname:
Date of Birth:
Forename(s): 
Study No.:
Plasmid structure - digests:
Hindlll/Notl Sail Notl/Sfil
Plasmid structure - scFv sequence matches reference:
Microbiology:
Endotoxin level: OD 260/280 ratio:
DNA concentration after sterile fill:........... ng/ml
Print name. Sign............................... Research Assistant
Print name. Sign...............................  Research Associate
Print name. Sign............................... Principal Investigator
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DNA vaccine preparation data sheet 8
Batch summary: 
Surname:
Date of Birth:
Forename(s): 
Study No.:
Quantity of plasmid purified:   mg in ........... ml
Quantity diluted for sterile fill:   mg
Number of vials filled:   o f ...........ml at ............ [xg/ml
Number of vials sent for endotoxin testing: ............
Number of vials sent for microbioogy testing:..................... ......
Number of vials sent for protein testing: ............
Number of vials issued for vaccination:
  Date: DD / MM
Date: DD / MM
Date: DD / MM
Date: DD / MM /
Date: DD / MM
Date: DD / MM
Number of vials used for research:
Date: DD /
Date: DD / MM
YY
YY
YY
YY
YY
YY
Number of vials remaining in storage at end of trial:
Signed: Name:
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DNA vaccine preparation data sheet 9
Sterile fill production record part 1 -  process data 
Surname: Forename(s):
Date of Birth: Study No.:
Product volume: 
Serology:
Start time: ................
Logged to freezer at:
No. of labels issued:
.ml Processing date: D D  / M M  / YY
Known No result
Finish time:
istroyed:
Affix label here
Filter pressure test:
1) PASS / FAIL 2) PASS / FAIL
3) PASS / FAIL 4) PASS / FAIL
5) PASS / FAIL 6) PASS / FAIL
7) PASS / FAIL 8) PASS / FAIL
No. product vials filled:
Signed: Name:
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DNA vaccine preparation data sheet 10
Sterile fill production record part 2 -  disposables record
Surname: Forename(s):
Date of Birth: Study No.:
Processing date: DD / MM / Y Y
Manufacturer Lot #
Vials ......................  ....................
Syringes................... ....................... ....................
Needles 
Filters 
TS broth
Signed: .............................  Name:
Sterilisation Run #
315
DNA vaccine preparation data sheet 11
Patient status:
Surname: Forename(s):
Date of Birth: Study No.:
WHO performance status:
Platelet count >100xl09L No
>2
M band on serum electrophoresis
Anti-DNA antibodies:
Rheumatoid factors:
Anti-muscle antibodies:
No
No
No
No
Yes
Yes
Yes
Yes
INFECTIOUS DISEASE SCREEN. TO BE COMPLETED BY 
CAMBRIDGE CENTRE
Date sample for screening taken
Anti-HBs antibodies:
Anti-HBc antibodies:
Anti-HCV antibodies:
Anti-HIV 1/2 antibodies:
TPHA negative:
DD / MM /..YY
No
No
No
No
Yes
Yes
Yes
Yes
Yes
No
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